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ABSTRACT 
Theonellamides A-F were isolated from Theonella swinhoei by Fusetani and co-workers. 
Despite considerable synthetic effort to produce theonellamide F by the Shioiri group in the 
early 1990’s, the total synthesis of a theonellamide has yet to be reported. We report herein our 
efforts toward some of the required amino acid residues and construction of the western ring of 
theonellamide C. 
 We describe the synthesis of an uncoded amino acid, (2S,4R)-ɣ-hydroxy-α-amino adipic 
acid (Ahad), a building block for theonellamide C. We initially investigated the Corey-Lygo 
method for the catalytic asymmetric generation of the Cα stereocenter. Unfortunately, the 
alkylation of glycine benzophenone imines with a series of electrophiles, including [(S)-benzyl-3-
(tert-butyl dimethylsilyl)oxy]-4-iodobutanoate (104a), was unsuccessful due to low inherent 
reactivity and steric hindrance. 
A second approach was based on MacMillan’s enantioselective organocatalytic amine 
conjugate addition. Addition of CbzNHOTBS (136a) to (E)-benzyl-4-oxo-but-2-enoate (149), in 
the presence of catalytic (S)-2-diphenyl[trimethylsilyl)oxy]methylpyrrolidine (165) led to β-amino 
aldehyde (S)-benzyl 2-[(benzyloxycarbonyl)(tert-butyldimethylsilyloxy)amino-4-oxo-butanoate, 
(148a). A Wittig reaction between 148a and methyl-(triphenylphosphoranylidene)-acetate (142) 
afforded (2S,4E)-1-benzyl-2-[(benzyloxycarbonyl)(tert-butyldimethylsilyloxy)-amino-6-methyl-
hex-4-enedioate (147a). The ɣ-hydroxy group was installed intramolecularly with 4:1 d.r. by 
treatment of 147a with TBAF. Hydrogenolysis was carried out to give unprotected Ahad. 
The next challenge was to find the right combination of protecting groups for Ahad that 
would be compatible with the synthesis of the western hemisphere of theonellamide C. We 
performed model studies on α-aminoadipic acid (α-AAA) which revealed that the δ-COOMe, 
introduced in the Wittig reaction, was incompatible with a Cα-acetol ester and a Nα-Alloc 
 xvi 
 
carbamate. α-AAA and Ahad bearing a δ-COOtBu group were synthesized in an analogous 
fashion. The Ahad building block was synthesized in 11 steps and 6.5% overall yield. In 
readiness for coupling; the tert-butyl ester was cleaved to afford the free δ-acid.  
Two tetrapeptides were assembled: Boc-Asn-HyAsn(OTBS)-Phe-β-Ala-OAll (249) and 
the simplified Fmoc-Asn(Trt)-Asn(Trt)-Phe-β-Ala-OAll (254). Removal of the N-terminal Fmoc-
group from 254 and coupling with a suitably protected -histidinoalanine acid afforded a linear 
hexapeptide that is a precursor to the western hemisphere of theonellamide C. 
1 
 
CHAPTER 1: THEONELLAMIDES A-F: INTRODUCTION 
1.1 Occurrence of Theonellamides 
Sponges are widely found across the world and appeared more than six million years 
ago. Bergmann's pioneering work in the 1950s on the isolation of sterols and novel nucleosides 
made sponges a target for extensive studies to isolate new substances.1 These research 
activities led to the discovery of a variety of new compounds, often structurally novel and highly 
biologically active metabolites.2 Sponges of the family Lithistida, which include the genera 
Discodermia and Theonella, are a prominent source of bioactive secondary metabolites. These 
secondary metabolites include macrolides such as swinholide A,3 along with cyclic and linear 
peptides such as cyclotheonamides,4 onnamides5 and theonellamides.6  
 
 
Figure 1.1 Chemical structures of theonellamide F, theonegramide and theopalauamide. 
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Matsunaga et al. first reported the isolation and characterization of theonellamide F (1) 
(Figure 1.1) in 19896 and then theonellamides A-E in 19957 as bicyclic dodecapeptides from a 
Theonella sp. collected off Hachijo-jima Island in Japan. Subsequently, Bewley and Faulkner 
isolated the closely related compound theonegramide (2) in 1994,8 followed by theopalauamide 
(3) in 19989 from the same marine species.  
Early studies by Bewley and co-workers reported that a number of symbiotic bacteria 
live in association with Theonella swinhoei.10,11 The sponge contains four cell populations: 
sponge cells, unicellular heterotrophic bacteria (eubacteria), unicellular cyanobacteria and 
filamentous heterotrophic bacteria (filaments).  All populations of associated bacteria are 
located extracellularly. The unicellular cyanobacterium Aphanocapsa feldmanni has been the 
only species identified based on ultrastructural studies. The unicellular cyanobacteria occur only 
in the ectosome (cortical part of sponge) while the filamentous bacteria reside only in the 
endosome (membrane-bounded compartment inside the sponge).  Heterotrophic eubacteria 
and sponge cells occur in both endosome and ectosome.   
The separation of four cell populations was followed by dissociation and differential 
centrifugation of the cell suspension which led to cell types of >90% purity (Figure 1.2). Analysis 
of the four cell fractions by HPLC and 1H NMR spectroscopy showed that the unicellular 
cyanobacteria and sponge cells lacked bioactive metabolites.  The polyketide swinholide A (4) 
was present in the fraction of eubacteria and theopalauamide (3) occurred in the filamentous 
bacteria. 
Theonellamides were isolated in limited quantities from nature. From 15 kilograms of 
sponge, Fusetani and coworkers isolated: theonegramides A (200 mg), B (19 mg), C (32 mg), D 
(14 mg), E (30 mg), and F (500 mg).6’
7 Therefore, collaborative investigations have focused on 
theonellamides A and F in a variety of assays. 
3 
 
 
Figure 1.2 Swinholide A and theopalauamide are derived from different types of cells in 
Theonella swinhoei. Copyright 1998, John Wiley and Sons, reprinted with permission (p. 219). 
 
1.2 Structural Characteristics of Theonellamides  
Theonellamides A-F are characterized by a bridging -histidinoalanine (-HAL) residue. 
There are some other features common to all family members. All contain allo-threonine, serine 
and phenylalanine at positions AA1-AA3 respectively and serine, asparagine and erythro-β-
hydroxyasparagine at positions AA5-AA7. Also, at the AA4 position there is (5E,7E)-3-amino-4-
hydroxy-6-methyl-8-phenyl-5,7-octadienoic acid (Apoa) or its 4’-brominated derivative (Aboa). In 
position AA10 is (2S,4R)-α-amino-ɣ-hydroxy adipic acid (Ahad) or α-amino adipic acid (AAA). 
4 
 
There are further structural variations including glycosylation. Theonellamide A bears a β-D-
galactose covalently linked to the imidazole -nitrogen and isoserine at AA9 instead of β-
alanine. Theonellamides D and E contain a β-D-arabinoside and β-D-galactoside respectively. 
There is p-bromophenylalanine (BPA) in theonellamides D-F and β-methyl-p-
bromophenylalanine (BMPA) in theonellamides A and B at position AA8, whereas theonellamide 
C contains unmodified phenylalanine (Figure 1.3).  
 
Figure 1.3 Amino acid composition of theonellamides A-F, theonegramide and theopalauamide. 
Details of the structure elucidation of eHyAsn have been described in Douglas Wong’s 
dissertation.12 The origins and structure determination of Ahad will be detailed in Chapter 2. 
1.3 Initial Biological Studies 
Initial studies by Matsunaga and co-workers on theonellamides A-F showed that they 
are antifungal and cytotoxic agents. They demonstrated cytotoxicity against P388 murine 
leukemia cells, with IC50 values of 5.0, 1.7, 2.5, 1.7, 0.9 and 2.7 µg/mL respectively.
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Theonellamide E (9) was shown to be the most cytotoxic. Glycosylation seems to have little 
effect on the cytotoxicity of the theonellamides. In addition, congener F was toxic to L120 
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leukemia cells with an IC50 value of 3.2 µg/mL. Theonellamide F (1) also showed activity against 
fungi of Candida spp., Trichophyton spp., and Aspergillus spp.  
In later studies, Watabe et al. reported that theonellamide F induced the formation of 
vacuoles (fluid-filled compartments in the cytoplasm) in 3Y1 rat embryonic fibroblasts.13,14 At 
higher concentrations, theonellamide F induced not only the formation of large vacuoles 
equivalent to the size of a cell, but also remarkable morphologic changes. The theonellamide F 
induced vacuoles contain an ATPase and thus maintain a slightly acidic pH. The disturbance of 
intralysosomal (within a lysosome) pH affects the function of lysosomal proteases that are 
responsible for autophagic degradation of organelles. The formation of vacuoles is a well-known 
marker of microbial activity that often precedes cell autophagy, although the mechanism is not 
well understood. Theonellamides are the first low molecular weight compounds to induce 
extraordinarily large vacuoles and thus are good molecular probes for studies on intracellular 
membrane structures. 
The novelty of the molecular architecture of these theonellamides prompted Wada et al.15 to 
probe whether they bind to proteins. They immobilized theonellamide A (5) to affinity gel beads 
and screened for binding to proteins in rabbit liver. As a prerequisite to this screening process, 
theonellamide A (5) was treated with sodium periodate, cleaving the vicinal 2,3- and 3,4-diols of 
the β-D-galactose and liberating aldehydic handles for the covalent attachment of the molecule 
to beads. Compound 10 was then reacted with hydrazine-containing Affi-Gel beads to give 
TNM A-conjugated gel beads 11 (Scheme 1.1). Rabbit liver tissue extracts were exposed to the 
TNM A-conjugated gel beads for two hours and two major proteins were found to bind to the 
beads.  
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Scheme 1.1 Preparation of theonellamide A - conjugated gel beads. 
 
The proteins which bound to the beads were identified as 17β-hydroxysteroid 
dehydrogenase IV and glutamate dehydrogenase (Scheme 1.2). 17β-Hydroxysteroid 
dehydrogenases mediate interconversion of estrone and estradiol and type IV of this enzyme 
oxidizes estradiol (12) to estrone (13).  Theonellamide activates the conversion of α-
ketoglutarate (15) from glutamate (14) by glutamate dehydrogenase, but has no effect on the 
reverse reaction.  
 
Scheme 1.2 Function of 17β-hydroxysteroid dehydrogenase IV and glutamate dehydrogenase. 
 
The effect of theonellamides on 17β-hydroxysteroid dehydrogenase IV might be the 
cause of its cytotoxicity. The studies described above, probing the origin of the metabolite, and 
its possible roles in biology, reflect the novelty of the molecular architecture.  
1.4 More Recent Biological Studies: Chemical Genetics 
A central problem in chemical biology is to determine the mode-of-action (MOA) of new 
compounds. Rich functional information has been obtained from scoring ~5000 viable yeast 
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haploid deletion mutant strains for hypersensitivity to a diverse set of compounds, a process 
termed chemical genetic profiling. Cells with gene deletions that are deemed hypersensitive to a 
specific compound can give clues about its MOA. In the yeast Saccharomyces cerevisiae, 
~6000 potential genes have been characterized by the genome sequencing project.   
With this genetic profiling method Boone et al.16 found that two extracts containing 
natural products stichloroside (16) (Figure 1.4) and theopalauamide (3) showed very similar 
chemical-genetic profiles (correlation coefficient of 0.892). Thus, these compounds shared a 
common MOA in yeast and this illustrates that chemical-genetic profiling is an effective means 
of functional classification of natural product extracts. Moreover, stichloroside-resistant mutants 
also displayed theopalauamide resistance, suggesting that the compounds function similarly. 
 
 
Figure 1.4 Structure of stichloroside.  
There are limitations to these assays. Haploinsufficiency is the state of a diploid 
organism having only a single copy of a particular gene, the other copy being inactive due to 
mutation. An approach based on this status is unlikely to identify a drug target that is the 
product of an enzyme rather than the enzyme itself. Moreover, these protocols (one or the 
other) based upon clustering of chemical-genetic profiles are difficult to implement because they 
depend upon the assembly of a relatively large compendium of reference profiles. Hence, Ho et 
al.17 developed a new strategy by generating a library of molecular barcoded yeast open 
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reading frames (MoBY-ORF) to clone wild-type versions of mutant, drug-resistant genes by 
complementation using a minimal amount of bioactive compound. Each gene of this MoBY-ORF 
library is controlled by its native promoter and terminator. Cloning by complementation with the 
MoBY-ORF library is an assay that can be carried out with any S. cerevisiae strain.   
Using the MoBY-ORF complementation assay, they identified an essential enzyme 
involved in an early step of the ergosterol biosynthesis pathway: mevalonate pyrophosphate 
decarboxylase (MVD1). 
 
Scheme 1.3 Ergosterol biosynthesis pathway. 
A theopalauamide-resistant mutant (theoR) was made to determine whether or not the 
compound targets a product of the MVD1 pathway. The theoR mutant was partially resistant to 
amphotericin B (a sterol-binding antifungal compound). Experiments showed that deletion 
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mutants erg2, erg31 and erg32, which participate in the second and third steps of ergosterol 
biosynthesis, were resistant to theopalauamide. 
To test the hypothesis that theopalauamide (3) and stichloroside (16) bind to ergosterol 
(22), exogenous ergosterol was added to cultures containing toxic levels of these compounds 
alongside amphotericin B (23), a polyene antifungal drug, and ketoconazole (24) (Figure 1.5), 
another antifungal compound that inhibits Erg11p, different ergosterol biosynthetic enzyme. 
Exogenous ergosterol rescued the toxicity of theopalauamide, stichloroside and amphotericin B, 
but had no effect on ketoconazole’s toxicity. This observation suggested that, like amphotericin 
B, both theopalauamide and stichloroside may interact on a molecular level with ergosterol.  
 
Figure 1.5 Structures of amphotericin B, ketoconzole and nystatin. 
The Ho Group also studied the effect of these compounds using fluorescent markers 
released from phosphatidylcholine liposomes that contained various levels of ergosterol to show 
that theopalauamide and stichloroside interact with ergosterol. Theopalauamide (10 µg/mL) 
caused a maximal 30% leakage of calcein from liposomes containing 20% ergosterol in their 
membrane, whereas it had no effect on liposomes lacking ergosterol. Stichloroside (16) and 
nystatin (25) also caused ergosterol-enhanced leakage, and were more potent than 
theonellamide. Thus, theopalauamide, stichloroside and nystatin disrupt ergosterol-containing 
membranes specifically. 
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A similar experiment showed that fluorescently labeled theonellamide A bound to 
ergosterol specifically in an in vitro lipid-binding assay. Theonellamide A (5) was conjugated to 
AMCA to give compounds described by structure 26 (Figure 1.6). Aminomethyl coumarin 
acetate (AMCA) is a blue-fluorescent dye used to label antibodies, proteins and other molecules 
for fluorescence imaging.  
 
Figure 1.6 Structure of theonellamide A-fluorophore conjugates. 
The theopalauamide-resistant yeast strain (theoR) was also resistant to theonellamide A, 
previously established to be toxic to wild-type S. cerevisiae.16,17 Ho et al.17  demonstrated that 
fluorescently labeled theonellamide A stained the cell surface of wild-type budding yeast, but 
only weakly stained the plasma membrane of theoR mutant cells. All these studies suggest that 
theopalauamide and theonellamide A represent a novel class of sterol-binding compound and 
behave similarly.  
The specificity of lipid-binding properties and the mechanism of their antifungal activity 
remained ambiguous. In 2010 Yoshida and co-workers18 reported on the production of  
theonellamide affinity beads by a photo-affinity immobilization method (similar to the earlier work 
by the Wada group, Scheme 1.1) and tried to identify the binding proteins from fusion yeast 
cells. They were unable to detect any proteins that specifically bound to theonellamide F. 
Therefore, they decided to search for chemical-genetic interactions using a set of strains 
expressing all 5000 protein-coding ORFs of the fission yeast Schizosaccharomyces pombe, 
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which might provide insights into the genes and pathways targeted by general bioactive 
metabolites.  
They generated a chemical-genomic profile of theonellamide F using a collection of 
fission yeast strains in which each open reading frame is expressed under the control of an 
inducible promoter. Strains showing a significantly altered sensitivity compared to the control 
strain were selected. A total of 20 profiles were obtained and analyzed by 2D-hierarchical 
clustering analysis. They found a weak correlation between amphotericin B (23) and nystatin 
(25) (correlation = 0.18 for each of these compounds with respect to theonellamide F), implying 
that the MOA of theonellamide F is only partially shared with these sterol-binders. The most 
sensitive strain of yeast overexpressed SPAC26A3.09, which encodes a homolog of Rho-type 
GTPase activating protein Rga2, a small GTPase that plays a role in a signaling pathway of cell 
polarity and in 1,3-β-D-glucan synthesis in fission yeast. The second most sensitive strain 
overexpressed pck1, which encodes a protein kinase C homolog that regulates 1,3-β-D-glucan 
synthesis. 2D-Hierarchical clustering analysis showed a modest linkage (correlation coefficient 
= 0.35) between theonellamide F and FK463 (28) (Figure 1.7), a frontline clinical antifungal drug 
(common name Micafungin) that inhibits the synthesis of 1,3-β-D-glucan.  
 
Figure 1.7 Chemical structure of FK463 (28). 
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Of the 32 genes from generated chemical-genomic profile of theonellamide F, 12 were in 
common with those affected by FK463, suggesting that the MOA of theonellamide F and FK463 
are functionally related. They compared the morphology of cells after exposure to each drug. 
Cell lysis was observed at the growing ends in fungi treated with FK463, whereas theonellamide 
F did not lead to any signs of cell lysis. Unexpectedly, calcofluor white (Cfw) staining showed 
strong signals due to increased 1,3-β-D-glucan at the growing ends and/or the medial region of 
the cell treated with theonellamide F. Thus, theonellamide F appears to counteract FK463 
action by enhancing 1,3-β-D-glucan synthesis. 
Further experimental results suggested that the major pathway for 1,3-β-D-glucan 
synthesis upon theonellamide F treatment is the direct activation of Bgs1 (1,3-β-D-glucan-UDP 
glucosyltransferase) by Rho1. Theonellamide A (5) was  fluorescently labeled as its TNMF-BF 
derivative 27 (TNMF-BF = theonellamide F-boron-dipyrromethane conjugate) by Yoshida and 
co-workers18 to determine the subcellular localization of the theonellamide-binding molecule 
(Figure 1.6). The in vitro binding assay revealed that TNM-BF (27, Figure 1.6) recognizes 
ergosterol (22), cholesterol (29), cholestanol (30) and 5α-cholest-7-en-3β-ol (31) (Figure 1.8). 
Thus, theonellamide F recognizes 3β-hydroxysterols, a class of lipid molecules, rather than a 
protein. 
 
Figure 1.8 Structures of 3β-Hydroxysterols. 
Mutations to genes in the ergosterol biosynthetic pathway (Scheme 1.3) have shown 
sensitivity to polyene antibiotics in yeast. Mutants lacking the enzymes Erg2, or simultaneous 
deletion of Erg31 and Erg32, displayed high tolerance to theonellamide F and a decreased 
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ability of the cells to bind theonellamide F. Deletion of other enzymes (Erg5, Δsts1/Erg4), 
resulted in slight resistance to theonellamide F. Calcein (a fluorescent dye) was added to S. 
pombe cells that had been treated with theonellamide F for nine hours.  Entry of calcein over the 
plasma membrane was observed, suggesting that cells do not retain their membrane integrity in 
the presence of thenellamide F. Moreover, calcein diffusion into theonellamide F treated cells 
gradually increased over time and in a dose-dependent manner. 
The MOA of theonellamide F is different from that of the polyene antibiotics. A typical 
morphological change in yeast cells after treatment with polyene antibiotics is enlargement of 
vacuoles whereas the vacuoles of theonellamide F-treated cells became marginally fragmented. 
This finding is in contrast with earlier rat fibroblast experiments where theonellamides caused 
the formation of extremely large vacuoles (Section 1.3).  The other characteristic aspect of 
polyene antibiotics is their acute fungicidal effect while theonellamide F showed gradual time 
dependent toxicity. In agreement with Ho and co-workers, Yoshida concluded that the 
theonellamides represent a new class of sterol-binding agents. 
In 2013, Yoshida et al. published new results from surface plasmon resonance (SPR) 
and solid-state 2H NMR experiments leading them to postulate a mechanism for sterol 
recognition by theonellamide F in lipid bilayers.19 Earlier studies by the same research group 
had evaluated the binding of amphotericin B (23) 20 and amphidinol21 to palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (32, POPC) liposomes. They performed analogous experiments with 
theonellamide A, studying the interaction of theonellamide A with POPC liposomes containing 
ergosterol (22), cholesterol (29), or epicholesterol (33) (Figure 1.9). Surface plasmon resonance 
(SPR) revealed that the incorporation of 10 mole percent cholesterol or ergosterol into POPC 
membranes significantly enhances the affinity of theonellamide F for the membrane, particularly 
initial binding to the membrane surface. Conversely, binding of the peptide to epicholesterol 
(diastereomer of cholesterol, varying in configuration at C3) liposomes and pure POPC 
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liposomes was weak by comparison. This demonstrated the preference of the peptide for the 
3β-hydroxysterol-containing membranes. 
 
 
 
 
 
 
 
 
 
Figure 1.9 Chemical structure of POPC, cholesterol, ergosterol and epicholesterol. 
Yoshida et al. also conducted solid-state 2H NMR experiments using cholesterol, 
ergosterol and epicholesterol. These compounds were labeled by deuterium at C3 and 
incorporated into POPC liposomes in the absence and presence of theonellamide A. The axial 
rotation in NMR for sterol molecules in lipid bilayers undergoes fast lateral diffusion and gives 
quadrupolar splitting which depends on the tilt angle of the C−2H bond with respect to the 
rotation axis and the wobbling of the molecule. Experiments conducted using 3-d-cholesterol 
(29D) and 3-d-ergosterol (22D) showed similar results. In the absence of peptide (Figure 1.10 A 
and C), a characteristic triplet peak was observed, indicating fast rotational motion of the sterol 
in the POPC bilayers. 
However, a stark attenuation of the splitting signal was observed upon addition of the 
peptide (Figure 1.10 B and D), suggesting that the molecular rotation falls into an intermediate 
motional speed with correlation times of 10−4 to 10−5 seconds. On the contrary, the characteristic 
splitting didn’t change much for 3-d-epicholesterol (33D) containing POPC liposomes (Figure 
1.10 E and F). The 2H NMR experiments showed that theonellamide A inhibits the fast rotational 
motion of cholesterol and ergosterol.  
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Figure 1.10 2H NMR spectra of 3-d-sterol incorporated into POPC bilayers in the absence (A, C, 
and E) and presence (B, D, and F) of TNM-A. 3-d-Cholesterol (A and B), 3-d-ergosterol (C and 
D), and 3-d-epicholesterol (E and F). Copyright 2013, ACS Publications reprinted with 
permission (p. 220). 
 
On this background of intriguing biological activity, the theonellamides present a worthy 
target for total synthesis. They present a formidable chemical challenge that requires the 
asymmetric synthesis of unusual amino acids and their assembly into a demanding bicyclic 
array. 
1.5 Previous Studies Directed Toward the Synthesis of Theonellamides 
Nearly two decades ago, Tohdo, Hamada and Shioiri reported progress towards the 
synthesis of theonellamide F in the form of conference proceedings and 
communications.22,23,24,25 The synthesis has never been completed. They formed the two rings 
independently but never described plans for the formation of the bicycle. They presumably 
targeted theonellamide F because it was the first structure to be revealed; none of the other 
theonellamides have been the subject of synthetic studies.  
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In 1994, Tohdo et al. published a short letter on their efforts toward the synthesis of what 
they termed as the northern hemisphere* of theonellamide F.24 The synthesis of pertinent 
building blocks will be discussed in relevant chapters of this dissertation. The construction of the 
western hemisphere was carried out by a fragment condensation approach (Scheme 1.4).  
Synthesis of the Ahad-HAL tripeptide is illustrated on the left hand side of Scheme 1.4. 
At the outset, the protecting group of the Ahad α-amine was switched from Boc (compound 34) 
to Troc (compound 35). This was done in order that both protecting groups could be removed 
simultaneously from linear precursor 47 prior to cyclization. The δ-COOH of Ahad lactone 35 
was coupled with the free amine of HAL 36 to give tripeptide 37. In readiness for coupling, the 
tert-butyl ester was cleaved under acidic conditions to afford acid 38. 
The remaining tetrapeptide was assembled as shown in the right hand side of Scheme 
1.4. p-Bromophenylalanine derivative 39 was coupled with the trichloroethyl (TCE) ester of β-
alanine (40) to give dipeptide 41. Elongation of the peptide in the C→N terminal direction was 
accomplished by Boc deprotection and homologation with eHyAsn building block 42, giving 
tripeptide 43. Analogous deprotection and coupling with Boc-Asn-OH (44) was accompanied by 
loss of the TBS ether under acidic conditions. The β-OH of the eHyAsn residue was reprotected 
as the more robust TBDPS ether to obtain compound 45. In readiness for coupling, the tert-
butyloxycarbonyl group was cleaved under Lewis acidic conditions to afford amine 46. They 
used diphenylphosphoryl azide [DPPA, (C6H5O)2P(O)N3 (49)] and diethyl phosphorocyanidate 
[DEPC, (C2H5O)2P(O)CN) (50)] for the various coupling reactions. These coupling reagents 
were introduced by Shioiri in the 1970’s.26 In readiness for coupling, the tert-butyloxycarbony 
group was cleaved under Lewis acidic conditions to afford amine 46. 
*They drew the molecule rotated 90° relative to representations in this dissertation. Thus their 
references to northern and southern hemispheres correlate with our western and eastern 
hemispheres respectively. 
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Scheme 1.4 Assembly of the western hemisphere of theonellamide F. 
*They drew the molecule rotated 90° relative to representations in this dissertation. Thus, their 
references to northern and southern hemispheres correlate with our western and eastern 
hemispheres respectively. 
 
*They drew the molecule rotated 90° relative to representations in this dissertation. Thus, their 
references to northern and southern hemispheres correlate with our western and eastern 
hemispheres respectively.  
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The tripeptide acid 38 was coupled with tetrapeptide amine 46 by using DEPC. The 
linear precursor 47 was treated with lithium hydroxide followed by cyclization with DPPA to give 
the western hemisphere of theonellamide F, viz. compound 48. While these coupling reagents 
gave reasonable results for small peptides, more hindered couplings and the key cyclization 
steps were low yielding. The synthesis involves 10 steps (longest linear sequence) with an 
overall yield of 7.9%. Moreover, they incorporated the Ahad residue into the cyclic peptide in its 
lactone form. We believe that the Ahad residue should be incorporated into the cyclic peptides 
in the open chain form and that the rigidity of the lactone may have a contributing factor to the 
low-yielding cyclization of the western ring in the synthetic effort of Tohdo et al.  
1.6 Research Goals of This Dissertation 
Despite considerable synthetic effort to produce theonellamide F by the Shioiri group in 
the early 1990s, a total synthesis of a theonellamide has yet to be reported.  An efficient 
chemical synthesis of these compounds offers benefits such as an alternative to cultivation from 
natural sources and the potential to produce analogs and explore new ideas about their 
emerging biological role. We chose to synthesize theonellamide C (7) in our laboratory as it is 
the simplest congener to make, requiring the synthesis of the least number of amino acids, prior 
to fragment condensations and cyclizations. 
My goal was to synthesize the western hemisphere of theonellamide C (7). In common 
with the other theonellamide congeners, theonellamide C (7) has ten amino acids and one bis-
amino acid in total. The two hemispheres of theonellamide C (7), designated east and west, 
each have five amino acids and the bicycle is bridged by a -histidinoalanine (-HAL) residue. 
1.7 Retrosynthetic Analysis 
There are four amino acids in theonellamide C (7) that are not commercially available. 
These are Aboa ④, eHyAsn ⑦, Ahad ⑩, and -HAL. Since the major element of 
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conformational restraint in the molecule is the -HAL residue, we plan to construct this bis-
amino acid and build on the two rings sequentially. It is desirable to perform fragment couplings 
with carboxy components that are not prone to epimerization at Cα; three residues provide this 
opportunity: β-Ala ⑨ and Ahad ⑩ in the western ring and Aboa ⑤ in the eastern ring. 
Capitalizing on the opportunities provided by these non-epimerizable residues, the major 
cyclization disconnection for the western hemisphere is between residues ⑨ and ⑩ (Scheme 
1.5). This leads to cyclization precursor 49. The deprotection of the Alloc and Allyl groups will be 
accomplished simuntaneously by using Pd(0) catalysys, followed by subsequent cyclization. 
Further disconnection of compound 49 leads to tetrapeptide 52, -HAL (53) and Ahad (54) 
residues. 
 
Scheme 1.5 Retrosynthesis of the western hemisphere of theonellamide C. 
This dissertation will highlight the synthesis of the Ahad residue (Chapters 2, 3 and 4) 
and the ⑥-⑨ tetrapeptide (western hemisphere, Chapter 5) (both building blocks shown in red 
boxes) and peptide assembly for the western hemisphere of theonellamide C. 
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CHAPTER 2: INITIAL APPROACH TO (2S,4R)-α-AMINO-γ-HYDROXY ADIPIC ACID (AHAD): 
COREY-LYGO METHOD 
 
 
2.1 Structural Determination of (2S,4R)-α-Amino-γ-Hydroxy Adipic Acid (Ahad) 
Theonellamide F (1) showed UV maxima at 283 nm, 294 nm and 315 nm.6 Upon acid 
hydrolysis with 6N HCI at 110 °C for 16 hours compound 1 generated several ninhydrin-positive 
spots on TLC. The hydrolysate was dissolved in triethylamine/formic acid buffer (pH 3.41) and 
subjected to HPLC. This HPLC analysis of the hydrolysate indicated the presence of asparagine 
(Asn), allo-threonine (aThr), phenylalanine (Phe), β-alanine (β-Ala) and two residues of serine 
(Ser). The stereochemistry of the standard amino acid residues was determined by chiral GC-
MS analysis of derivatives.  
 Scheme 2.1 Ahad structure elucidation from theonellamide F degradation. 
Preparative ion-exchange chromatography showed a single peak corresponding to 
compounds 55a and 55b (Scheme 2.1) which eluted after β-Ala in the acid hydrolysate HPLC 
analysis. The (M+H)+ ion at m/z 178 was observed in the fast atom bombardment (FAB) mass 
spectrum of the amino acid derivatives, suggesting that 55a and 55b were a diastereomeric 
mixture of aminohydroxyadipic acids. According to 1H and 13C NMR analysis, these 
diastereomeric mixtures were isolated as an equilibrium mixture of ɣ-lactones 57a, 57b and 
triethylammonium salts of dicarboxylic acids 56a, 56b formed during evaporation of 
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triethylammonium formate buffer. The isolated mixture was treated with 2-(tert-
butoxycarbonyloxyimino)-2-phenylacetonitrile (BocON) and triethylamine, followed by 
acidification to promote lactonization and esterification with diazomethane. The two 
diastereomers were separated by normal phase HPLC to afford lactones 58a and 58b (Scheme 
2.1).  
When the acidic hydrolysate was analyzed after a shorter reaction time, the (2S,4R) 
isomer (trans) was detected as the major isomer. The ratios of 4S to 4R isomers were 1:4, 1:2, 
and 1:1.5, upon acidic hydrolysis for 2, 4, and 8 hours, respectively, as analyzed by chiral GC-
MS analysis. The CD spectrum of 58a, showed a positive Cotton effect at 217 nm.27  Therefore 
the configuration at C2 of both isomers was deemed to be S. The two diastereomers were 
distinguished based on the 1H NMR signals for H3 and H3’. For cis-2,4-disubstituted ɣ-lactones, 
two separate signals are observed;  a single signal is observed for the trans diastereomer 
(Figure 2.1). Proton NMR studies showed that the isomer 58a appeared to be the cis-lactone, 
by comparison with the data on synthetic model compounds prepared by Stoddart and 
coworkers.28  
 
Figure 2.1 Comparison of H3 signals 1H NMR of cis- and trans-disubstituted lactones.      
Accordingly, the cis-lactone 58a had (2S,4S) stereochemistry, while the trans-lactone 
58b, had the (2S,4R) stereochemistry, as deduced from the 1H NMR spectrum. The C-4 
hydroxyl group might have been epimerized through a backside attack of the carboxyl group 
during lactonization (Scheme 2.2). Moreover, equilibration to the more stable cis-2,4-
disubstituted ɣ-lactone may have enhanced the (2S,4S) diastereomer. 
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Scheme 2.2 Lactonization through backside attack of the carboxyl group at C4. 
Therefore, Matsunaga and co-workers concluded that (2S,4R)-2-amino-4-hydroxyadipic 
acid (55a) was the constituent of theonellamide F (1), while the (2S,4S) isomer was an artifact 
of the isolation procedure. 
2.2 Biogenesis of Ahad and α-AAA 
Structure elucidation of the theonellamides showed that they contain (2S,4R)-α-amino-ɣ-
hydroxy adipic acid (Ahad) (55a) (Schemes 2.1 and 2.3). 
 
Scheme 2.3 Biogenesis of adipic acids. 
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Theonegramide and theopalauamide contain (2S)-α-amino-adipic acid (α-AAA, 64, 
Scheme 2.3), which lacks the ɣ-hydroxy group. In mammals and higher plants metabolic 
degradation of lysine29 gives saccharopine (62), formed by condensation of lysine (60) and α-
ketoglutarate (61). In eukaryotes, normal metabolic degradation of lysine (60) gives α-AAA (64). 
Whereas, metabolic degradation of adipic acid (65) gives (3R)-3-hydroxyadipic acid (66) which 
is excreted in the urine and observed in the serum of ketoacidosis patients.30 α-Amino-ɣ-hydroxy 
adipic acid (Ahad, 55a) would appear to be of novel, or mixed, biogenesis. Aside from the 
appearance in theonellamides (vide supra), there has been only one other report of Ahad by 
Blass and Macheboeuf who proposed the occurrence of Ahad in cultures of Vibrio cholera, 
based on elemental analysis but without spectroscopic evidence.31  
2.3 Previous Syntheses of (2S,4R)-γ-Hydroxy-α-Amino Adipic Acid (Ahad) 
In 1957 Benoiton and co-workers synthesized γ-hydroxyglutamic acids.32 By analogy, 
Kristensen et al. reported the synthesis of a mixture of all four streoisomers of Ahad in 198033 
(Scheme 2.4). Condensation of the anion of ethyl acetamidocyanacetate (68) with 3-acetoxy-4-
chlorobutyronitrile (67), followed by hydrolysis and decarboxylation, afforded a mixture of four 
isomers of 55 which was separated into racemates of the two diastereoisomers by ion-
exchange chromatography and preparative high voltage electrophoresis. 
 
Scheme 2.4 Synthesis of four stereoisomers of Ahad by Kristensen et al.     
 In 1994, Tohdo et al.22,23 reported the synthesis of Ahad in optically active form 
(Scheme 2.5). They took commercially available N-tert-butoxycarbonyl-(S)-aspartic acid β-
benzyl ester (70) and converted it to Boc-(S)-Asp-OMe (71). The β-carboxyl group of 71 was 
activated with carbonyldiimidazole (CDI) and the resulting imidazolide was reacted with the 
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magnesium enolate of ethyl hydrogen malonate to yield β-keto ester 72 which was reduced 
stereoselectively. The yield and diastereomeric excess of the reduced products 73a and 73b 
were measured following acid-catalyzed lactonization. The best result was obtained by 
asymmetric hydrogenation with Noyori’s Ru-(R)-BINAP catalyst to give a mixture of 73a and 
73b that was converted to the γ-lactones 74a and 74b (ratio of 27:1) by treating with a catalytic 
amount of trifluoroacetic acid. Hydrolysis of compound 74a with lithium hydroxide followed by 
relactonization with acid gave the lactone 75a. Tohdo et al. used this ɣ-lactone functionality as 
“intramolecular protection” for their Ahad building block as discussed in Chapter 1, Section 1.5. 
 
Scheme 2.5 Synthesis of the Ahad lactone by Tohdo et al. 
 The α-carboxylic acid is not part of the peptide backbone and may be important for 
stabilization of an imidazolium cation in the full theonellamide structure.  As described earlier, 
Ahad 55a was isolated as the corresponding ɣ-lactone 57a following acidic degradation of the 
theonellamides. The work of Benson Edagwa in the Taylor Laboratory with 4,5-
dihydroxyleucine34 alerted us to the fact that there would be a high risk of epimerization at Cα 
while opening the ɣ-lactone. Michl had shown earlier that epimerization of Nα-acyl and Nα-
carbamoyl ɣ-lactones occurs through oxazolone formation.35  On this basis, we have concerns 
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for the stereochemical integrity of 75a in Scheme 2.5. For this reason, we wanted to avoid the ɣ-
lactone formation moiety throughout our synthesis. 
2.4 Retrosynthesis of Ahad via Alkylation of a Glycine Ester Enolate 
Our Ahad building block has two stereocenters: Cα and Cɣ (Scheme 2.6). We planned to 
establish the Cɣ configuration in an electrophilic reaction partner and focus our attention on the 
Corey-Lygo method for the catalytic asymmetric generation of the Cα stereocenter. Corey and 
Lygo independently developed a new class of asymmetric phase-transfer catalyst derived from 
Cinchona alkaloids36 and applied them to the enantioselective synthesis of α-amino acids.  
Retrosynthetically, it can be imagined that an Ahad building block might be arrived at via 
stereoselective alkylation of the enolate of glycine derivative 76 (commercially available) with an 
electrophile (Scheme 2.6).  
 
Scheme 2.6 Retrosynthesis of Ahad.      
2.5 Phase-Transfer Catalysis (PTC) and the Corey Lygo Approach 
2.5.1 The Concept 
Phase-transfer catalysis (PTC)37 facilitates the migration of a reactant in a 
heterogeneous system from one phase into another phase where a reaction can take place.38 
An inexpensive, commercially available source of effective chiral phase-transfer catalysts is the 
family of Cinchona alkaloids (Figure 2.2). These alkaloids can be transformed into quaternary 
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ammonium salt catalysts in one or two steps.39 Furthermore, these alkaloids are available as 
pseudoenantiomers (quinine and quinidine, e.g., 77 and 78) that can achieve similar levels of 
asymmetric induction with the opposite sense of enantioselectivity.37 An interfacial mechanism 
is implicated for lipophilic quaternary ammonium catalysts (Q+X-) when basic conditions are 
employed in PTC, as illustrated in Scheme 2.7. The interfacial mechanism involves formation of 
a contact ion pair between the quarternary ammonium cation (Q+) and the anionic organic 
nucleophile (enolate, M+) that is generated at the interface by an inorganic base. The generated 
quarternary ammonium cation complex (enolate, Q+) transfers the anionic organic nucleophile 
into the organic phase, where it can react with the organic electrophile (R-X).40  
 
Fig 2.2 Cinchona-derived chiral phase-transfer catalysts. 
 
 
  
 
 
Scheme 2.7 Phase transfer alkylation of imine. 
One reason for the enantioselectivities obtained in the presence of quaternary 
ammonium salts would be reaction via an ion-pair arrangement 81 (Scheme 2.8).36a,41 In this 
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arrangement the preferential attack would occur via the Si-face as the Re-face of the enolate 
carbon is blocked by the quinoline ring of the quaternary ammonium salt. 
 
Scheme 2.8 Possible ion pair arrangement that explains facial selectivity. 
2.5.2 Previous Examples 
 Previous examples of the alkylation of esters of glycine benzophenone imine with 
relatively complex electrophiles encouraged us to pursue such an approach to the 
stereoselective formation of Cα in Ahad. Zhu and coworkers used the Corey-Lygo method for 
the synthesis of (-)-quinocarcin (85)42 and lemonomycinone amide (87) (Scheme 2.9).43  
 
Scheme 2.9 Application of Corey-Lygo alkylation to complex molecules.     
The preparation of intermediate 84 for the total synthesis of (-)-quinocarcin (85) is shown 
in Scheme 2.9. Following Corey’s procedure, the enantioselective alkylation of N-
(diphenylmethylene)glycine tert-butyl ester 76b was performed with 2-bromo-5-tert-
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butyldimethylsilyloxybenzyl bromide (82) in the presence of O-allyl-N-(9-anthracenylmethyl) 
cinchonidinium bromide (86), followed by chemoselective hydrolysis of the imine functionality 
gave the amino ester 83 in 87% yield. Cleavage of the silyl ether gave amino phenol 84 in 91% 
yield. 
Also, Tohdo et al. utilized Nq-benzylcinchonidinium chloride (90) as a phase transfer 
catalyst44 for the preparation of Nα-Boc-(S)-p-bromophenylalanine (39) which occurs in 
theonellamide F. The asymmetric alkylation of the Schiff base 76b was carried out with p-
bromobenzyl bromide (88) using catalyst 90 to obtain 89 (Scheme 2.10). Acid hydrolysis 
followed by neutralization and treatment with Boc2O afforded the required Boc derivative 39.    
 
Scheme 2.10 Preparation of (S)-Nα-Boc-p-bromophenylalanine by Tohdo et al. 
 
2.6 Synthesis of an Electrophile for Ahad Synthesis 
As depicted in Scheme 2.6, we required an appropriate electrophile. The initial steps in 
the synthesis of this electrophile were accomplished using an established procedure reported 
independently by Lee et al.45 and Bellamy et al.46 Bellamy described the synthesis of (R)-
carnitine (95) according to Scheme 2.11. Starting from D-malic acid (91), the formation of 
dibenzyl ester 92 was performed. Chemoselective reduction of the α-hydroxyester of compound 
92 was carried out by using BH3.SMe2 to obtain diol 93. This chemoselectivity was first observed 
by Moriwake.47 The reaction involves the formation of a boroxolane-type intermediate 96 
(Scheme 2.11). The chemoselectivity observed in the reduction might be derived from the fact 
that relatively short B-O bond length in 96 vs. 97 and low entropy factor for the more feasible 
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formation of 96 than that of boroxane-type intermediate 97. Monotosylation of the diol 93 led to 
compound 94, a key intermediate en route to the synthesis of (R)-carnitine (95). Similar 
reactions were carried out by Lee et al. for the synthesis of (2S,3R)-2-benzyl-3,4-epoxybutanoic 
acid (BEBA) (98) (shown in a box in Scheme 2.11).45   
 
Scheme 2.11 Synthetic manipulations of malic acid by Lee et al. and Bellamy et al. 
Kocienski et al.43 synthesized the analogous methyl ester 101 in their efforts toward the 
total synthesis of (-)-lipstatin. Enantiomerically pure dimethyl (S)-(-)-malate (99) was selectively 
reduced to diol 100. The primary hydroxyl function of the resultant diol 100 was converted to the 
tosylate 101.48  
 
Scheme 2.12 Synthesis of intermediate electrophile for total synthesis of (-)-lipstatin by 
Kocienski et al.      
    
We repeated the reactions as shown in Scheme 2.11 using D-malic acid (91). However, 
we obtained only low yields of tosylate 94 under the conditions reported by Kocienski et al. 
Galvez and coworkers reported that conversion of a diol to a stannylene acetal enhanced the 
nucleophilicity of the oxygen, while still promoting regioselectivity (shown in a box in Scheme 
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2.13).42 Diol 93 was successfully monotosylated using this strategy. Protection of the remaining 
secondary alcohol as both TBS ether 103a and TBDPS (more hindered) ether 103b was 
achieved. The primary tosylates 103a and 103b were each treated with sodium iodide/acetone 
to obtain another pair of electrophiles 104a and 104b with iodide as a good leaving group. 
Moreover, another less hindered electrophile was synthesized without the protection of the 
secondary alcohol, viz. 102. 
 
Scheme 2.13 Synthesis of electrophiles. 
In conclusion, we made a series of potential electrophiles to do the alkylation from less 
sterically hindered 102 to more bulky group on secondary alcohol 103 and from good leaving 
group tosylate 94 to better leaving group iodide 104. 
2.7 Alkylation of Glycine Ester Enolates 
The next step was to alkylate a glycine anion synthon with the electrophiles synthesized 
in Scheme 2.13. According to the literature, glycine benzophenone imine tert-butyl ester 76b 
has typically been used in these reactions; the tert-butyl ester can be cleaved under the same 
conditions as the benzophenone imine in a single step. For our synthesis we chose the 
corresponding ethyl ester 76a as it is less expensive and simple examples demonstrate that the 
ethyl ester is equally effective (Table 2.1). 
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In order to develop some experience of the asymmetric phase-transfer alkylation of 
imine 76 we repeated some known examples from the literature.  
There are two sets of conditions employed for alkylation with some differences. 
1. Corey’s conditions:36a ten equivalents of CsOH.H2O, five equivalents of electrophile, 
CH2Cl2, -60 °C. An example was shown earlier in Zhu’s synthesis of (-) quinocarcin 
(85) (Scheme 2.9).42,43  
2. Lygo’s conditions:36b,39 50 percent aqueous KOH/NaOH, water, five equivalents of 
electrophile, toluene, -60 °C to room temperature. An example was shown earlier in 
Tohdo’s synthesis of p-bromophenylalanine (39) (Scheme 2.10).  
We initially investigated the alkylation of glycine benzophenone imine ethyl ester (76a) 
with allyl bromide as alkylating agent employing 10 equivalents of base (Table 2.1, Entry 1). The 
same reaction conditions were applied with glycine benzophenone imine tert-butyl ester 76b, 
leading to a comparable yield of the product (Entry 2). Corey36a reported 97% e.e. for the latter 
alkylation. The enantioselectivity of the product from Entry 2 was determined to be 92% e.e. by 
chiral HPLC. We applied the same reaction conditions to a commercially available iodobutane, a 
linear aliphatic alkyl halide, and the yields from both the glycine derivatives were comparable 
(Entries 3 and 4). Lygo’s conditions36b were also tested and the yield was much the same for 
alkylation of both the glycine enolates (Entry 5 and 6). Furthermore, we tried the Lygo conditions 
using a mixture of solvents (Entry 7). The low yield suggested that the ethyl ester hydrolysis was 
competing kinetically with enolate formation and alkylation under the strongly basic conditions.  
Excited that we could achieve the alkylation in good yield under Corey’s conditions, we 
subjected our more complex electrophile 103b to the reaction conditions; no product was 
isolated (Entry 8). Therefore, we switched from the tosylate 103b, to the iodide 104b as a 
superior leaving group (Entry 9). Again no product was isolated. One reason for this could be 
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that the electrophile is unreactive due to the adjacent, bulky TBDPS ether. Therefore, we 
reduced the size of the adjacent protecting group, to the smaller TBS ether. No product was 
isolated from the attempted alkylation using 104a (Entry 10). We raised the temperature to room 
temperature; but again no desired product was formed (Entry 11). We presume that the TBS 
group also provides steric hindrance to the displacement reaction. The reaction was also 
performed, without success, on unprotected alcohol 102 (Entry 12). Proton transfer is a potential 
problem here. 
Table 2.1 Alkylations of glycine enolates. 
 
Entry Glycine Electrophile Conditions Result 
1 76a CH2=CH2CH2Br CsOH.H2O, CH2Cl2, -78→-60 °C, 22 h 95% 
2 76b CH2=CH2CH2Br CsOH.H2O, CH2Cl2, -78→-60 °C, 22 h 85% 
3 76a CH3(CH2)3I CsOH.H2O, CH2Cl2, -78→-60 °C, 22 h 54% 
4 76b CH3(CH2)3I CsOH.H2O, CH2Cl2, -78→-60 °C, 22 h 53% 
5 76a CH3(CH2)3I 50 % aq. KOH, H2O, PhMe, RT, 24 h 50% 
6 76b CH3(CH2)3I 50 % aq. KOH, H2O, PhMe, RT, 24 h 46% 
7 76b CH3(CH2)3I 50 % aq. KOH, CH2Cl2-PhMe (7:1), 24 h 34% 
8 76a 103b CsOH.H2O, CH2Cl2, -78→-60 °C, 22 h - 
9 76a 104b CsOH.H2O, CH2Cl2, -78→-60 °C, 22 h - 
10 76a 104a CsOH.H2O, CH2Cl2, -78→-60 °C, 22 h - 
11 76a 104a CsOH.H2O, CH2Cl2, RT, 22 h - 
12 76b 102 CsOH.H2O, CH2Cl2, -78→-60 °C, 22 h - 
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Collectively, the results described show that activated alkyl halides (e.g., allyl bromide in 
Table 2.1 and benzylic bromides in Schemes 2.9 and 2.10) are the best electrophiles for these 
reactions. The need to engage a five-fold excess of electrophile in these alkylations is not widely 
appreciated and is a drawback when synthetically valuable electrophiles are involved. Even 
then, the use of excess electrophile didn’t afford our desired product. Also, the neighboring silyl 
ether provides severe steric hindrance to the displacement reaction. 
We employed commercially available methyl 4-bromobut-2-enoate (107) as the 
electrophile and successful asymmetric alkylation of the glycine imine 76b was achieved as 
shown in Scheme 2.14.  
 
Scheme 2.14 Alkylation of glycine imine with an allylic bromide. 
While looking for a suitable method for diastereoselective epoxidation, or conjugate 
addition of an O-nucleophilic species, we became aware of another approach that might deliver 
the 1,3-syn amino alcohol in a more reliable fashion. This will be the subject of Chapter 3. 
2.8 Experimental Section 
2.8.1 General Methods 
All reactions were performed under a dry nitrogen atmosphere unless otherwise noted. 
Reagents were obtained from commercial sources and used directly; exceptions are noted. 
Diisopropylethylamine, 2,4,6-collidine, pyridine, triethylamine and 2,6-lutidine were dried and 
distilled from CaH2 and stored over KOH pellets. Methanol was distilled from Mg turnings and 
stored over 4 Å molecular sieves. Flash chromatography was performed using silica gel (32-63 
µ) from Dynamic Absorbents Inc. Reactions were followed by TLC on precoated silica plates 
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(200 µm, F-254 from Dynamic Adsorbents Inc.). The compounds were visualized by UV 
fluorescence or by staining with phosphomolybdic acid (PMA), cerium-ammonium-molybdate 
(CAM), ninhydrin, potassium permanganate, or 2,4-dinitrophenylhydrazine (2,4-DNP) stains. 
HPLC was performed on Waters 600E multisolvent delivery system (Waters 2487 dual λ 
absorbance detector). Optical rotations were recorded on JASCO P-2000 digital polarimeter. 
NMR spectra were recorded on a Bruker AV-400-liquid spectrometer. Proton NMR data is 
reported in ppm downfield from TMS as an internal standard. High resolution mass spectra were 
recorded using either an Agilent 6210 time-of-flight MS, or a Hitachi MS-8000 3DQ LC-ion trap 
mass spectrometer with electrospray ionization.   
2.8.2 Procedures 
 (S)-Dibenzyl 2-hydroxysuccinate (92) 
Benzyl alcohol (1.50 mL, 1.61 g, 14.90 mmol, 2.00 equiv.) and p-toluenesulfonic acid 
monohydrate (14 mg, 0.074 mmol, 0.01 equiv.) were added to a solution of D-malic acid (91) 
(1.00 g, 7.46 mmol, 1.00 equiv.) in dry toluene (12 mL). The reaction mixture was heated under 
reflux with a Dean-Stark apparatus to effect the azeotropic removal of water. When no more 
water appeared in the distillate, the mixture was allowed to cool to rt and washed with saturated 
aqueous NaHCO3 (25 mL) and brine (25 mL). The organic layer was dried over MgSO4, filtered 
and evaporated. The residue was purified by flash column chromatography on silica gel with 
Hex:EtOAc (4:1) as eluent to give the dibenzyl ester 92 as a colorless oil (80%). Rf 0.42 (4:1 
Hex-EtOAc). [α]D
25 +42.98 (c 2.5, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ 2.80 (dd, J = 16.4, 6.1 
Hz, 1H), 2.86 (dd, J = 16.4, 4.7 Hz, 1H), 3.41 (br s, 1H), 4.52 (dd, J = 5.9, 4.8 Hz, 1H), 5.06 (s, 
2H), 5.13 (s, 2H), 7.24-7.33 (m, 10H); 13C NMR (CDCl3, 100 MHz) δ 38.8, 66.8, 67.5, 67.6, 
128.3, 128.4, 128.5, 128.6, 128.7, 135.2, 135.6, 170.3, 173.2. HRMS (ESI) calcd for C18H19O5 
(M+H)+ 315.1227, obsd 315.1220. 
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 (S)-Benzyl 3,4-dihydroxybutanoate (93) 
Borane-dimethylsulfide complex (175 µL, 0.350 mmol, 2.0 M solution in THF, 1.10 
equiv.) was added dropwise over 15 min to a solution of (S)-dibenzyl-2-hydroxysuccinate (92) 
(100 mg, 0.318 mmol, 1.00 equiv.) in dry THF (1 mL) at 0 °C under N2. After 1 h of stirring, 
sodium borohydride (0.6 mg, 0.016 mmol, 0.05 equiv.) was added and the mixture was stirred 
overnight at rt. The mixture was quenched by the addition of methanol (1.5 mL) and stirring 
continued for 30 min. The solvent was evaporated and the residue purified by column 
chromatography on silica gel (1:1 Hex-EtOAc) to obtain diol 93 as a colorless oil (41 mg, 61%). 
Rf  0.31 (1:1 Hex-EtOAc).  [α]D
25 +18.84 (c 1, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ 2.49 (dd, J = 
16.3, 4.3 Hz, 1H) 2.55 (dd, J = 16.3, 8.4 Hz, 1H), 3.35 (br s, 2H)  3.48 (dd, J = 11.4, 6.4 Hz, 1H) 
3.62 (dd, J = 11.4, 3.5 Hz, 1H), 4.08-4.17 (m, 1H), 5.13 (s, 1H), 7.30-7.35 (m, 5H); 13C NMR 
(CDCl3, 100 MHz) δ 37.8, 65.7, 66.7, 68.6, 128.3, 128.4, 128.6, 135.6, 172.3. HRMS (ESI) calcd 
for C11H14NaO4 (M+Na)
+ 233.0784, obsd 233.0793. 
 (S)-Benzyl 3-hydroxy-4-(tosyloxy)butanoate (94) 
To a solution of diol 93 (200.0 mg, 0.95 mmol, 1.00 equiv.) in dry CH2Cl2 (2.5 mL) was 
added successively nBu2SnO (7.0 mg, 0.03 mmol, 0.03 equiv.), a solution of Et3N (135 µL, 98.4 
mg, 0.97 mmol, 1.02 equiv.) in dry CH2Cl2 (2.5 mL) and p-toluenesulfonyl chloride (190.7 mg, 
0.97 mmol, 1.02 equiv.) at rt. The mixture was stirred for 6 h, then treated with brine (10 mL) 
The aqueous layer was extracted with CH2Cl2 (4 x 15 mL). The combined organic layers were 
dried with anhydrous MgSO4, filtered and concentrated. The residue was purified by silica gel 
column chromatography (2:1 Hex-EtOAc) to obtained tosylated product 94 (222 mg, 64%), Rf 
0.43 (1:1 Hex-EtOAc). [α]D
25 +7.34 (c 1.5, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ 2.00 (br s, 1H), 
2.45 (s, 3H), 2.53 (dd, J = 16.6, 4.8 Hz, 1H), 2.62 (dd, J = 16.7, 7.5 Hz, 1H), 4.04 (d, J = 8.3 Hz, 
2H), 4.25-4.28 (m, 1 H), 5.14 (s, 2H), 7.26-7.39 (m, 7H), 7.78 (d, J = 8.3 Hz, 2H); 13C NMR 
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(CDCl3, 100 MHz) δ 21.7, 37.4, 66.0, 66.9, 71.9, 128.0, 128.2, 128.5, 128.7, 130.0, 132.5, 
135.3, 145.2, 171.4. HRMS (ESI) calcd for C18H21O6S (M+H)
+ 365.1053, obsd 365.1043. 
 (S)-Benzyl 3-hydroxy-4-iodobutanoate (102) 
Sodium iodide (42 mg, 0.274 mmol, 2.0 equiv.) was added to a solution of (S)-Benzyl 3-
hydroxy-4-(tosyloxy)butanoate (94) (50 mg, 0.137 mmol, 1.0 equiv.) in acetone (5 mL). The 
mixture was stirred and heated at reflux overnight. Saturated aqueous NaHCO3 (4 mL) was 
added and the mixture extracted with diethyl ether (3 x 10 mL). The combined organic layers 
were washed with brine (5 mL), dried over MgSO4, filtered and concentrated. Flash 
chromatography on silica gel (Hex-EtOAc 4:1) afforded as a brownish yellow oil 102 (24 mg, 
55%). Rf 0.46 (2:1 Hex-EtOAc). [α]D
25 +12.31 (c 1, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ 2.00 (br 
s, 1H), 2.60 (dd, J = 15.4, 7.1 Hz, 1H), 2.73 (dd, J = 15.4, 4.9 Hz, 1H), 3.21-3.30 (m, 2H), 4.05 
(app. pent, J = 5.5 Hz, 1H), 5.09 (d, J = 12.3 Hz, 1H), 5.14 (d, J = 12.3 Hz, 1H), 7.25-7.35 (m, 
5H); 13C NMR (CDCl3, 100 MHz) δ 9.0, 37.8, 66.7, 128.3, 128.4, 128.6, 135.6, 172.3. HRMS 
(ESI) calcd for C11H14IO (M+H)
+  320.9817, obsd 320.9821. 
 (S)-Benzyl 3-[(tert-butyldimethylsilyl)oxy]-4-(tosyloxy)butanoate (103a) 
2,6-Lutidine (178 µL, 163 mg, 1.5 mmol, 3.0 equiv.) was added dropwise to a solution of 
(S)-benzyl 3-hydroxy-4-(tosyloxy)butanoate (94) (185 mg, 0.5 mmol, 1.0 equiv.) in dry CH2Cl2 
(7.5 mL) under N2 at rt. The mixture was stirred for 30 min before the dropwise addition of 
TBDMSOTf (140 µL, 161 mg, 0.6 mmol, 1.2 equiv.). The mixture was stirred overnight, the 
solvent evaporated and the residue purified by silica gel chromatography, eluting with 2:1→1:1 
(Hex-EtOAc), to give TBS ether 103a (206 mg, 85%); Rf 0.38 (1:1 Hex-EtOAc). [α]D
25 +8.01 (c 1, 
CHCl3). 
1H NMR (CDCl3, 400 MHz) δ 0.02 (s, 3H), 0.03 (s, 3H), 0.81 (s, 9H), 2.45 (s, 3H), 2.49 
(dd, J = 15.4, 6.9 Hz, 1H), 2.56 (dd, J = 15.4, 5.2 Hz, 1H), 3.93-4.00 (m, 2H), 4.3-4.35 (m, 1H), 
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5.06 (d, J = 12.3 Hz, 1H), 5.12 (d, J = 12.3 Hz, 1H), 7.32-7.38 (m, 5H), 7.77-7.79 (m, 4H), 13C 
NMR (CDCl3, 100 MHz) δ -5.1, -4.7, 17.9, 21.6, 25.6, 39.5, 66.5, 67.2, 72.3, 128.0, 128.2, 
128.3, 128.6, 129.9, 132.8, 135.6, 144.9, 170.3. HRMS (ESI) calcd for C24H35O6SSi (M+H)
+ 
479.1918, obsd 479.1925. 
 (S)-Benzyl 3-[(tert-butyldiphenylsilyl)oxy]-4-(tosyloxy)butanoate (103b) 
2,6-Lutidine (168 µL, 155 mg, 1.44 mmol, 3.5 equiv.) was added dropwise to a solution 
of (S)-benzyl 3-hydroxy-4-(tosyloxy)butanoate (94) (150 mg, 0.41 mmol, 1.0 equiv.) in dry 
CH2Cl2 (7.5 mL) under N2 at rt. The mixture was stirred for 30 min before the dropwise addition 
of TBDPSOTf (320 µL, 320 mg, 0.82 mmol, 2.0 equiv.). The mixture was stirred overnight, the 
solvent evaporated and the residue purified by silica gel chromatography, eluting with 5:1 (Hex-
EtOAc) to yield TBDPS ether 103b (141 mg, 57%). Rf 0.62 (1:1 Hex-EtOAc). [α]D
25 +5.76 (c  
0.75, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ 0.98 (s, 9H), 2.41 (s, 3H), 2.54 (d, J = 5.9 Hz, 2H), 
3.89-3.98 (m, 2H). 4.23-4.27 (m, 1H), 4.90 (d, J = 12.3 Hz, 1H), 4.99 (d, J = 12.3 Hz, 1H), 7.21-
7.53 (m, 10H), 7.54-7.59 (m, 5H);  13C NMR (CDCl3, 100 MHz) δ 19.3, 21.8, 26.9, 39.0, 66.6, 
67.9, 71.8, 127.8, 128.1, 128.4, 128.7, 129.9, 130.1, 132.9, 133.0, 133.1, 135.0, 135.7, 135.9, 
136.0, 144.9, 170.2. HRMS (ESI) calcd for C34H39O6SSi (M+H)
+ 603.2231, obsd 603.2212. 
 (S)-Benzyl 3-[(tert-butyldimethylsilyl)oxy]-4-iodobutanoate (104a) 
Sodium iodide (392 mg, 2.08 mmol, 8.0 equiv.) was added to a solution of (S)-benzyl 3-
[(tert-butyldimethylsilyl)oxy]-4-(tosyloxy)butanoate 103a (125 mg, 0.26 mmol, 1.0 equiv.) in 
acetone (5 mL). The mixture was stirred and heated at reflux overnight. Saturated aqueous 
NaHCO3 (10 mL) was added and the mixture extracted with diethyl ether (5 x 15 mL). The 
combined organic layers were washed with brine (20 mL), dried over MgSO4, filtered and 
concentrated. Flash chromatography on silica gel (Hex-EtOAc 5:1) afforded as a brownish 
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yellow oil 104a (88 mg, 78%). Rf 0.58 (2:1 Hex-EtOAc). [α]D
25 +10.01 (c 1, CHCl3). 
1H NMR 
(CDCl3, 400 MHz) δ 0.04 (s, 3H), 0.11 (s, 3H), 0.87 (s, 9H), 2.60 (dd, J = 15.4, 7.1 Hz, 1H), 2.73 
(dd, J = 15.4, 4.9 Hz, 1H), 3.21-3.30 (m, 2H), 4.05 (app. pent, J = 5.5 Hz, 1H), 5.09 (d, J = 12.3 
Hz, 1H), 5.14 (d, J = 12.3 Hz, 1H), 7.25-7.35 (m, 5H); 13C NMR (CDCl3, 100 MHz) δ -4.9, -4.5, 
12.8, 17.9, 25.7, 42.6, 66.5, 68.4, 128.3, 128.4, 128.6, 135.7, 170.7. HRMS (ESI) calcd for 
C17H28IO3Si (M+H)
+  435.0847, obsd 435.0831. 
 (S)-Benzyl 3-[(tert-butyldiphenylsilyl)oxy]-4-iodobutanoate (104b) 
Sodium iodide (169 mg, 1.13 mmol, 8.0 equiv.) was added to a solution of (S)-benzyl 3-
[(tert-butyldiphenylsilyl)oxy]-4-(tosyloxy)butanoate (103b) (85 mg, 0.14 mmol, 1.0 equiv.) in 
acetone (3.5 mL). The mixture was stirred and heated at reflux overnight. Saturated aqueous 
NaHCO3 (7 mL) was added and the mixture extracted with diethyl ether (5 x 10 mL). The 
combined organic layers were washed with brine (15 mL), dried over MgSO4, filtered and 
concentrated. Flash chromatography on silica gel (Hex-EtOAc 5:1) afforded 104b as a yellow oil 
(50 mg, 64%). Rf 0.58 (2:1 Hex-EtOAc). [α]D
25 +5.01 (c 1, CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 
1.05 (s, 9H), 2.65 (dd, J = 15.7, 6.1 Hz, 1H), 2.75 (dd, J = 15.7, 5.9 Hz, 1H), 3.20 (d, J =  4.6 Hz, 
2H), 3.92-3.98 (m, 1H), 5.65 (d, J = 12.4 Hz, 1H), 5.04 (d, J = 12.4 Hz, 1H), 7.25-7.45 (m, 10H), 
7.62-7.69 (m, 5H); 13C NMR (CDCl3, 100 MHz) δ -0.0, 13.4, 19.3, 26.9, 42.2, 66.4, 68.7, 127.7, 
127.8, 128.2, 128.5, 129.9, 130.0, 133.2, 135.8, 135.9, 170.4. HRMS (ESI) calcd for C27H32IO3Si 
(M+H)+  559.1160, obsd 559.1153. 
 Ethyl 2-[(diphenylmethylene)amino]pent-4-enoate (Table 2.1, Entry 1) 
Allyl bromide (144 µL, 199.6 mg, 1.65 mmol, 5.0 equiv.) was added dropwise to a 
mixture of ethylglycinate benzophenone imine (76a) (88.2 mg, 0.330 mmol, 1.0 equiv.), O(9)-
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allyl-N-9-anthracenylmethylcinchonidium bromide (86) (20.0 mg, 0.033 mmol, 0.1 equiv.) and 
CsOH.H2O (554.2 mg, 3.300 mmol, 10.0 equiv.) in CH2Cl2 (3 mL) at -78 °C. The mixture was 
warmed to -60 °C and stirred vigorously for 24 h. The suspension was diluted with ether (30 
mL), washed with water (2 x 10 mL), brine (20 mL), dried over MgSO4, filtered and 
concentrated. Flash chromatography on silica gel (Hex-EtOAc 4:1) afforded ethyl 2-
[(diphenylmethylene)amino]pent-4-enoate as a yellow colored oil (82 mg, 80%). Rf 0.39 (1:1 
Hex-EtOAc). [α]D
25 +9.81 (c 1, CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 1.25 (t, J = 7.1 Hz, 3H), 
2.61 (dd, J = 14.0, 7.5 Hz, 1H), 2.68 (dd, J = 13.0, 7.0 Hz, 1H), 4.10-4.22 (m, 3H), 5.01 (d, J = 
10.8 Hz, 1H), 5.06 (dd, J = 16.5, 1.38 Hz, 1H), 5.63-5.74 (m , 1H), 7.16-7.46 (m, 7H), 7.48-7.57 
(m, 3H); 13C NMR (CDCl3, 100 MHz) δ 14.2, 38.1, 60.9, 65.3, 117.5, 127.9, 128.0, 128.3, 128.5, 
128.8, 132.4, 134.4, 139.6, 170.5, 171.8. HRMS (ESI) calcd for C20H22NO2 (M+H)
+  308.1620, 
obsd 308.1614. 
 tert-Butyl 2-[(diphenylmethylene)amino]pent-4-enoate (Table 2.1, Entry 2) 
Allyl bromide (74 µL, 102.2 mg, 0.845 mmol, 5.0 equiv.) was added dropwise to a 
mixture of tert-butylglycinate benzophenone imine (76b) (50.0 mg, 0.170 mmol, 1.0 equiv.), 
O(9)-allyl-N-9-anthracenylmethylcinchonidium bromide (86) (10.2 mg, 0.017 mmol, 0.1 equiv.) 
and CsOH.H2O (283.8 mg, 1.700 mmol, 10.0 equiv.) in CH2Cl2 (3 mL) at -78 °C. The mixture 
was warmed to -60 °C and stirred vigorously for 24 h. The suspension was diluted with ether (30 
mL), washed with water (2 x 10 mL), brine (20 mL), dried over MgSO4, filtered and 
concentrated. Flash chromatography on silica gel (Hex-EtOAc 4:1) afforded tert-butyl 2-
[(diphenylmethylene)amino]pent-4-enoate as a yellow oil (48 mg, 85%, 92% e.e.). The 
enantiomeric excess was determined by HPLC analysis using Chiralcel OD-H column (5% 
iPrOH-Hex, 0.5 mL/min); major enantiomer tr = 8.7 min and minor enantiomer tr = 17.7 min; 
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Detection 254 nm. Rf 0.40 (1:1 Hex-EtOAc). [α]D
25 +8.21 (c 1, CHCl3); 
1H NMR (CDCl3, 400 
MHz) δ 1.44 (s, 9H), 2.59 (dd, J =14.0, 7.5 Hz, 1H), 2.67 (dd, J = 14.0, 6.6 Hz, 1H), 4.00 (dd, J 
= 7.4, 5.4 Hz, 1H), 5.0 (d, J = 10.1 Hz, 1H), 5.06 (d, J = 17.1 Hz, 1H), 5.67-5.78 (m, 1H), 7.16-
7.56 (m, 10 H); 13C NMR (CDCl3, 100 MHz) δ 28.1, 38.2, 65.9, 81.0, 117.2, 128.0, 128.3, 128.4, 
128.5, 128.8, 130.1, 130.2, 132.4, 134.8, 136.7, 139.8, 170.1, 170.9. HRMS (ESI) calcd for 
C22H26NO2 (M+H)
+  336.1958, obsd 336.1966. 
 Ethyl 2-[(diphenylmethylene)amino]hexanoate (Table 2.1, Entry 3) 
Iodobutane (34 µL, 54.5 mg, 0.296 mmol, 1.2 equiv.) was added dropwise to a mixture 
of ethylglycinate benzophenone imine (76a) (66.2 mg, 0.250 mmol, 1.0 equiv.), O(9)-allyl-N-9-
anthracenylmethylcinchonidium bromide (86) (15.0 mg, 0.025 mmol, 0.1 equiv.) and 50% 
aqueous KOH (0.5 mL) in toluene (3 mL) at rt. The mixture was stirred vigorously for 24 h and 
extracted with EtOAc (4 x 15 mL). The combined organic layers were washed with brine (20 
mL), dried over MgSO4, filtered and concentrated. Flash chromatography on silica gel (Hex-
EtOAc 4:1) afforded ethyl 2-[(diphenylmethylene)amino]hexanoate as a yellow oil (40 mg, 50%). 
Rf 0.43 (2:1 Hex-EtOAc). [α]D
25 +20.50 (c 1, CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 0.83 (t, J = 7.4 
Hz, 3H), 1.17-136 (m, 7H), 1.89 (dd, J = 15.0, 7.5 Hz, 2H), 4.04 (t, J = 6.6 Hz, 1H), 4.16 (t, J = 
7.0 Hz, 2H), 7.25-7.61 (m, 6H), 7.79-7.81 (m, 4H) ; 13C NMR (CDCl3, 100 MHz) δ 13.8, 14.2, 
19.3, 28.3, 32.9, 66.9, 127.9, 128.0, 128.3, 128.5, 128.8, 130.0, 130.2, 132.4, 137.6, 169.9, 
170.2. HRMS (ESI) calcd for C21H26NO2 (M+H)
+  324.1960, obsd 324.1953. 
 tert-Butyl 2-[(diphenylmethylene)amino]hexanoate (Table 2.1, Entry 4) 
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Iodobutane (97 µL, 155.5 mg, 0.845 mmol, 5.0 equiv.) was added dropwise to a mixture 
of tert-butylglycinate benzophenone imine (76b) (50.0 mg, 0.170 mmol, 1.0 equiv.), O(9)-allyl-N-
9-anthracenylmethylcinchonidium bromide (86) (10.2 mg, 0.017 mmol, 0.1 equiv.) and 
CsOH.H2O (283.8 mg, 1.700 mmol, 10.0 equiv.) in CH2Cl2 (3 mL) at -78 °C. The mixture was 
warmed to -60 °C and stirred vigorously for 24 h. The suspension was diluted with ether (30 
mL), washed with water (2 x 10 mL), brine (20 mL), dried over MgSO4, filtered and 
concentrated. Flash chromatography on silica gel (Hex-EtOAc 4:1) afforded tert-butyl 2-
[(diphenylmethylene)amino]hexanoate as a yellow oil (38 mg, 51%). Rf 0.44 (1:1 Hex-EtOAc). 
[α]D
25 +15.01 (c 1, CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 0.92 (t, J = 7.4 Hz, 3H), 1.37-1.43 (m, 
2H), 1.46 (s, 9H), 1.80 (pent, J = 7.1 Hz, 2H), 3.19 (t, J = 7.0 Hz, 2H), 4.12 (s, 1H), 7.17-7.41 
(m, 10H); 13C NMR (CDCl3, 100 MHz) δ 6.8, 12.9, 23.6, 28.1, 35.5, 56.4, 81.0, 127.7, 128.0, 
128.6, 128.7, 130.3, 136.2, 139.4, 169.8, 171.4. HRMS (ESI) calcd for C23H30NO2 (M+H)
+  
352.2271, obsd 352.2282. 
 (S,E)-6-tert-butyl-1-methyl-5-[(diphenylmethylene)amino]hex-2-enedioate (108) 
(E)-Methyl-4-bromobut-2-enoate (107) (151 mg, 0.845 mmol, 5.0 equiv.) was added 
dropwise to a mixture of tert-butylglycinate benzophenone imine (76b) (50 mg, 0.170 mmol, 1.0 
equiv.), O(9)-allyl-N-9-anthracenylmethylcinchonidium bromide (86) (11 mg, 0.017 mmol, 0.1 
equiv.) and CsOH.H2O (2834 mg, 1.700 mmol, 10.0 equiv.) in CH2Cl2 (5 mL) at -78 °C. The 
mixture was warmed to -60 °C and stirred vigorously for 24 h. The suspension was diluted with 
ether (30 mL), washed with water (2 x 10 mL), brine (20 mL), dried over MgSO4, filtered and 
concentrated. Flash chromatography on silica gel (Hex-EtOAc 5:1) afforded compound 108 as a 
yellow oil (60 mg, 89%). Rf 0.30 (4:1 Hex-EtOAc). [α]D
25 +39.24 (c 1, CHCl3); 
1H NMR (CDCl3, 
400 MHz) δ 1.46 (s, 9H), 2.59 (dd, J =14.0, 7.5 Hz, 1H), 2.67 (dd, J = 14.0, 6.6 Hz, 1H), 3.73 (s, 
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3H), 4.00 (dd, J = 7.4, 5.4 Hz, 1H), 5.0 (d, J = 10.1 Hz, 1H), 5.06 (d, J = 17.1 Hz, 1H), 5.67-5.78 
(m, 1H), 7.16-7.56 (m, 10 H); 13C NMR (CDCl3, 100 MHz) δ 28.1, 38.2, 65.9, 81.0, 117.2, 128.0, 
128.3, 128.4, 128.5, 128.8, 130.1, 130.2, 132.4, 134.8, 136.7, 139.8, 168.8, 170.1, 170.9. 
HRMS (ESI) calcd for C24H28NO4 (M+H)
+  394.2610, obsd 394.2614. 
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2.8.3 Spectra 
Compound 92 (Scheme 2.11) - 1H NMR spectrum 
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Compound 92 (Scheme 2.11) - 13C NMR spectrum 
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Compound 93 (Scheme 2.11) - 1H NMR spectrum 
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Compound 93 (Scheme 2.11) - 13C NMR spectrum 
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Compound 94 (Scheme 2.13) - 1H NMR spectrum 
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Compound 94 (Scheme 2.13) - 13C NMR spectrum 
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Compound 102 (Scheme 2.13) - 1H NMR spectrum 
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Compound 102 (Scheme 2.13) - 13C NMR spectrum
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Compound 103a (Scheme 2.13) - 1H NMR spectrum 
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Compound 103a (Scheme 2.13) - 13C NMR spectrum 
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Compound 103b (Scheme 2.13) – 1H NMR spectrum 
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Compound 103b (Scheme 2.13) - 13C NMR spectrum 
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Compound 104a (Scheme 2.13) – 1H NMR spectrum 
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Compound 104a (Scheme 2.13) - 13C NMR spectrum 
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Compound 104b (Scheme 2.13) – 1H NMR spectrum 
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Compound 104b (Scheme 2.13) – 13C NMR spectrum 
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Table 2.1, Entry 1 – 1H NMR spectrum 
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Table 2.1, Entry 1 – 13C NMR spectrum 
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Table 2.1, Entry 2 – 1H NMR spectrum
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Table 2.1, Entry 2 – 13C NMR spectrum 
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Table 2.1, Entry 3 – 1H NMR spectrum 
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Table 2.1, Entry 3 – 13C NMR spectrum 
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Table 2.1, Entry 4 – 1H NMR spectrum 
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Table 2.1, Entry 4 – 13C NMR spectrum 
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Compound 108 (Scheme 2.14) – 1H NMR spectrum 
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Compound 108 (Scheme 2.14) – 13C NMR spectrum 
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CHAPTER 3: AN AMINE CONJUGATE ADDITION APPROACH TO AHAD 
3.1 Conjugate Addition Reactions to Afford β-Amino Acids 
Conjugate addition reactions are well known in organic chemistry. Most familiar is the 
conjugate addition of organometallic reagents to α,β-unsaturated carbonyl compounds for 
assembling structurally complex organic molecules.49 For example, addition of the 
functionalized organocuprate reagent obtained from iodide 110 to the chiral cyclopentenone 111 
occurred in a trans-selective fashion to give intermediate compound 112 (Scheme 3.1) which 
was used for the synthesis of prostaglandin E2.
50,51,52 
 
Scheme 3.1 Preparation of intermediate for the synthesis of prostaglandin E2 through conjugate 
addition.      
                       
Over the last two decades, there has been an increasing interest in functionalized β-
amino acids and their derivatives53 due to their biologically important properties and their 
occurrence in natural products (Figure 3.1). β-Alanine (113) is a β-amino acid that occurs in the 
western hemisphere of theonellamide C (1) (Figure 1.1, Chapter 1). (3R)-β-Leucine54 (114) 
exists in equilibrium with (2S)-α-leucine and their interconversion is catalyzed by leucine-2,3-
aminomutase.55 β-Arginine is found in the natural dipeptide antibiotic TAN 1057 (115).56 N-
Acetyl-β-phenylalanine (116) is a substrate for a bacterial tRNA(Phe) peptidyltransferase.57 β-
Amino-α-phenylpropionic acid is present in the antibiotic betacine (117) which displays a broad 
spectrum of antibacterial activity58 and its derivatives show important neurophysiological control 
properties.59 
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Figure 3.1 β-Amino acids (highlighted in red where they are part of a natural product). 
A potentially straightforward method for the synthesis of β-amino acids is the conjugate 
addition of nitrogen nucleophiles to α,β-unsaturated carboxylic acid derivatives (Scheme 3.2).  
 
Scheme 3.2 General retrosynthesis of conjugate amine addition.                             
This reaction is also known as an aza-Michael reaction wherein there is 1,4-addition of a 
nitrogen nucleophile to the β-carbon vinylogously attached to an electron-withdrawing group.60 
There are two major approaches to achieve asymmetric induction: by using chiral auxiliaries, 
typically amines (Scheme 3.3-A), or enantiomerically pure starting materials, e.g. a chiral 
acceptor (Scheme 3.3-B) 
 
Scheme 3.3 Examples of the aza-Michael reaction.         
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The first example of an enantioselective conjugate amine addition was reported by 
Jørgensen in 1996.61 They used a titanium BINOL catalyst 125 to catalyze the addition of 
benzyloxyamine (BnONH2) to N-acyloxazolidinone 123. N-Substituted hydroxylamines are more 
nucleophilic than O-substituted hydroxylamines which are useful precursors for β-amino 
acids.62’
62b, 63 High conversions were obtained, but enantioselectivity was moderate (up to 42% 
e.e.) (Scheme 3.4) 
 
Scheme 3.4 Enantioselective conjugate amine addition using BINOL catalyst.                      
Sibi and co-workers have made major contributions to the field of amine conjugate 
additions. They developed a highly enantioselective protocol for the conjugate addition of O-
benzylhydroxylamine to 3,5-dimethylpyrazole-derived enamide 126 using catalytic amounts of a 
chiral Lewis acid prepared from magnesium bromide diethyl etherate and a bisoxazoline 129.53 
β-Amino acid derivatives, e.g., 127, were synthesized in good chemical yields and high e.e. The 
high e.e.’s obtained were accounted by use of Lewis acid along with catalyst (Scheme 3.5).  
       
Scheme 3.5 Conjugate addition using a chiral catalyst and Lewis acid.       
The use of azide as a nucleophile in conjugate addition reactions is also well known.64 
Jacobsen et al. demonstrated the conjugate addition of hydrazoic acid (HN3) to α,β-unsaturated 
imides (e.g. 130) using a chiral aluminium(III)salicylaldimine complex catalyst 132 (Scheme 
3.6).65 
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Scheme 3.6 Conjugate addition using azide as nucleophile.          
Miller and co-workers developed milder reaction conditions for azidation under metal-
free conditions, in which the azide was generated from a mixture of trimethylsilyl azide (TMSN3) 
and pivalic acid in toluene.66,66b, 67 β-Amino acid derivative 134 was obtained in 92% e.e. by 
conjugate addition of azide to enamide 133 mediated by β-turn tripeptide 135 (Scheme 3.7).  
       
Scheme 3.7 Preparation of β-azido derivative.    
3.2 MacMillan Conjugate Addition 
MacMillan and coworkers have developed organocatalysts to achieve a highly chemo- 
and stereoselective amine conjugate addition that is founded upon a rationally designed N-
centered nucleophile, as depicted in Scheme 3.8. 68,69,70  
 
Scheme 3.8 Iminium catalyzed amination requires selective amine participation.                 
They showed that the rate determining step for conjugate addition reactions involving 
carbon and hydrido nucleophiles is the reversible formation of iminium ions from chiral amine 
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catalysts and α,β-unsaturated aldehydes. Moreover, the MacMillan Group illustrated a design 
plan for the enantioselective conjugate amination using iminium catalysis. 
In their design, they stipulated that the amine required to function as a 1,4-addition 
nucleophile must not participate in iminium activation; this presents a racemic pathway via TS-II 
(Scheme 3.8). Moreover, the catalyst, a chiral secondary amine, must perform as an iminium 
catalyst (giving rise to TS-I) but not compete as a nucleophile. The reaction should be kinetically 
controlled, whereby irreversible loss of the nucleophile’s proton (Nu-H) must accompany the 
stereodefining heteroatom addition step. More importantly, this deprotonation step removes the 
possibility of an equilibrium-controlled process involving a reversible N-addition step, a 
thermodynamic pathway that would demand the formation of product mixture. N-
Silyloxycarbamates were deemed to be the best candidates for these requirements and act as 
as the nucleophilic component on the basis that the N−O functionality enhances nucleophilicity 
at the nitrogen center via the α-effect (Figure 3.2)71 (estimated pKa of NH in a silyloxycarbamate 
is 9.0 whereas pKa of regular carbamate is nearly 13).  
 
Figure 3.2 Carbamate nucleophilicity enhanced by the α-effect. 
They successfully applied the organocatalytic amine addition to various substrates. For 
example, exposure of 2-hexenal 137 to the asymmetric amination conditions followed by 
oxidation provided the corresponding β-amino acid 138 with excellent enantioselectivity. The 
cleavage of the N-O bond was accomplished under mildly reducing conditions (Zn/AcOH) 
(Scheme 3.9).72  
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Scheme 3.9 Two-step synthesis of a β-amino acid.  
They also showed that the amino-oxy moiety can be strategically exploited to generate 
1,3-amino alcohols (Scheme 3.10). Hexenal amination was followed by in situ Wittig 
homologation to afford the unsaturated ester 143 in a single step (Scheme 3.10).  
 
Scheme 3.10 Enantioselective synthesis of a 1,3-amino alcohol. 
The amino enoate 143 was exposed to a fluoride ion source which then enabled both 
silyl group removal and intramolecular oxy-Michael addition to afford isoxazolidine 144 with 
excellent yield and diastereocontrol (99% yield, 10:1 syn/anti). The N−O bond was reduced with 
samarium diiodide (SmI2) to afford the 1,3-amino alcohol 145 in high yield (70% yield over three 
steps).73 
3.3 Application of the MacMillan Strategy to Ahad 
According to Scheme 3.11, a new retrosynthesis was designed for Ahad, based on 
MacMillan’s enantioselective organocatalytic amine conjugate addition. The γ-hydroxy group 
would be installed intramolecularly; exposure of 147 to fluoride ion would generate an oxyanion 
that would add in a conjugate fashion to the α,β-unsaturated ester. Wittig homologation of 
aldehyde 148 would afford the α,β-unsaturated ester 147. Conjugate addition of Cbz-NHOTBS 
(136) to a chiral iminium ion generated from aldehyde 149 would occur diastereoselectively to 
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generate the first stereocenter of Ahad. The stereocenter of the chiral auxiliary/catalyst is only 
transient.  
 
Scheme 3.11 Second generation retrosynthesis of Ahad.        
The benzyl tert-butyldimethylsilyloxycarbamate 136a and benzyl tert-
butyldiphenylsilyloxycarbamate 136b were prepared, according to the literature,70 from 
commercially available benzyl hydroxycarbamate (150) (Scheme 3.12).  
 
Scheme 3.12 Synthesis of silyloxy carbamate nucleophiles.                
α,β-Unsaturated aldehyde 149 was synthesized according to Scheme 3.13. 
Diethyl(benzyloxycarbonylmethyl)phosphonate 152 was prepared by hydrolysis of the 
carboxylate ester of triethylphosphonoacetate (151) and conversion to the benzyl ester. 
Compound 154 was prepared via a Horner-Emmons reaction in a biphasic reaction mixture of 
cyclohexane and an aqueous solution of glyoxal dimethyl acetal (153).74,75 Hydrolysis of the 
dimethyl acetal in compound 154 was attempted with various reagents: 10 mole percent p-
toluenesulfonic acid in acetone,74,75 10 mole percent iodine in acetone76 and 25 percent 
aqueous acetic acid.77 The best result was obtained with HCl in acetone78 which led to the 
formation of aldehyde 149 (Scheme 3.13). 
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Scheme 3.13 Synthesis of aldehyde 149  
In order to develop some experience of the enantioselective organocatalytic amine 
conjugate addition, we repeated a known example from the literature.70 We investigated the 
exposure of crotonaldehyde (155) to benzyl tert-butyldimethylsilyloxycarbamate (136a) in the 
presence of the (R,R)-imidazolidinone catalyst 140 with p-toluenesulfonic acid (Scheme 3.14). 
This provided the β-amino aldehyde product 156 that was subjected to Wittig homologation to 
afford the unsaturated ester 157. Although we recognized that we would need the (S,S)-catalyst 
to give the (2S,4R) stereochemistry of Ahad, we began investigations with the (R,R)-catalyst 
140 because it was on-hand. 
 
Scheme 3.14 Enantioselective organocatalytic conjugate amination.         
MacMillan’s 2006 communication stated that variation in the carbamate (Boc, Cbz, 
Fmoc) and trialkylsilyl (TBS, TBDPS) groups is possible. Therefore, we tried the conjugate 
addition of benzyl tert-butyldimethylsilyloxycarbamate 136a to aldehyde 149 under their 
standard reactions conditions. Unfortunately, no product 148a was isolated (Scheme 3.15). 
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Scheme 3.15 Attempted synthesis of β-amino aldehyde 148a.                 
While the scope for variation in reaction components was emphasized in their paper, we 
note with interest that the conjugate addition of tert-butyl-(tert-butyldiphenylsilyloxy)carbamate 
(141b) with methyl 3-formoylacrylate (158) was reported in the presence of a stronger acid co-
catalyst (trifluoroacetic acid, TFA) (Scheme 3.16). A more hindered/stable silyloxycarbamate 
and elevated reaction temperature afforded compound 159. This example is particularly relevant 
to our similarly electron-deficient electrophile. 
 
Scheme 3.16 Conjugate amine addition to electron deficient electrophile.  
Therefore, we switched from the tert-butyldimethylsilyl group (TBS), to the tert-
butyldiphenylsilyl (TBDPS) protecting group for our hydroxylamine nucleophile. We presume 
that the TBS group is less stable than the TBDPS protecting group in the presence of a strong 
acid (TFA). The conjugate addition of compound 136b to compound 149 was performed using 
the TFA salt of (R,R) chiral amine catalyst 140 (Scheme 3.17). This afforded compound 148b in 
31% yield. These addition reactions were impossible to follow by TLC because the intermediate 
iminium species was hydrolyzed on silica gel but progress can be monitored by 1H NMR (Figure 
3.3). The product of conjugate addition showed the disappearance of olefinic H1 and H2 and 
appearance of Hα and Hβ on sp3 C. Wittig reaction of aldehyde 148b with methyl-
(triphenylphosphoranylidene)-acetate (142) afforded unsaturated ester 147b (Scheme 3.17). 
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Scheme 3.17 Synthesis of α,β-unsaturated ester 147b. 
 
 
Figure 3.3 Monitoring the conjugate addition reaction by 1H NMR.  
In terms of the mechanism of the reaction, the lone pair on the nitrogen attacks the 
carbonyl carbon of the aldehyde to form the complex 160. Protonation of the aminal facilitates 
the elimination of water. The intermediate iminium ion species 162 is planar and the amine 
nucleophile will come from the opposite face of the tBu and Bn groups flanking the iminium ion 
nitrogen to give the desired product after hydrolysis (Scheme 3.18). 
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Scheme 3.18 Mechanism of  stereoselctive conjugate addition. 
Treatment of compound 147b with tetra-n-butylammonium fluoride (TBAF) in the 
presence of acetic acid removed the TBDPS ether but did not give the cyclized product (2R,4S)-
163 (Scheme 3.19). The low yield of the conjugate addition product and subsequent difficulties 
in achieving the intramolecular oxy-Michael addition to afford the isoxazolidine led us to 
investigate other organocatalysts which are commercially available and may meet our 
requirements. 
 
Scheme 3.19 Attempted synthesis of isoxazolidine. 
In 2007, Cordova et al.79 used a chiral pyrrolidine-based catalyst 165 for these types of 
conjugate addition reactions. They reported that simple proline-derived compounds catalyze 
highly enantioselective conjugate additions of protected N-silyloxycarbamates to α,β-
unsaturated aldehydes. The reaction gives access to the β-amino aldehydes in good yields and 
82–99% e.e. Reactions were conveniently performed at room temperature (Scheme 3.20). 
 
Scheme 3.20 Enantioselective conjugate amine addition using a pyrrolidine-based catalyst. 
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Therefore, we investigated the conjugate addition of CbzNHOTBS 136a to α,β-
unsaturated aldehyde 149 with catalyst 165. We obtained our first desired stereocenter as 2S. 
This catalyst gave us a better yield of the conjugate addition product 148a compared with the 
MacMillan catalyst 140. Compound 148a was then subjected to a Wittig reaction to obtain 147a 
(Scheme 3.21). 
 
Scheme 3.21 Synthesis of α,β-unsaturated ester 147a. 
Treatment of compound 147a with fluoride ion facilitated silyl group removal with 
concomitant, intramolecular oxy-Michael addition to afford isooxazolidine (2S,4R)-163. Initially, 
we attempted the reaction with 1.5 equivalents each of tetrabutylammonium fluoride solution 
and acetic acid, but no product was observed. Switching to tetrabutylammonium fluoride 
solution containing 5 percent water gave a 65% yield of the product. Compound (2S,4R)-163 
was then subjected to hydrogenolysis80 to afford unprotected Ahad 167 (Scheme 3.22). 
 
Scheme 3.22 Synthesis of unprotected Ahad.         
The next challenge was to find the right combination of protecting groups for Ahad that 
would be compatible with the synthesis of the western hemisphere of theonellamide C. Chapter 
4 will address this issue of protecting group strategy and will reveal that the δ-COOMe, 
introduced in the Wittig reaction, was incompatible with other protecting groups on Ahad.   
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3.4 Experimental Section 
3.4.1 General Methods 
The general methods are as described in Chapter 2. 
3.4.2 Procedures 
 Benzyl (tert-butyldimethylsilyl)oxycarbamate (136a) 
Triethylamine (249 µL, 181 mg, 1.79 mmol, 1.2 equiv.) was added to a solution of 
benzyl-N-hydroxycarbamate (250 mg, 1.49 mmol, 1.0 equiv.) in dry CH2Cl2 (5 mL) under N2. 
The mixture was cooled to 0 °C and TBSCl (270 mg, 1.79 mmol, 1.2 equiv.) was added. The 
reaction mixture was warmed to rt and stirred overnight. The mixture was washed with water (5 
mL) and brine (5 mL) and the organic layer was dried over MgSO4, filtered and concentrated. 
Flash chromatography on silica gel (Hex-EtOAc 4:1→1:2) afforded 136a as a clear oil (321 mg, 
77%). Rf 0.66 (2:1 Hex-EtOAc). 
1H NMR (CDCl3, 400 MHz) δ 0.15 (s, 6H), 0.94 (s, 9H), 5.16 (s, 
2H), 7.02 (s, 1H), 7.30-7.35 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ -5.8, 18.0, 25.9, 67.6, 128.3, 
128.4, 128.5, 135.7, 158.6. HRMS (ESI) calcd for C14H24NO3Si (M+H)
+ 282.1520, obsd 
282.1516. 
 Benzyl tert-butyldiphenylsilyloxycarbamate (136b) 
Triethylamine (0.83 mL, 0.605 g, 5.98 mmol, 2.0 equiv.) was added to a solution of 
benzyl-N-hydroxycarbamate (0.500 g, 2.99 mmol, 1.0 equiv.) in dry CH2Cl2 (15 mL) under N2. 
The mixture was cooled to 0 °C and TBDPSCl (1.55 mL, 1.644 g, 5.98 mmol, 2.0 equiv.) was 
added. The reaction mixture was warmed to rt and stirred overnight. The mixture was washed 
with water (30 mL) and brine (25 mL) and the organic layer was dried over MgSO4, filtered and 
concentrated. Flash chromatography on silica gel (Hex-EtOAc 8:1→5:1) afforded as 136b a 
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clear oil (910 mg, 75%). Rf 0.39 (2:1 Hex-EtOAc). 
1H NMR (CDCl3, 400 MHz) δ 1.12 (s, 9H), 
5.07 (s, 2H), 6.97 (s, 1H), 7.24-7.45 (m, 11H), 7.70-7.73 (m, 4H); 13C NMR (CDCl3, 100 MHz) δ 
19.1, 26.9, 67.6, 127.7, 127.9, 128.4, 128.6, 129.7, 130.3, 131.7, 134.9, 135.6, 135.8, 157.9. 
HRMS (ESI) calcd for C24H27NNaO3Si (M+Na)
+ 428.1652, obsd 428.1643. 
 Benzyl 2-(diethoxyphosphoryl)acetate (152) 
Triethylphosphonoacetate (151) (500 µL, 560 mg, 2.49 mmol, 1.00 equiv.) was dissolved 
in 1M NaOH (1 mL, 2.49 mmol, 1.0 equiv.) and stirred at 60 °C overnight. The ethanol formed in 
the reaction was evaporated and aqueous layer was acidified to pH 2 with 10% KHSO4. The 
aqueous layer was extracted with CH2Cl2 (4 x 15 mL) and dried over MgSO4, filtered and 
concentrated to give the carboxylic acid (373 mg) which was dissolved in dry MeOH (5 mL). 
Cesium carbonate (310 mg, 0.95 mmol, 0.50 equiv.) was added and the mixture stirred for 2 h 
under N2. The mixture was concentrated, dissolved in DMF (5 mL) and cooled to 0 °C. Benzyl 
bromide (274 µL, 391 mg, 2.28 mmol, 1.20 equiv.) was added, the mixture warmed to rt, stirred 
overnight, diluted with EtOAc (10 mL), washed with water (15 mL) and brine (15 mL). The 
organic layer was dried over MgSO4, filtered and concentrated. Flash chromatography on silica 
gel (EtOAc-Hex 1:1→2:1) afforded 152 as a colorless oil (326 mg, 60%). Rf 0.53 (2:1 EtOAc-
Hex). 1H NMR (CDCl3, 400 MHz) δ 1.29 (t, J = 7.1 Hz, 6H), 2.99 (d, 
3JH-P = 21.5 Hz, 2H), 4.09-
4.16 (m, 4H), 5.18 (s, 2H), 7.30-7.40 (m, 5H); 13C NMR (CDCl3, 100 MHz) δ 16.3 (
3J = 16.3 Hz), 
34.4 (1JC-P = 134.2 Hz), 62.7 (
2J = 6.3 Hz), 67.3, 128.3, 128.4, 128.5, 135.4, 165.6. HRMS (ESI, 
-ve) calcd for C13H18O5P (M-H)
-  285.0897, obsd 285.0897. 
 (2E)-Benzyl 4,4-dimethoxybut-2-enoate (154) 
Cesium carbonate (2.20 g, 6.75 mmol, 1.5 equiv.) was added to a solution of benzyl 2-
(diethoxyphosphoryl)acetate 152 (1.28 g, 4.5 mmol, 1.0 equiv.) in cyclohexane (20 mL). The 
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suspension was heated to 65 °C and then 2,2-dimethoxyacetaldehyde (153) (15.6 mL of a 60 
wt.% solution in H2O, 937 mg, 9.0 mmol, 2.0 equiv.) was added. The biphasic mixture became 
clear pale yellow and stirred for 2 h at 65 °C. Saturated aqueous NH4Cl (25 mL) was added and 
the mixture was extracted with EtOAc (4 x 25 mL). The combined organic layers were washed 
with brine (25 mL), dried over MgSO4, filtered and concentrated. Flash chromatography on silica 
gel (Hex-EtOAc 2:1) afforded compound 154 as a colorless oil (947 mg, 89%). Rf 0.56 (1:1 Hex-
EtOAc). 1H NMR (CDCl3, 400 MHz) δ 3.32 (s, 6H), 4.94 (d, J = 3.0 Hz, 1H), 5.19 (s, 2H), 6.19 
(d, J = 15.9 Hz, 1 H), 6.81 (dd, J = 15.8, 3.9 Hz, 1H), 7.30-7.37 (m, 5H); 13C NMR (CDCl3, 100 
MHz) δ 52.8, 66.4, 100.5, 124.4, 128.2, 128.3, 128.6, 135.8, 143.2, 165.6. HRMS (ESI) calcd for 
C13H17O4 (M+H)
+  237.1160, obsd 237.1153. 
 (2E)-Benzyl 4-oxobut-2-enoate (149) 
A solution of (2E)-benzyl 4,4-dimethoxybut-2-enoate 154 (150 mg, 0.635 mmol) in 
acetone (30 mL) was treated with 2M HCl (0.3 mL) and stirred at rt for 2 d. The acetone was 
evaporated and residue was treated with water (5 mL) and extracted with CHCl3 (3 x 15 mL). 
The combined organic layers were dried over MgSO4, filtered and concentrated. Flash 
chromatography on silica gel (Hex-EtOAc 2:1) afforded aldehyde 149 as a colorless oil (90 mg, 
75%). Rf 0.46 (1:1 Hex-EtOAc). 
1H NMR (CDCl3, 400 MHz) δ 5.26 (s, 2H), 6.74 (d, J = 15.9 Hz, 
1H), 6.98 (dd, J = 15.9, 7.6 Hz, 1H), 7.32-7.39 (m, 5H), 9.72 (d, J = 7.6 Hz, 1H); 13C NMR 
(CDCl3, 100 MHz) δ 67.5, 128.5, 128.7, 135.0, 140.0, 140.6, 164.7, 192.43. HRMS (ESI) calcd 
for C11H11O3 (M+H)
+ 191.0712, obsd 191.0719. 
(R)-Benzyl-2-[(benzyloxycarbonyl)(tert-butyldiphenylsilyloxy)amino]-4-      
oxobutanoate (148b) 
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A solution of (2R,5R)-2-tert-butyl-5-benzyl-3-methylimidazolidine-4-one (140) (12.8 mg, 
0.052 mmol, 0.2 equiv.) in CHCl3 (0.75 mL) was treated with trifluoroacetic acid (4.0 µL, 5.9 mg, 
0.052 mmol, 0.2 equiv.) and stirred for 10 min at 4 °C. The aldehyde 149 (50.0 mg, 0.260 mmol, 
1.0 equiv.)  was added, followed by the addition of the silyloxycarbamate nucleophile 136b 
(105.0 mg, 0.26 mmol, 1.0 equiv.) in one portion, stirred for 48 h at 4 °C and the reaction 
mixture was then filtered through a plug of silica, eluted with Et2O then concentrated. 
Purification by silica gel chromatography (Hex-EtOAc 5:1) provided compound 148b as a clear 
oil (35 mg, 31%). Rf 0.32 (4:1 Hex-EtOAc). [α]D
25 +32.72 (c 0.8, CHCl3); 
1H NMR (CDCl3, 400 
MHz) δ 1.04 (s, 9H), 2.50 (dd, J = 17.9, 5.2 Hz, 1H), 3.11 (ddd, J = 17.9, 8.0, 1.1 Hz, 1H), 4.80 
(d, J = 12.0 Hz, 1H), 4.88 (d, J = 12.0 Hz, 1H), 4.98 (d, J = 12.4 Hz, 1H), 5.02-5.05 (m, 2H) 7.05 
(dd, J = 7.8, 1.4 Hz, 2H), 7.22-7.42 (m, 14H), 7.57 (d, J = 7.5 Hz, 4H), 9.42 (s, 1H); 13C NMR 
(CDCl3, 100 MHz) δ 19.5, 27.0, 42.8, 60.3, 67.3, 68.3, 127.5, 127.6, 128.1, 128.2, 128.3, 128.4, 
128.5, 128.7, 130.1, 130.2, 131.7, 132.0, 135.1, 135.2, 136.3, 158.7, 168.9, 197.9. HRMS (ESI) 
calcd for C35H38NO6Si (M+H)
+ 596.2712, obsd 596.2719. 
 (R,E)-6-benzyl 1-methyl 5-[(benzyloxycarbonyl)(tert-
butyldiphenylsilyloxy)amino]hex-2-enedioate (147b) 
 
A solution of (R)-benzyl 2-[(benzyloxycarbonyl)(tert-butyldiphenylsilyloxy)amino]-4-
oxobutanoate 148b (20.0 mg, 0.034 mmol, 1.0 equiv.) in chloroform (1 mL) was treated with 
methyl (triphenylphosphorylidine)acetate (142) (16.8 mg, 0.050 mmol, 1.5 equiv.) at 0 °C and 
allowed to warm to rt. The reaction mixture was stirred for 20 h, concentrated to a viscous oil, 
and the triphenylphosphine oxide byproduct was precipitated by the addition of Et2O. The solid 
was removed by filtration and the filtrate concentrated. Flash chromatography on silica gel (Hex-
EtOAc 8:1→4:1) afforded an α,β-unsaturated ester 147b as a colorless oil (18 mg, 82%). Rf 
0.31 (4:1 Hex-EtOAc). [α]D
25 +38.12 (c 0.6, CHCl3); 
1H NMR (CDCl3, 400 MHz) δ 1.01 (s, 9H), 
2.68-2.84 (m, 2H), 3.69 (s, 3H), 4.59 (dd, J = 8.4, 6.3 Hz, 1H), 4.71 (d, J = 12.0 Hz, 1 H), 4.82 
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(d, J = 12.0 Hz, 1H), 4.86 (d, J = 12.4 Hz, 1H), 5.04 (d, J = 12.4 Hz, 1H), 5.65 (d, J = 15.7 Hz, 
1H), 6.64 (dt, J = 22.8, 7.2 Hz, 1H), 7.02 (d, J = 6.6 Hz, 2H), 7.12-7.42 (m, 15H), 7.56 (t, J = 8.0 
Hz, 3H); 13C NMR (CDCl3, 100 MHz) δ 19.5, 26.9, 31.4, 51.4, 64.3, 67.1, 68.2, 123.5, 127.4, 
127.5, 128.2, 128.3, 128.5, 128.7, 129.9, 130.1, 131.8, 132.3, 135.2, 135.3, 136.2, 136.3, 144.1, 
158.9, 166.4, 168.9. HRMS (ESI) calcd for C38H42NO7Si (M+H)
+ 652.2725, obsd 652.2712. 
 (S)-benzyl-2-{[(benzyloxy)carbonyl)][(tert-butyldimethylsilyl)oxy]amino}-4-
oxobutanoate (148a) 
 
A solution of benzyl (tert-butyldimethylsilyl)oxycarbamate 136a (207.0 mg, 0.736 mmol, 
1.4 equiv.) in chloroform (1 mL) was treated with (S)-2-
{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (165) (34.0 mg, 0.105 mmol, 0.2 equiv) and 
acetic acid (9 µL, 9.4 mg, 0.105 mmol, 0.2 equiv.) and stirred for 10 min at rt. Benzyl 4-oxo-but-
2-enoate (149) (100.0 mg, 0.525 mmol, 1.0 equiv.) was added and the reaction mixture was 
stirred for 3.5 h at rt, concentrated and the residue was subjected to silica gel chromatography 
(Hex-EtOAc 5:1) and provided compound 148a as a colorless oil (239 mg, 69%). Rf 0.30 (2:1 
Hex-EtOAc). [α]D
25 -13.5 (c 0.9, CHCl3).  
1H NMR (CDCl3, 400 MHz) δ 0.08 (s, 3H), 0.12 (s, 3H), 
0.87 (s, 9H), 2.87 (dd, J = 17.7, 5.8 Hz, 1H), 3.26 (dd, J = 17.7, 5.7 Hz, 1H), 5.07-5.18 (m, 5H), 
7.26-7.40 (m, 10H), 9.81 (s, 1H); 13C NMR (CDCl3, 100 MHz) δ -4.8, -4.7, 18.1, 25.8, 42.7, 60.1, 
67.5, 68.6, 128.1, 128.3, 128.5, 128.5, 128.6, 135.3, 159.2, 169.1, 198.2. HRMS (ESI) calcd for 
C25H34NO6Si (M+H)
+  472.215, obsd 472.2139. 
(2S,4E)-6-benzyl-1-methyl-5-{[(benzyloxy)carbonyl][(tert-
butyldimethylsilyl)oxy]-amino}hex-2-enedioate (147a) 
 
 
A solution of (S)-benzyl 2-{[(benzyloxy)carbonyl][(tert-butyldimethylsilyl)oxy]amino}-4-
oxobutanoate (148a) (137.0 mg, 0.290 mmol, 1.0 equiv.) in chloroform (2.5 mL) was treated 
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with methyl (triphenylphosphorylidine)acetate (142) (164.0 mg, 0.435 mmol, 1.5 equiv.) at 0 °C 
and allowed to warm to rt. The reaction mixture was stirred for 1.5 h and concentrated to a 
viscous oil. Flash chromatography on silica gel (Hex-EtOAc 5:1) afforded the α,β-unsaturated 
ester as colorless oil 147a (140 mg, 91%). Rf 0.30 (2:1 Hex-EtOAc); [α]D
25 -41.2 (c 0.4, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ 0.07 (s, 3H), 0.09 (s, 3H), 0.85 (s, 9H), 2.78-2.93 (m, 2H), 3.73 (s, 
3H), 4.64 (dd, J = 8.9, 6.1 Hz, 1H), 5.07 (d, J = 12.0 Hz, 1H), 5.10 (d, J = 12.2 Hz, 1H), 5.12 (d, 
J = 12.0 Hz, 1H), 5.16 (d, J = 12.0 Hz, 1H), 5.94 (d, J = 15.7 Hz, 1H), 6.97 (dt, J = 15.7, 7.0 Hz, 
1H), 7.26-7.40 (m, 10H); 13C NMR (CDCl3, 100 MHz) δ -4.8, -4.7, 18.1, 25.8, 31.1, 51.5, 64.2, 
67.2, 68.5, 123.6, 128.2, 128.3, 128.4, 128.5, 128.5, 128.6, 135.2, 144.3, 168.8. HRMS (ESI) 
calcd for C28H38NO7Si (M+H)
+  528.2412, obsd 528.2420. 
(2S,4E)-1-Benzyl-6-methyl2-{[(benzyloxy)carbonyl][(tert-
butyldimethylsilyl)oxy]amino}hex-5-enedioate (One–pot procedure) (147a) 
 
A solution of benzyl (tert-butyldimethylsilyl)oxycarbamate (136a) (305.00 mg, 1.05 mmol, 
1.4 equiv.) in chloroform (1 mL) was treated with (S)-2-
{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (165) (50.35 mg, 0.15 mmol, 0.2 equiv), followed 
by the addition of acetic acid (10 µL, 9.28 mg, 0.15 mmol, 0.2 equiv.) and stirred for 10 min at rt. 
Benzyl 4-oxo-but-2-enoate (149) (147.20 mg, 0.77 mmol, 1.0 equiv.) was added and the 
reaction mixture was stirred for 3.5 h at rt. Upon completion (determined by TLC), methyl 
(triphenylphosphorylidine)acetate (142) (357.00 mg, 0.75 mmol, 1.5 equiv.) was added in one 
portion. The reaction mixture was stirred for 2.5 h and then concentrated to a viscous oil. Flash 
chromatography on silica gel (Hex-EtOAc 5:1) afforded the α,β-unsaturated ester as colorless 
oil 147a (280 mg, 71%). Rf 0.30 (2:1 Hex-EtOAc). NMR data was identical to that obtained via 
the two-step procedure. 
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 (2S,4R)-Dibenzyl 2-(6-methoxy-2-oxoethyl)isoxazolidine-1,2-dicarboxylate 
(163) 
 
To a solution of (2S,5E)-6-benzyl 1-methyl 5-[{(benzyloxy)carbonyl}{(tert-
butyldimethylsilyl)oxy}amino]hex-2-enedioate (147a) (105 mg, 0.198 mmol, 1.0 equiv.) in CHCl3 
(1 mL) was added acetic acid (17 µL, 17 mg, 0.297 mmol, 1.5 equiv.). The mixture was cooled 
to 0 °C and TBAF (297 µL, 1 M in THF with 5% H2O, 0.297 mmol, 1.5 equiv.) was added. The 
reaction was allowed to stir at 0 °C for 4 d. Reaction was monitored by TLC and upon 
completion, the reaction mixture was concentrated and applied directly to a flash column, eluting 
with 4:1→2:1 (Hex-EtOAc), to obtain (3S,5R)-dibenzyl 5-(2-methoxy-2-oxoethyl)isoxazolidine-
2,3-dicarboxylate 163b as a colorless oil (50 mg, 65%); Rf 0.23 (2:1 Hex-EtOAc). [α]D
25 -33.9 (c 
0.5, CHCl3).  
1H NMR (CDCl3, 400 MHz) δ 2.23 (ddt, J = 12.8, 7.9, 4.8 Hz, 1H), 2.60 (dd, J = 
16.4, 7.8 Hz, 1H), 2.83-2.93 (m, 2H), 3.68 (s, 3H), 4.35 (app. p, J = 7.1 Hz, 1H), 4.88 (dd, J = 
9.5, 5.7 Hz, 1H), 5.19 (d, J = 2.4 Hz, 2 H), 5.21 (s, 2H), 7.33-7.36 (m, 10H); 13C NMR (CDCl3, 
100 MHz) δ 36.9, 37.9, 52.0, 60.6, 67.4, 68.4, 128.1, 128.2, 128.4, 128.5, 128.5, 128.6, 135.2, 
135.5, 156.9, 170.0. HRMS (ESI) calcd for C22H24NO7 (M+H)
+ 414.1547, obsd 414.1548. 
 
 
 
 
 
 
 
88 
 
 
 
3.4.3 Spectra 
Compound 136a (Scheme 3.12) - 1H NMR spectrum 
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Compound 136a (Scheme 3.12) - 13C NMR spectrum 
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Compound 136b (Scheme 3.12) - 1H NMR spectrum 
 
  
91 
 
 
 
Compound 136b (Scheme 3.12) – 13C NMR spectrum 
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Compound 152 (Scheme 3.13) - 1H NMR spectrum 
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Compound 152 (Scheme 3.13) - 13C NMR spectrum 
 
94 
 
 
 
Compound 154 (Scheme 3.13) - 1H NMR spectrum 
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Compound 154 (Scheme 3.13) - 13C NMR spectrum 
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Compound 149 (Scheme 3.13) - 1H NMR spectrum 
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Compound 149 (Scheme 3.13) - 13C NMR spectrum 
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Compound 148b (Scheme 3.17) - 1H NMR spectrum 
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Compound 148b (Scheme 3.17) - 13C NMR spectrum 
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Compound 147b (Scheme 3.17) - 1H NMR spectrum 
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Compound 147b (Scheme 3.17) – 13C NMR spectrum 
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Compound 148a (Scheme 3.21) - 1H NMR spectrum 
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Compound 148a (Scheme 3.21) – 13C NMR spectrum 
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Compound 147a (Scheme 3.21) - 1H NMR spectrum 
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Compound 147a (Scheme 3.21) - 13C NMR spectrum 
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Compound 163 (Scheme 3.22) - 1H NMR spectrum 
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Compound 163 (Scheme 3.22) - 13C NMR spectrum 
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CHAPTER 4: PROTECTING GROUP STRATEGY FOR (2S,4R)-α-AMINO-γ-HYDROXY 
ADIPIC ACID (AHAD) AND α-AMINO ADIPIC ACID (α-AAA) 
 
 
4.1 The Protecting Group Challenge 
A major challenge in the synthesis of the Ahad building block was selection of the right 
combination of protecting groups that would be compatible with the total synthesis of 
theonellamide C. The proposed assembly of the western hemisphere is illustrated in Scheme 
4.1. The amino terminus of tetrapeptide 52 will first be coupled to the D-Ala carboxylic acid of 
the τ-histidinoalanine residue 53. Following appropriate deprotections, the free δ-acid of the 
Ahad building block 170 will be coupled with the L-His primary amine of 169, thereby leading to 
cyclization precursor 49. Our goal is to deblock the C-terminal allyl group and the N-terminal 
allyloxycarbonyl group simultaneously with Pd(0), and then cyclize to obtain the western 
hemisphere of theonellamide C (Scheme 4.1). 
 
Scheme 4.1 Proposed assembly of the western hemisphere of theonellamide C. 
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A successful protecting group strategy for the Ahad building block requires (Figure 4.1): 
1. Nα-protection as an allyloxy carbonyl (Alloc) carbamate will enable deprotection by Pd(0) 
concomitantly with the allyl ester as a prelude to cyclization. 
2. The Cα-COOH is not part of the macrocycle and therefore requires “permanent” 
protection. Our intent is for all side chain protecting groups to be fluoride-labile.  
3. The Cɣ-OH (side chain) also requires permanent protection, viz., fluoride lability.  
4. The Cδ-COOH protecting group should be removed under conditions where all other 
protecting groups are inert, to enable conjugation to -HAL. 
 
Figure 4.1 Schematic representation of protecting group requirements for Ahad residue. 
These challenges prompted us to use α-amino adipic acid (α-AAA) 64 as a model 
system. The difference between Ahad and α-amino adipic acid (Figure 4.2) is that the former is 
γ-hydroxylated; the latter appears in other congeners of the theonellamides. Moreover, α-AAA is 
commercially available and we can work initially with racemic α-AAA (US$64.20/g) and 
penultimately L-α-AAA (US$171.50/g).  
 
Figure 4.2 Structure of amino adipic acid and Ahad. 
We investigated the acetol ester81,82 (Ac*) and the 2-(trimethylsilyl)ethoxymethyl (SEM) 
ester83,84 as candidates for protecting the α-carboxylic acid. Both these protecting groups have 
been found to be stable to hydrogenolytic and acidolytic conditions normally used in peptide 
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synthesis. Fluoride ion treatment has been demonstrated to cleave acetol and SEM esters 
(Figure 4.3), compatible with a global side chain deprotection of the TBS ether in the final 
stages of theonellamide synthesis.  
                                                                           
Figure 4.3 Structure of acetol and SEM ester protecting groups. 
4.2 Acetol Esters 
Kundu introduced the use of acetol esters to peptide synthesis in 1992.81  He 
synthesized several N-protected amino acid acetol esters with acetol using DCC/DMAP and 
showed that the acetol esters were stable to acidolytic (HCl/dioxane, TFA/CH2Cl2) and 
hydrogenolytic (H2, Pd-C) conditions routinely used in peptide synthesis for the removal of Boc 
and Cbz groups respectively. The deprotection of an acetol ester can be carried out using 
tetrabutylammonium fluoride solution in tetrahydrofuran (THF) at room temperature (Scheme 
4.2).  
 
Scheme 4.2 Synthesis and deprotection of acetol esters. 
Acetol esters have not seen much utilization. An exception was in 2001, when Rebek82 
used an acetol ester in the synthesis of the marine cyclopeptide dendroamide C (Scheme 4.3) 
and differentiated three acids (benzyl, tert-butyl and acetol) from each other. First, the acetol 
ester 177 was prepared by removing the benzyl ester from 176 via hydrogenolysis and re-
protecting the free acid with acetol using the Yamaguchi method. After removal of the 
trichloroethyl (TCE) ester, compound 178 was then incorporated into protected linear tripeptide 
180. Deblocking of the trichloroethyl ester afforded the free acid and deprotection of the N-
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terminus under acidic conditions afforded the linear precursor. Cyclization was performed in 
DMF with PyBOP activation in the presence of diisopropylethylamine, yielding the orthogonally 
protected triester 181 in 24% yield from protected linear trimer 180. The acetol ester was 
removed using TBAF to obtain free acid 182 (Scheme 4.3), without affecting the benzyl and tert-
butyl esters. 
 
Scheme 4.3 Use of acetol ester by Rebek et al. in dendroamide C synthesis. 
4.3 SEM Esters 
Joullié et al. used the SEM ester as a protecting group in their total synthesis of 
didemnins A, B, and C.84 The synthesis of a fragment of didemnin B is illustrated in Scheme 4.4. 
The acid of Cbz-N-methyl-D-leucine-OH (183) was protected as its 2-(trimethylsilyl)ethyl ester 
via a carbodiimide-mediated coupling with trimethylsilylethanol. After removal of the Cbz group 
by hydrogenolysis, coupling of the N-methyl-D-leucine trimethylsilylethyl ester 184 and the 
protected lactyl proline acid 185 was achieved by premixing bis(2-oxo-3-
112 
 
oxazolidinyl)phosphonic chloride (BOP-CI) and triethylamine with the acid 185, and adding a 
solution of the secondary amine 184 and base to the solution of activated species. 
Simultaneous removal of the two silyl groups was effected with tetrabutylammonium fluoride in 
DMF to afford compound 187 (Scheme 4.4). 
Scheme 4.4 SEM ester in the synthesis of didemnins A, B and C. 
4.4 Synthesis of α-AAA-α-Esters 
4.4.1 Precedents for N-Protection 
Herin and coworkers protected (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid 
(188) as its allyloxycarbamate.85  They used two equivalents of allyl chloroformate in the 
reaction. 
 
Scheme 4.5 Protection of amino group as an Alloc carbamate. 
Later on we came across a procedure by Hachisako et al.86 where they protected the L-
2-aminoadipic acid (-)-(64) as its benzyloxycarbamate (Scheme 4.6). 
 
Scheme 4.6 Cbz protection of α-AAA. 
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Initially we followed the procedure by Herin and coworkers for protection of the primary 
amine in (±)-2-aminoadipic acid (±)-64 as its allyloxycarbamate, but product was obtained in low 
yield.  We got a mixture of two species, one was more polar and corresponded to the product 
192 and the other compound was less polar and we suspected that the cyclic anhydride 193 
was forming with the use of two equivalents of allylchloroformate (Scheme 4.7). 
 
Scheme 4.7 Cyclic anhydride formation in preparation of an Nα-Alloc carbamate. 
Our next attempt at Alloc-protection of (±)-64 was by analogy to the procedure for the 
synthesis of Nα-Cbz adipic acid by Hachisako with slight modifications. The reaction time was 
changed from two hours to four hours at 0 °C and after the work-up, the aqueous layer was 
extracted thoroughly several times with ethyl acetate to afford compound (±)-192 in good yield 
(Scheme 4.8).  
 
Scheme 4.8 Protection of amino group as an Alloc carbamate. 
Baldwin and coworkers have demonstrated that it is possible to selectively esterify the α-
carboxylic acid of α-amino adipic acid (Scheme 4.9), since its pKa is about one unit lower than 
the δ-carboxylic acid.87               
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Scheme 4.9 Regioselective esterification of Cα-COOH by Baldwin et al.                         
The synthesis of the acetol ester is illustrated in Scheme 4.10. Regioselective 
esterification of the α-acid in compound 192 was attempted by forming the mono-cesium salt 
and then reacting with chloroacetone.  
 
Scheme 4.10 Protection of Cα-COOH as acetol ester.        
The product mixture containing compound 195 was subjected, without any purification, 
to methyl ester formation using an excess of trimethylsilyldiazomethane. The overall yield, after 
purification by silica gel chromatography, was low because of poor regioselectivity during 
formation of the first ester and the lack of purification following the previous two steps. The 
major product obtained after purification on silica gel chromatography was in fact the dimethyl 
ester 197, not the desired compound 196 (Scheme 4.11). 
 
Scheme 4.11 Synthesis of fully protected α-AAA.   
The SEM group was investigated in an analogous series of reactions to the acetol 
protecting group (Scheme 4.12). 
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Scheme 4.12 Mixture of products in synthesis of fully protected α-AAA. 
Despite the poor overall yields, compounds 196 and 200 were available in reasonable 
quantities to explore chemoselective liberation of δ-COOH. 
4.5 Liberation of δ-COOH from Protected α-AAA Derivatives 
Nicolaou and coworkers had reported a mild and selective method for the hydrolysis of 
methyl esters with trimethyltin hydroxide.88 They showed that the methyl ester is hydrolyzed 
preferentially, even in the presence of ethyl and isopropyl esters, in good yield, for both aromatic 
and aliphatic systems (Scheme 4.13). 
 
Scheme 4.13 Selective hydrolysis of methyl esters with trimethyltin hydroxide.                  
We therefore hoped that these reaction conditions would be selective in our α-AAA 
derivatives in which the α-COOH ester is a substituted ethyl ester in each case. We thus 
attempted to hydrolyze the methyl ester in the presence of the acetol ester protecting group. We 
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tried several small-scale reactions, varying the reaction temperature and the stoichiometry of 
trimethyltin hydroxide; but the desired product was invariably obtained in very low yield (Scheme 
4.14). 
 
Scheme 4.14 Mixture of products after hydrolysis of methyl ester in compound 196. 
The 1H NMR spectrum of the product mixture showed retention of the methyl ester 
functionality. Analysis of the reaction mixture by LCMS showed that four species were present 
(Table 4.1). The major peak corresponded to acetol deprotection (compound 206). The other 
minor peaks corresponded to starting material 196, the product of methyl ester hydrolysis 195, 
and fully deprotected diacid 192. The distribution of compounds is summarized in Table 4.1. 
Likewise, treatment of compound 200 with trimethyltin hydroxide led to cleavage of the 
SEM ester in preference to the methyl ester (Scheme 4.15). Analysis of the product mixture by 
LCMS showed a major peak corresponding to SEM ester deprotection (compound 206). The 
other minor peaks corresponded to starting material 200, desired product 198, and fully 
deprotected diacid 192 (Table 4.1). 
 
 
Scheme 4.15 Mixture of products obtained after treatment of diester (±)-200 with trimethyltin 
hydroxide.         
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Table 4.1 Composition of product mixture, following hydrolysis by trimethyltin hydroxide, as 
determined by LCMS.  
 
Compound Ac* SEM 
Fully protected starting material 196 (11.5%) 200 (2.7%) 
δ-COOMe cleavage 195 (12.5%) 198 (18.1%) 
α-COOR cleavage 206 (69.5%) 206 (77.7%) 
Diacid (double cleavage) 192 (6.5%) 192 (1.6%) 
 
In summary, both SEM and acetol esters were cleaved in preference to methyl esters 
upon hydrolysis using trimethyltin hydroxide. After consideration of this problem and assessing 
potential substitutes for the methyl ester, we decided to pursue a tert-butyl ester. The δ-tert-
butyl ester ought to be removed under acidic conditions which should not affect the other 
protecting groups of the Ahad building block. 
Using racemic α-AAA, the synthesis of the building block was repeated with a tert-butyl 
ester for racemic adipic acid. Compound 192 was protected as its α-acetol ester and then 
subjected to isobutylene under acidic conditions to form 6-tert-butyl 1-(2-oxopropyl)-2-
[{(allyloxy)carbonyl}amino]hexanedioate (207) (Scheme 4.16). 
 
Scheme 4.16 Synthesis of α-AAA with δ-COOtBu ester.                 
As expected, the cleavage of the tert-butyl ester was effected using TFA without any 
harm to the acetol or Alloc protecting groups (Scheme 4.17). Chemoselective deprotection of 
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the acetol ester was also demonstrated using TBAF. Conversely, we observed some cleavage 
of the SEM ester under acidic conditions in the reaction; therefore, we gave preference to the 
acetol ester. 
 
Scheme 4.17 Orthogonal deprotection of acetol and tert-butyl esters.        
L-2-Aminoadipic acid was subjected to these series of reactions to obtain α-tert-butyl-δ-
(2-oxopropyl)-L-N-allyloxycarbonyl-2-aminoadipate. 
4.6 Synthesis of Ahad Building Block  
Following these model studies, the next task was to make the Ahad precursor with a δ-
tert-butyl ester instead of a methyl ester as described in Chapter 3. As shown in Scheme 4.18, 
the analogous reactions were performed with the tert-butyl ester protecting group being 
introduced using the commercially available phosphorane during the Wittig reaction to produce 
209. At this time we measured the enantiomeric purity of compound 209 by chiral HPLC and 
obtained 87.4% e.e. Treatment of compound 209 with tetrabutylammonium fluoride solution with 
5% water in tetrahydrofuran facilitated silyl group removal but didn’t cyclize to give compound 
210. Increasing the temperature from 0 °C to room temperature had no impact. We added 
cesium carbonate to the reaction mixture after two days to make the solution more basic. 
Addition of cesium carbonate did facilitate the cyclization but the yield was very low. 
We treated compound 209 with tetrabutylammonium fluoride solution in 1M THF with 
acetic acid at room temperature and obtained the major syn isooxazolidine 210 in good yield 
with a 3.8:1.0 d.r. (Scheme 4.18). The major diastereomer was confirmed to have syn relative 
119 
 
stereochemistry by a NOESY experiment which showed a cross peak between α and γ protons 
(5.6% nOe). The syn diastereomer could be further purified by normal phase HPLC, although in 
practice the minor diastereomer was gradually removed during chromatography following the 
next few reaction steps. 
 
Scheme 4.18 Synthesis of isooxazolidine precursor to Ahad.   
While MacMillan and co-workers had employed samarium diiodide (Chapter 3, Section 
3.2) to reductively cleave the N-O bond in a compound analogous to 210 (shown in a box in 
Scheme 4.19),70 Sibi and coworkers showed that exposure to standard hydrogenolytic 
conditions also effectively cleaves N-O bonds (Scheme 4.19).80  
 
Scheme 4.19 Precedents for cleavage of N-O bond. 
We anticipated that exposure of 210 to standard hydrogenolysis conditions would 
simultaneously remove the Cbz and benzyl ester protecting groups, along with cleavage of the 
N-O bond. Hydrogenolysis was performed to give compound 213 ready for introduction of a 
suitable suite of protecting groups. The free amine was protected as its allyloxycarbamate by 
analogy to the procedure for racemic α-AAA. Esterification of the α-acid was attempted by the 
addition of half an equivalent of cesium carbonate, followed by chloroacetone. The major 
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product isolated from the reaction mixture was lactone 216 (Scheme 4.20). We also attempted 
coupling of the α-acid to acetol in the presence of activating agents, for instance under 
Yamaguchi conditions (precedent shown in a box in Scheme 4.20).89 The only product isolated 
from various reaction conditions was the lactone 216. Activated acyl species, including the 
acetol ester, were susceptible to nucleophilic attack by the ɣ-OH, mandating that we protect the 
secondary alcohol before the carboxylic acid. 
 
Scheme 4.20 Attempted synthesis of Ahad. 
As we neared the completion of our Ahad synthesis we sought an approach to correlate 
our amino acid with that obtained from degradation of the theonellamides.  In 1989, Matsunaga 
et al. deduced the structure of Ahad with the aid of NMR studies as described in Chapter 2, 
Section 2.1. 
 They treated a 1:2 mixture of triethylammonium salts of 2-amino-4-hydroxyadipic acids 
with 2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile (BocON) followed by methylation and 
normal phase HPLC separation afforded methylated Boc-lactone 58b. They found out that the 
minor trans-lactone that has (2S,4R) stereochemistry is the native constituent of theonellamide 
C.  
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Scheme 4.21 Lactone formation reported by Matsunaga et al. 
We compared the NMR data of Matsunaga’s lactone 58b with the undesired product 
isolated from α-acid esterification of Ahad precursor (Scheme 4.20). Nuclear magnetic 
resonance data for compound 216 showed resemblance to that of the (2S,4R) lactone 58b. 
Moreover lactone 216 afforded further confirmation of the (2S,4R) stereochemistry since the Hβ 
protons gave rise to a multiplet at 2.4-2.8 ppm, consistent with a trans-1,4-disubstituted ɣ-
lactone (Table 4.2).28 
Table 4.2. NMR data of lactones 58b and 216 
  Matsunaga et al.   Yadav and Taylor 
δ 5.01 (m, 1NH, 1Hα) δ 5.22-5.30 (m, 1NH, 1Hα) 
δ 4.38 (ddd, J = 6.4, 9.8, 9.8 Hz, 1Hɣ) 
δ 4.48 (dd, J = 16.1, 9.3 Hz, 1Hɣ) 
 
δ 2.73 (m, 2Hδ) δ 2.38-2.79 (m, 2Hδ & 1Hβ) 
δ 2.50 (m, 2Hβ) δ 2.14-2.17 (m, 1Hβ) 
 
Indeed, Matsunaga et al. stated that the C-4 hydroxyl group might have been epimerized 
through a backside attack of the carboxyl group during lactonization. Moreover, equilibration to 
the more stable cis-2,4-disubstituted ɣ-lactone may have enhanced the amount of (2S,4S) 
diastereomer. We also observed the same results during the lactone formation of (2S,4R) 
compound 167 (Scheme 4.22). The NMR experiments showed that we also obtained the more 
stable (2S,4S) cis-lactone 58a.  
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Scheme 4.22 Preparation of ɣ-lactone 58a by Yadav and Taylor. 
Lajoie and coworkers had shown that a free alcohol can be masked with TBSCl in the 
presence of a free acid.90 They protected the alcohol of the Cbz-protected serine 220 as a TBS 
ether with TBSCl (Scheme 4.23).  
 
Scheme 4.23 Protection of alcohol as TBS ether. 
We attempted the protection of the alcohol in compound 214 with stoichiometric 
quantities of TBSCl and 2,6-lutidine. Carbodiimide-mediated coupling of the resulting crude acid 
with acetol gave rise to compound 222.91  Chemoselective cleavage of the tert-butyl ester with 
tert-butyldimethylsilyl triflate was carried out in readiness for coupling to the L-His amino group 
of -HAL in the western hemisphere of theonellamide C (Scheme 4.24).92 
 
Scheme 4.24 Synthesis of orthogonally protected Ahad. 
4.7 Experimental Section 
4.7.1 General Methods 
The general methodas are as described in Chapter 2. 
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4.7.2 Procedures 
 2-(Allyloxycarbonylamino)adipic acid (192) 
(±)-α-Aminoadipic acid (64) (250 mg, 1.55 mmol, 1.0 equiv.) was added to a solution of 
sodium hydroxide (223 mg, 5.60 mmol, 3.6 equiv.) in water (12.5 mL) at 0 °C. Allyl 
chloroformate (247 µL, 281 mg, 2.35 mmol, 1.5 equiv.) was added dropwise over 30 min and 
stirring continued for 4 h in an ice bath. The mixture was washed with diethyl ether (20 mL). The 
aqueous layer was acidified to pH 2 by the addition of conc. HCl and extracted with EtOAc (4 x 
20 mL). The combined extracts were dried over MgSO4, filtered and concentrated to give (±)-2-
(Allyloxycarbonylamino)adipic acid (192) (350 mg, 92%). Rf 0.29 (6:4:1 CHCl3-MeOH-H2O). 
1H 
NMR (CD3OD, 400 MHz) δ 1.67-1.74 (m, 3H), 1.87-190 (m, 1H), 2.33 (t, J = 6.8 Hz, 2H), 4.14 
(dd, J = 8.0, 4.4 Hz, 1H), 4.54 (d, J = 5.3 Hz, 2H), 4.97 (br s, 1H), 5.18 (dd, J = 10.5, 1.4 Hz, 
1H), 5.31 (dd, J = 17.2, 1.5 Hz, 1H), 5.93 (ddt, J = 15.9, 10.6, 5.3 Hz, 1H); 13C NMR (CD3OD, 
100 MHz) δ 19.4, 29.1, 31.2, 52.0, 63.5, 114.5, 131.3, 155.6, 172.7, 174.0. HRMS (ESI) calcd 
for C10H15NNaO6 (M+Na)
+  268.0792, obsd 268.0786. 
(L)-N-Allyloxycarbonyl-2-amino-adipic acid was prepared using L-2-aminoadipic acid 
(100 mg) according to the same procedure to give (-)-193 (130 mg, 89%). [α]D
25 -7.82 (c 1.0, 
MeOH). 
 2-(Allyloxycarbonylamino)-6-methyl-1-(2-oxopropyl)-adipate (196) 
Cesium carbonate (166 mg, 0.51 mmol, 0.5 equiv.) was added to a solution of (±)-N-
allyloxycarbonyl-2-amino-adipic acid (192) (250 mg, 1.02 mmol, 1.0 equiv.) in dry MeOH (1 mL). 
The mixture was stirred for 2 h under N2 at rt. The mixture was concentrated, dissolved in DMF 
(2 mL) and cooled to 0 °C. Chloroacetone (97 µL, 113 mg, 1.22 mmol, 1.2 equiv.) was added, 
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the mixture warmed to rt, stirred overnight, diluted with H2O (15 mL) and extracted with EtOAc 
(3 x 25 mL). The combined organic layers were dried over MgSO4, filtered and and 
concentrated to give the mixture containing acid 5-[{(allyloxy)carbonyl}amino]-6-oxo-6-(2-
oxopropoxy)hexanoic acid as a colorless oil (300 mg) that was dissolved in acetonitrile (3 mL) 
and methanol (300 µL). Trimethylsilyldiazomethane (498 µL, 2 M solution in Et2O, 0.99 mmol, 
1.1 equiv.) added dropwise and stirred for 2.5 h at rt under N2. The mixture was concentrated 
and applied to a flash column. Elution with a gradient of 3:1→1:1 (Hex-EtOAc) gave 2-
(Allyloxycarbonylamino)-6-methyl-1-(2-oxopropyl)-adipate (196) as a colorless oil (64 mg, 20%). 
Rf 0.40 (2:1 EtOAc-Hex). 
1H NMR (CDCl3, 400 MHz) δ 1.73-1.82 (m, 3H), 1.97-2.02 (m, 1H), 
2.15 (s, 3H), 2.37 (t, J = 6.4 Hz, 2H), 3.66 (s, 3H), 4.42-4.46 (m, 1H), 4.56 (d, J = 5.5 Hz, 2H), 
4.63 (d, J = 16.8 Hz, 1H), 4.88 (d, J = 16.8 Hz, 1H), 5.21 (dd, J = 10.4, 1.3 Hz, 2H), 5.28-5.35 
(m, 2H), 5.90 (ddt, J = 16.1, 10.5, 5.5 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 20.5, 26.0, 31.7, 
33.3, 51.6, 53.5, 65.9, 68.7, 117.9, 132.5, 155.8, 171.7, 173.5, 200.6. HRMS (ESI) calcd for 
C14H21NNaO7 (M+Na)
+  338.1216, obsd 338.1220. 
 2-(Allyloxycarbonylamino)-6-methyl-1-(2-trimethylsilyl-ethoxy-
methyl)-adpate (200) 
 
 
Cesium carbonate (166 mg, 0.51 mmol, 0.5 equiv.) was added to a solution of (±)-N-
allyloxycarbonyl-2-amino-adipic acid (192) (250 mg, 1.02 mmol, 1.0 equiv.) in dry MeOH (1 mL). 
The mixture was stirred for 2 h under N2 at rt. The mixture was concentrated, the residue 
dissolved in DMF (2 mL) and cooled to 0 °C. 2-(Trimethylsilyl)ethoxymethyl chloride (217 µL, 
204 mg, 1.22 mmol, 1.2 equiv.) was added, the mixture warmed to rt, stirred overnight, diluted 
with H2O (15 mL) and extracted with EtOAc (3 x 30 mL). The combined organic layers were 
dried over MgSO4, filtered and concentrated to give a mixture containing acid 5-
[{(allyloxy)carbonyl}amino]-6-oxo-6-[{(2-(trimethylsilyl)ethoxy}methoxy]hexanoic acid as a 
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colorless oil (370 mg) that was dissolved in acetonitrile (4 mL) and methanol (400 µL). 
Trimethylsilyldiazomethane (541 µL, 2 M solution in Et2O, 1.08 mmol, 1.1 equiv.) added 
dropwise and the mixture stirred for 2.5 h at rt under N2. The mixture was concentrated and 
applied to a flash column. Elution with a gradient of 3:1→1:1 (Hex-EtOAc) gave 2-
(Allyloxycarbonylamino)-6-methyl-1-(2-trimethylsilyl-ethoxy-methyl)-adpate (200) as a colorless 
oil (99 mg, 25%). Rf 0.49 (2:1 EtOAc-Hex). 
1H NMR (CDCl3, 400 MHz) δ 0.01 (s, 9H) 0.95 
(app.t, J = 8.4 Hz, 2H), 1.68-1.73 (m, 3H), 1.87-1.92 (m, 1H), 2.31-2.38 (m, 2H), 3.65 (s, 3H), 
3.66-3.73 (m, 2H), 4.35-4.38 (m, 1H), 4.56 (d, J = 5.4 Hz, 2H), 5.20 (dd, J = 10.4, 1.3 Hz, 2H), 
5.26-5.36 (m, 3H), 5.90 (ddt, J = 16.1, 10.6, 5.4 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ -1.5, 
18.0, 20.4, 20.6, 31.8, 33.3, 33.5, 51.6, 52.4, 53.5, 53.6, 65.8, 67.9, 68.2, 88.9, 89.9, 117.8, 
132.6, 155.8, 171.9, 172.7, 173.3. HRMS (ESI) calcd for C17H31NNaO7Si (M+Na)
+ 412.1762, 
obsd 412.1748. 
 2-(Allyloxycarbonylamino)-6-(tert-butyl)-1-(2-oxo-propyl)-adipate (207) 
Cesium carbonate (332 mg, 1.02 mmol, 0.5 equiv.) was added to a solution of (±)-N-
allyloxycarbonyl-2-amino-adipic acid (192) (500 mg, 2.04 mmol, 1.0 equiv.) in dry MeOH (4 mL). 
The mixture stirred for 2 h under N2 at rt. The mixture was concentrated, dissolved in DMF (5 
mL) and cooled to 0 °C. Chloroacetone (194 µL, 226 mg, 2.44 mmol, 1.2 equiv.) was added, the 
mixture warmed to rt, stirred overnight, diluted with H2O (30 mL) and extracted with EtOAc (3 x 
40 mL). The combined organic layers were dried over MgSO4, filtered and and concentrated to 
give acid 5-[{(allyloxy)carbonyl}amino]-6-oxo-6-(2-oxopropoxy)hexanoic acid as a colorless oil 
(500 mg) that was dissolved in CH2Cl2 (10 mL) and added p-TsOH (663 mg, 3.49 mmol, 2.1 
equiv.). The reaction mixture was added to condensed isobutylene (10 mL) and stirred for 3d at 
rt. The mixture was diluted with 20 mL CH2Cl2 and added sat. sol. of  NaHCO3 (25 mL), 
extracted the organic layer. The remaining aqueous layer was washed with CH2Cl2 (2 x 30 mL). 
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The combined organic layers were dried over MgSO4, filtered, concentrated and applied to a 
flash column. Elution with a gradient of 3:1→1:1 (Hex-EtOAc) gave 2-(allyloxycarbonylamino)-6-
(tert-butyl)-1-(2-oxo-propyl)-adipate (207) as a colorless oil (198 mg, 34%). Rf 0.32 (2:1 EtOAc-
Hex). 1H NMR (CDCl3, 400 MHz) δ 1.41 (s, 9H), 1.64-1.79 (m, 2H), 1.91-2.02 (m, 2H), 2.14 (s, 
3H), 2.25 (t, J = 6.9 Hz, 2H), 4.42 (dd, J = 12.4, 7.4 Hz, 1H), 4.55 (d, J = 5.4 Hz, 2H), 4.62 (d, J 
= 16.8 Hz, 1H), 4.75 (d, J = 16.8 Hz, 1H), 5.19 (dd, J = 10.4, 1.2 Hz, 1H), 5.26-5.39 (m, 1H), 
5.89 (ddt, J = 16.2, 10.6, 5.6 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 20.7, 26.0, 28.1, 31.6, 34.7, 
53.4, 65.9, 68.7, 80.4, 117.8, 132.6, 155.8, 171.8, 172.4. HRMS (ESI) calcd for C17H28NO7 
(M+H)+  358.1820, obsd 358.1826. 
 (L)-N-allyloxycarbonyl-2-amino-adipic acid (50 mg) was subjected to the same 
procedure to give α-tert-Butyl δ-(2-oxopropyl)-(L)-N-allyloxycarbonyl-2-aminoadipate (-)-207 (20 
mg, 30%). [α]D
25 -7.75 (c 1.0, MeOH). 
 2-(Allyloxycarbonylamino)-1-(2-oxopropyl)-adipic acid (195) 
To a solution of 2-(allyloxycarbonylamino)-6-(tert-butyl)-1-(2-oxo-propyl)-adipate (207) 
(25 mg, 0.069 mmol, 1.0 equiv.) in dry CH2Cl2 (2 mL) was added trifluoroacetic acid (2 mL) at 0 
°C and allowed to stir at 0 °C for 1 h. The reaction mixture was warmed to rt and stirred 
overnight, concentrated and applied to a flash column. Elution with a gradient of 3:1→4:1 
(EtOAc-Hex) gave 2-(Allyloxycarbonylamino)-1-(2-oxopropyl)-adipic acid (195) (15 mg, 65 %). 
Rf 0.23 (3:1 EtOAc-Hex). 
1H NMR (CDCl3, 400 MHz) δ 1.20-1.29 (m, 2H), 1.78-1.84 (m, 2H), 
2.17 (s, 3H), 2.43 (t, J = 7.1 Hz, 2H), 4.43-4.50 (m, 1H), 4.58 (d, J = 5.0 Hz, 2H), 4.65 (d, J = 
16.8 Hz, 1H), 4.80 ( d, J = 16.8 Hz, 1H), 5.22 (dd, J = 10.4, 1.1 Hz, 1H), 5.29 (d, J = 2.6 Hz, 
1H), 5.34 (s, 1H), 5.91 (ddt, J = 16.2, 10.7, 5.5 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ 20.4, 
26.0, 31.7, 32.9, 53.4, 66.0, 68.7, 118.0, 132.5, 155.9, 171.6, 176.6. HRMS (ESI) calcd for 
C13H19NNaO7 (M+Na)
+ 324.1054, obsd 324.1054. 
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 2-(Allyloxycarbonylamino)-6-(tert-butyl)adipate (208) 
To a solution of α-tert-butyl δ-(2-oxopropyl) N-allyloxycarbonyl-2-aminoadipate (207) (20 
mg, 0.056 mmol, 1.0 equiv.) in dry THF (1 mL) was added TBAF (111 µL, 1 M in THF, 0.112 
mmol, 2.0 equiv.)  at 0 °C and allowed to stir at 0 °C for 1 h. The reaction mixture was warmed 
to rt and stirred overnight, concentrated and applied to a flash column. Elution with a gradient of 
3:1→4:1 (EtOAc-Hex) gave 2-(Allyloxycarbonylamino)-6-(tert-butyl)adipate (208) (11 mg, 68 %). 
Rf 0.25 (2:1 EtOAc-Hex). 
1H NMR (CDCl3, 400 MHz) δ 1.41 (s, 9H), 1.64-1.79 (m, 2H), 1.91-
2.02 (m, 2H), 2.25 (t, J = 6.9 Hz, 2H), 4.42 (dd, J = 12.4, 7.4 Hz, 1H), 4.55 (d, J = 5.4 Hz, 2H), 
5.19 (dd, J = 10.4, 1.2 Hz, 1H), 5.26-5.39 (m, 1H), 5.89 (ddt, J = 16.2, 10.6, 5.6 Hz, 1H); 13C 
NMR (CDCl3, 100 MHz) δ 20.7, 28.1, 31.6, 34.7, 53.4, 65.9, 80.4, 117.8, 132.6, 155.8, 171.8, 
172.4. HRMS (ESI) calcd for C14H23NNaO6 (M+Na)
+  324.2020, obsd 324.2026. 
 (2S,4E)-1-Benzyl-2-[(benzyloxycarbonyl)(tert-butyldimethylsilyloxy-amino]-6-
tert-butyl-hex-4-enedioate (One–pot procedure) (209) 
 
 
A solution of benzyl (tert-butyldimethylsilyl)oxycarbamate (136a) (250.0 mg, 0.88 mmol, 
1.4 equiv.) in chloroform (1 mL) was treated with (S)-2-
{diphenyl[(trimethylsilyl)oxy]methyl}pyrrolidine (165) (41.0 mg, 0.12 mmol, 0.2 equiv), followed 
by the addition of acetic acid (7 µL, 7.5 mg, 0.12 mmol, 0.2 equiv.) and stirred for 10 min at rt. 
Benzyl 4-oxo-but-2-enoate (149) (121.0 mg, 0.63 mmol, 1.0 equiv.) was added and the reaction 
mixture was stirred for 3.5 h at rt. Upon completion (determined by TLC), tert-butyl-2-
(triphenylphosphoranylidene)acetate (237.0 mg, 0.63 mmol, 1.0 equiv.) was added in one 
portion. The reaction mixture was stirred for 1.5 h and then concentrated to a viscous oil. Flash 
chromatography on silica gel (Hex-EtOAc 12:1) afforded the α,β-unsaturated ester as colorless 
oil 209 (354 mg, 70%, 87.4% e.e.). The enantiomeric excess was determined by HPLC analysis 
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using Chiralcel OD-H column (5% iPrOH-Hex, 0.5 mL/min); major enantiomer tr = 20.1 min and 
minor enantiomer tr = 36.4 min; Detection 218 nm. Rf 0.30 (2:1 Hex-EtOAc). [α]D
25 -37.2 (c 0.5, 
CHCl3). 
1H NMR (CDCl3, 400 MHz) δ 0.08 (s, 3H), 0.10 (s, 3H), 0.85 (s, 9H), 1.47 (s, 9H), 2.76-
2.91 (m, 2H), 4.57 (dd, J = 8.7, 6.2 Hz, 1H), 5.06-5.18 (m, 4H), 5.84 (d, J = 15.6 Hz, 1H), 6.86 
(dt, J = 7.0, 15.6 Hz, 1H), 7.26-7.36 (m, 10H); 13C NMR (CDCl3, 100 MHz) δ -4.8, -4.7, 18.1, 
25.8, 28.1, 31.2, 64.5, 67.2, 68.4, 80.3, 125.8, 128.1, 128.2, 128.4, 128.5, 128.5, 128.6, 135.3, 
142.6, 159.1, 165.4, 168.9. HRMS (ESI) calcd for C31H44NO7Si (M+H)
+  570.2412, obsd 
570.2420. 
(3S,5R)-benzy-5-[(tert-butoxycarbonyl)methyl]-isooxazolidine-2-carboxylate 
(210) 
 
To a solution of (2S,4E)-1-benzyl-6-tert-butyl-2-[{(benzyloxy)carbonyl}{(tert-
butyldimethylsilyl)oxy}amino]hex-2-enedioate (209) (500.0 mg, 0.88 mmol, 1.0 equiv.) in CH2Cl2 
(3 mL) was added acetic acid (0.078 mL, 78.9 mg, 1.32 mmol, 1.5 equiv.). The mixture was 
cooled to 0 °C and TBAF (1.3 mL, 1 M in THF, 1.32 mmol, 1.5 equiv.) was added and allowed to 
stir at 0 °C for 30 min. The reaction mixture was warmed to rt and stirred for 2 days. Reaction 
was monitored by TLC and upon completion, the reaction mixture was concentrated and applied 
directly to a flash column, eluting with 4:1 (Hex-EtOAc), to obtain (2S,4R)-dibenzyl 2-{6-(tert-
butoxy)-oxoethyl}isoxazolidine-2,3-dicarboxylate 210 (344 mg, 55%). Rf 0.25 (2:1 Hex-EtOAc). 
[α]D
25 -23.25 (c 0.5, CHCl3).  
1H NMR (CDCl3, 400 MHz) δ 1.42 (s, 9H), 2.20 (ddt, J = 12.7, 9.1, 
5.9 Hz, 1 H), 2.48 (dd, J = 16.0, 8.0 Hz, 1H), 2.77-2.88 (m, 2H), 4.24-4.31 (m, 1H), 4.86 (dd, J = 
9.6, 5.9 Hz, 1H), 5.16 (d, J = 4.9 Hz, 1 H), 5.18 (d, J = 2.0 Hz, 1 H), 5.19 (d, J = 1.0 Hz, 1 H), 
5.22 (d, J = 4.0 Hz, 1 H), 7.26-7.37 (m, 10H); 13C NMR (CDCl3, 100 MHz) δ 28.0, 38.0, 38.4, 
60.6, 67.4, 68.4, 81.5, 128.2, 128.3, 128.4, 128.5, 128.6, 135.2, 135.5, 168.8, 170.1. HRMS 
(ESI) calcd for C25H30NO7 (M+H)
+ 456.5547, obsd 456.5548. 
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 (3S,5R)-3-(Allyloxycarbonylamino)-5-[(tert-butoxycarbonyl)-methyl]-2-
oxotetrahydrofuran (216) 
 
(2S,4R)-2-Amino-6-tert-butyl-4-hydroxyadipic acid (213): (3S,5R)-benzy-5-[(tert-
butoxycarbonyl)methyl]-isooxazolidine-2-carboxylate (210) (100 mg, 0.219 mmol, 1.0 equiv.)  
was dissolved in dry MeOH (2 mL) and 10 % Pd-C (93 mg, 0.879 mmol, 4.0 equiv.) was added. 
The suspension was stirred at rt overnight under an atmosphere of H2. The reaction mixture was 
filtered through Celite® and the filtrate concentrated to give the α-amino-carboxylic acid 213 as a 
colorless oil (40 mg). Rf  0.56 (6:4:1 CHCl3-MeOH-H2O). 
(2S,4R)-2-(Allyloxycarbonylamino)-6-tert-butyl-4-hydroxy-adipic acid (214): The amino 
acid was dissolved in a solution of sodium hydroxide (32 mg, 0.788 mmol, 3.6 equiv.) in water (2 
mL) at 0 °C and followed by dropwise addition of allyl chloroformate (28 µL, 32 mg, 0.263 mmol, 
1.2 equiv.) at 0 °C. The mixture was stirred an additional 1 h at 0 °C and then warmed to RT 
and stirred overnight. The reaction mixture was washed with diethyl ether (5 mL) to remove 
unreacted allylchloroformate. The aqueous layer was cooled to 0 °C and then acidified to ~pH 4 
by the dropwise addition of 0.5 M HCl. The aqueous layer was extracted with EtOAc (5x10 mL). 
The combined organic layers were dried over MgSO4, filtered and concentrated to obtain 6-tert-
butyl-N-allyloxycarbonyl-(2S,4R)-2-amino-4-hydroxy-α-oxohexanoic acid (214). Rf 0.54 (9:1 
CH2Cl2-MeOH) 
(3S,5R)-3-(Allyloxycarbonylamino)-5-[(tert-butoxycarbonyl)-methyl]-2-oxotetrahydrofuran 
(216): Cesium carbonate (36 mg, 0.109 mmol, 0.5 equiv.) was added to a solution of acid 214 in 
dry MeOH (4 mL). The mixture stirred for 2 h under N2 at rt. The mixture was concentrated, 
dissolved in DMF (5 mL) and cooled to 0 °C. Chloroacetone (21 µL, 24 mg, 0.263 mmol, 1.2 
equiv.) was added, the mixture warmed to rt, stirred overnight, diluted with H2O (5 mL) and 
extracted with EtOAc (3 x 5 mL). The combined organic layers were dried over MgSO4, filtered 
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and and concentrated to give a colorless oil that was dissolved in CH2Cl2 (2mL) and added 2,6-
Lutidine (254 µL, 235 mg, 2.190 mmol, 10.0 equiv.) and TBSOTf (402 µL, 463 mg, 1.752 mmol, 
8.0 equiv.).  Reaction mixture was stirred and concentrated to remove the CH2Cl2. Water (2 mL) 
was added to the reaction mixture which was then cooled to 0 °C and acidified to ~pH 4 by the 
dropwise addition of 0.5 M HCl. The acidic solution was then extracted with EtOAc (4 X 10 mL). 
The combined organic layers were dried over MgSO4, filtered and then concentrated to afford a 
viscous oil. Flash chromatography on silica gel (Hex-EtOAc 3:1) afforded the compound 216 as 
colorless oil (57 mg, 45% over 4 steps). Rf 0.54 (1:1 Hex-EtOAc). [α]D
25 -8.47 (c 2.5, CHCl3).  
1H 
NMR (CDCl3, 400 MHz) δ 1.45 (s, 9H), 2.14-2.17 (m, 1H), 2.38-2.79 (m, 3H), 4.48 (dd, J = 16.1, 
9.3 Hz, 1H), 4.58 (d, J = 5.3 Hz, 2H), 4.98 (dd, J = 16.1, 9.3 Hz, 1H), 5.22 (app. d, J = 10.4 Hz, 
1H), 5.30 (app. d, J = 16.4 Hz, 1H), 5.46 (d, J = 5.7 Hz, 1H), 5.90 (ddt, J = 16.4, 10.8, 5.6 Hz, 
1H); 13C NMR (CDCl3, 100 MHz) δ 28.0, 33.6, 40.6, 49.5, 66.2, 74.2, 81.9, 118.2, 132.3, 155.9, 
168.5, 174.6. HRMS (ESI) calcd for C14H21NNaO6 (M+Na)
+ 322.1261, obsd 322.1270. 
 (3S,5R)-3-(tert-butyl-carbamate)-5-[(methoxycarbonyl)-methyl]-2-oxo-
tetrahydrofuran (58a) 
 
Pd/C (10% w/w, 16 mg) was added to a solution of (2S,4R)-1-benzyl 2-tert butyl-2-(6-
methoxy-5-oxoethyl) isoxazolidine-4,5-dicarboxylate 163b (20 mg, 0.053 mmol, 1.0 equiv.) in 
dry MeOH (1ml). The vessel was evacuated and then opened up to an atmosphere of hydrogen 
and stirred overnight. The mixture was filtered through CeliteTM, washing well with MeOH (~25 
mL). The filtrate was concentrated to afford acid 167, dissolved in CH2Cl2 (2 mL), followed by 
addition of EDC (30 mg, 0.158 mmol, 3.0 equiv.) and DMAP (2 mg, 0.016 mmol, 0.3 equiv.). 
Reaction mixture was stirred overnight at rt under N2 atmosphere and then concentrated to 
afford a viscous oil. Flash chromatography on silica gel (Hex-EtOAc 3:1) afforded lactone 58a (3 
mg, 20%). Rf 0.29 (2:1 Hex-EtOAc). 
1H NMR* (CDCl3, 400 MHz) δ 1.50 (s, 9H), 2.20 (ddd, J = 
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12.6, 8.7, 5.6 Hz, 1H), 2.62 (dd, J = 16.4, 7.8 Hz, 1H), 2.81-2.86 (m, 1H), 2.90 (dd, J = 16.4, 5.6 
Hz, 1H), 3.70 (s, 3H), 4.33 (app. pent., J = 7.2 Hz, 1H), 4.75 (dd, J = 9.5, 5.6 Hz, 1H) ); 13C 
NMR (CDCl3, 100 MHz) δ 14.1, 28.1, 37.1, 38.0, 52.0, 61.8, 82.8, 156.3, 170.3, 170.6. HRMS 
(ESI) calcd for C12H18NO6 (M-H)
+  272.1140, obsd 272.1162. 
*1H NMR spectra of the title compound contaminated with ethyl acetate. 
(2S,4R)-2-(Allyloxycarbonylamino)-6-(tert-butyl)-4-(tert-
butyldimethylsilyloxy)-1-(2-oxopropyl)-adipate (222) 
 
(2S,4R)-2-Amino-6-tert-butyl-4-hydroxyadipic acid (213): (3S,5R)-benzy-5-[(tert-
butoxycarbonyl)methyl]-isooxazolidine-2-carboxylate (210) (80 mg, 0.176 mmol, 1.0 equiv.)  
was dissolved in dry MeOH (2 mL) and 10 % Pd-C (75 mg, 0.702 mmol, 4.0 equiv.) was added. 
The suspension was stirred at rt overnight under an atmosphere of H2. The reaction mixture was 
filtered through Celite® and the filtrate concentrated to give the α-amino-carboxylic acid 213 as a 
colorless oil (40 mg). Rf  0.56 (6:4:1 CHCl3-MeOH-H2O). 
(2S,4R)-2-(Allyloxycarbonylamino)-6-tert-butyl-4-hydroxy-adipic acid (214): The amino 
acid 213 was dissolved in 10% aqueous Na2CO3 solution (1.5 mL) and cooled to 0 °C in ice 
bath. Dioxane (1.5 mL) was added, followed by dropwise addition of allyl chloroformate (22 µL, 
25 mg, 0.211 mmol, 1.2 equiv.) at 0 °C. The mixture was stirred an additional 1 h at 0 °C and 
then warmed to RT and stirred overnight. The reaction mixture was washed with diethyl ether (5 
mL) to remove unreacted allylchloroformate. The aqueous layer was cooled to 0 °C and then 
acidified to ~pH 4 by the dropwise addition of 0.5 M HCl. The aqueous layer was extracted with 
EtOAc (5x10 mL). The combined organic layers were dried over MgSO4, filtered and 
concentrated to obtain compound 214. Rf  0.54 (9:1 CH2Cl2-MeOH) 
132 
 
(2S,4R)-2-(Allyloxycarbonylamino)-6-tert-butyl-4-(tert-butyl dimethylsilyloxy)-adipic acid: 
2,6-Lutidine (51 µL, 47 mg, 0.44 mmol, 2.5 equiv.) and TBSCl (66 mg, 0.44 mmol, 2.5 equiv.).  
were added sequentially to a solution of acid 214 in dry CH2Cl2 (2 mL) at rt under N2. Reaction 
mixture was stirred and concentrated to remove the CH2Cl2. Water (2 mL) was added to the 
reaction mixture which was then cooled to 0 °C and acidified to ~pH 4 by the dropwise addition 
of 0.5 M HCl. The acidic solution was then extracted with EtOAc (4 X 10 mL). The combined 
organic layers were dried over MgSO4, filtered and concentrated to give the carboxylic acid that 
was used directly in the next step without further purification. Rf 0.61 (95:5 CH2Cl2-MeOH). 
(2S,4R)-2-(Allyloxycarbonylamino)-6-(tert-butyl)-4-(tert-butyldimethylsilyloxy)-1-(2-
oxopropyl)-adipate (222): The carboxylic acid was dissolved in dry CH2Cl2 (2 mL) and cooled to 
0 ° C under N2 atmosphere. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide) (EDC) (68 mg, 
0.352 mmol, 2.0 equiv.) was added, followed by DMAP (6 mg, 0.0528 mmol, 0.3 equiv.) and 
acetol (36 µL, 39 mg, 0.528 mmol, 3.0 equiv.) at 0 °C. The reaction mixture was warmed to rt, 
stirred overnight and then concentrated to afford a viscous oil. Flash chromatography on silica 
gel (Hex-EtOAc 3:1) afforded the compound 222 as colorless oil (25 mg, 30% over 4 steps). Rf 
0.60 (1:1 Hex-EtOAc). [α]D
25 -13.25 (c 0.5, CHCl3).  
1H NMR (CDCl3, 400 MHz) δ 0.08 (s, 3H), 
0.09 (s, 3H), 0.89 (s, 9H), 1.45 (s, 9H), 1.93-1.99 (m, 1H), 2.17 (s, 3H), 2.30-2.51 (m, 3H), 4.29 
(app. pent. J = 5.9 Hz, 1H), 4.50 (ddd, J = 12.4, 7.7, 4.8 Hz, 1H), 4.57-4.78 (m, 4H), 5.20 (d, J = 
10.5 Hz, 1H), 5.30 (d, J = 16.0 Hz, 1H), 5.62 (d, J = 7.1 Hz, 1H), 5.90 (ddt, J = 16.0, 10.7, 5.3 
Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ -4.6, -4.7, 17.9, 26.1, 27.9, 28.1, 38.3, 43.1, 51.4, 65.9. 
67.2, 68.7, 80.9, 117.7, 132.7, 155.9, 171.7, 173.5, 201.0. HRMS (ESI) calcd for C23H42NO8Si 
(M+H)+ 488.2674, obsd 488.2684. 
(2S,4R)-2-(Allyloxycarbonylamino)-4-(tert-butyldimethylsilyloxy)-1-(2-
oxopropyl)-6- adipic acid (54) 
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2,6-Lutidine (107 µL, 99 mg, 0.924 mmol, 18.0 equiv.) was added dropwise to a solution 
of compound 222 (25 mg, 0.051 mmol, 1.0 equiv.) in dry CH2Cl2 (2 mL) under N2 at rt. The 
mixture was cooled to 0 °C and stirred for 5 min before the dropwise addition of TBSOTf (117 
µL, 135 mg, 0.510 mmol, 10.0 equiv.). Reaction mixture was warmed to rt and stirred for 6 h. A 
solution of potassium carbonate (8 mg, 0.061 mmol, 1.2 equiv.) in 10% H2O:THF (1 mL) was 
added and reaction mixture stirred for overnight at rt. The reaction mixture was concentrated to 
remove the CH2Cl2 and then acidified with saturated aqueous NaHSO4 to ~pH 4. Water (2 mL) 
was added to the reaction mixture. The acidic solution was then extracted with EtOAc (5 X 10 
mL). The combined organic layers were dried over MgSO4, filtered and then concentrated to 
afford a viscous oil. Flash chromatography on silica gel (Hex-EtOAc 1:2) afforded the compound 
54 as colorless oil (12 mg, 54%). Rf 0.34 (1:2 Hex-EtOAc). [α]D
25 -10.25 (c 0.5, CHCl3).  
1H NMR 
(CDCl3, 400 MHz) δ 0.08 (s, 3H), 0.09 (s, 3H), 0.89 (s, 9H), 1.93-1.99 (m, 1H), 2.17 (s, 3H), 
2.30-2.51 (m, 3H), 4.29 (app. pent. J = 5.9 Hz, 1H), 4.50 (ddd, J = 12.4, 7.7, 4.8 Hz, 1H), 4.57-
4.78 (m, 4H), 5.20 (d, J = 10.5 Hz, 1H), 5.30 (d, J = 16.0 Hz, 1H), 5.62 (d, J = 7.1 Hz, 1H), 5.90 
(ddt, J = 16.0, 10.7, 5.3 Hz, 1H); 13C NMR (CDCl3, 100 MHz) δ -2.4, 27.5, 33.3, 43.1, 45.4, 49.4, 
65.9. 71.2, 73.7, 117.7, 132.7, 155.9, 173.7, 175.1, 201.0. HRMS (ESI) calcd for C19H34NO8Si 
(M+H)+ 432.2084, obsd 432.2078. 
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4.7.3 Spectra 
Compound 192 (Scheme 4.8) - 1H NMR spectrum 
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Compound 192 (Scheme 4.8) - 13C NMR spectrum 
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Compound 196 (Scheme 4.11) – 1H NMR spectrum 
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Compound 196 (Scheme 4.11) - 13C NMR spectrum 
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Compound 200 (Scheme 4.12) – 1H NMR spectrum 
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Compound 200 (Scheme 4.12) - 13C NMR spectrum 
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Compound 207 (Scheme 4.16) – 1H NMR spectrum 
 
 
141 
 
 
 
Compound 207 (Scheme 4.16) - 13C NMR spectrum 
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Compound 195 (Scheme 4.17) – 1H NMR spectrum 
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Compound 195 (Scheme 4.17) – 13C NMR spectrum 
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Compound 208 (Scheme 4.17) – 1H NMR spectrum 
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Compound 208 (Scheme 4.17) – 13C NMR spectrum 
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Compound 209 (Scheme 4.18) – 1H NMR spectrum 
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Compound 209 (Scheme 4.18) - 13C NMR spectrum 
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Compound 210 (Scheme 4.18) – 1H NMR spectrum 
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Compound 210 (Scheme 4.18) - 13C NMR spectrum 
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Compound 216 (Scheme 4.20) – 1H NMR spectrum 
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Compound 216 (Scheme 4.20) – 13C NMR spectrum 
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Compound 58a (Scheme 4.22) – 1H NMR spectrum 
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Compound 58a (Scheme 4.22) – 13C NMR spectrum 
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Compound 222 (Scheme 4.24) – 1H NMR spectrum 
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Compound 222 (Scheme 4.24) – 13C NMR spectrum 
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Compound 54 (Scheme 4.24) – 1H NMR spectrum 
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Compound 54 (Scheme 4.24) – 13C NMR spectrum 
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CHAPTER 5: PEPTIDE FRAGMENT ASSEMBLY AND CYCLIZATION OF THE WESTERN 
HEMISPHER OF THEONELLAMIDE C 
 
 
5.1 Retrosynthesis for the Western Hemisphere of Theonellamide C 
 Revisiting our retrosynthetic analysis from Chapter 1, recall that our approach to the 
western hemisphere of theonellamide C involves major disconnections between -HAL/Asn, 
Ahad/β-Ala and -HAL/Ahad residues (Scheme 5.1). This leads to three building blocks: 
tetrapeptide 52, -HAL 53 and Ahad 222. In a forward sense, the initial peptide bond to be 
formed will be between the D-Ala acid component of -HAL and the amino-terminus of the 
tetrapeptide (I), followed by a condensation of the L-His amine component of -HAL with δ-acid 
of Ahad (II). Deallylation of the two termini will be accomplished simultaneously prior to 
cyclization of the amino-terminus of Ahad 222 with the carboxyl-terminus of tetrapeptide 52 (III). 
The site chosen for cyclization is ideal, since the β-Ala residue of the tetrapeptide is not 
susceptible to racemization during peptide bond formation. 
 
Scheme 5.1 Western hemisphere of theonellamide C: Retrosynthesis.  
5.2 Formation of a Dipeptide Containing erythro-HydroxyAsparagine (eHyAsn)  
The synthesis of tetrapeptide 52 required the preparation of an erythro-
hydroxyasparagine-phenylalanine (eHyAsn-Phe) dipeptide. Douglas Wong had made Boc-
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eHyAsn-Phe-OMe (223).93 His approach built directly on Boger’s synthesis of the tHyAsn 
diastereomer.94,95  
With dipeptide 223 in-hand, we sought to assemble the western fragment of 
theonellamide C. The methyl ester of dipeptide 223 was hydrolyzed with lithium hydroxide 
(Scheme 5.2). Unfortunately, the TBS group was lost on acidification, during work-up. We 
therefore hydrolyzed the ester with a single equivalent of LiOH and freezedried the mixture to 
give the lithium salt 224. The hydrochloride salt of β-alanine allyl ester (225) was prepared 
according to an analogous preparation of the corresponding benzyl ester.96 The lithium salt 224 
was coupled with 225. Poor yields led us to an alternative C-terminal protecting group that could 
be removed without byproducts or salt formation.  
 
Scheme 5.2 Formation of dipeptide. 
We needed more material to form the new dipeptide 234 containing a benzyl ester at the 
carboxyl end (Scheme 5.3). Therefore we repeated Wong’s synthesis of the dipeptide, with 
some modifications, to obtain useful quantities. Sharpless aminohydroxylation of the double 
bond in methyl p-methoxycinnamate (227) proceeded as described previously to give 228 
except that 228 did not precipitate from the reaction mixture as described. Flash 
chromatography was required for isolation. We then inverted the configuration at the 
stereogenic center bearing the OH substituent to give 229 by performing a Mitsunobu reaction 
with p-nitrobenzoate as the nucleophile. Wong had reported tetrahydrofuran (THF) as the 
solvent for this reaction and subjected the crude product mixture to the cleavage of the ester. In 
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the current work no desired product was isolated following this protocol. We then performed the 
Mitsunobu reaction with toluene as solvent. The reaction was monitored with TLC which showed 
appearance of a less polar product.  The p-nitrobenzoate ester was cleaved by azidolysis to 
obtain a 65% yield of inverted alcohol 229. The secondary alcohol was protected as its TBS 
ether using TBSCl and the methyl ester was ammonolyzed to generate the side chain amide, 
viz. compound 231. We swapped the Cbz group for the tert-butyl carbamate to give 232. The 
oxidative cleavage of the electron-rich aromatic ring was performed to obtain the carboxylic acid 
that was coupled with phenylalanine benzyl ester hydrochloride (233) to give dipeptide 234 
(Scheme 5.3). Detailed discussion of these reactions is given in the dissertation of Douglas 
Wong (Chapter 2).12 
 
Scheme 5.3 Synthesis of a dipeptide containing erythro-hydroxyasparagine. 
While performing the coupling reaction between acid 232 and amine 233 we were 
cognizant of side reactions with the unprotected side chain of asparagine.  
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5.3 Side Reactions of the Unprotected Side Chain Amide of Asparagine 
Asparagine (abbreviated as Asn or N, 237 and 238) is a non-essential amino acid which 
is coded for by AAU and AAC in mRNA. There is one carboxamide group on the side chain with 
one amino and one carboxyl group on the alpha carbon atom. Hence it can be considered an 
amide of aspartic acid (235 and 236). Asparagine is a neutral, polar, uncharged amino acid 
under any biologically relevant pH conditions.  
The amide group of asparagine can be slowly hydrolyzed to the carboxyl group to form 
aspartic acid. This conversion is related to the molecular basis of aging. 
 
Figure 5.1 Chemical structures of D- and L-aspartic acid and D- and L-asparagine. 
The carboxamido groups of asparagine should be suitably blocked during activation of 
the residues to prevent cyclization via the following two side reactions. 
1. Aspartimide Formation: This is a general problem for peptides incorporating asparagine 
and the likelihood depends on the sequence and situation. Treatment of aspartyl/glutamyl 
peptides with acid or base can lead to a rearrangement through a cyclic imide intermediate and 
produces a mixture of two peptides (Scheme 5.4).97 The aspartimide is more stable than the 
glutamimide, and more ω-peptide (isopeptide) is formed than α-peptide. The attack of the amide 
nitrogen at the side chain acyl carbon is influenced by the nature of Y and the nature of the 
residue located at C-terminal to the susceptible residue. The reaction occurs easily when the Y 
is a good leaving group and less readily when unsubstituted (Y = OH). The problem is solved by 
ester groups that are severely hindered. Bodanszky et al. showed that the amount of imide 
formed decreases in the order   OBzl>>OcHex>ODpn.98 [Dmpn = 2,4-dimethylpent-3-yl] 
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Scheme 5.4 Imide formation from a peptide sequence followed by generation of two peptide 
chains.  
 
 
One way of reducing this side reaction in the case of Asn is substitution on the 
carboxamido group which increases the solubility of derivatives in organic solvents and 
eliminates the side reactions. The carboxamide group does not undergo acylation or alkylation 
during chain assembly. 
2. Isoaspartimide formation upon activation of α-COOH of Asn. Upon activation of the Cα 
carboxylic acid, the unprotected side chain of asparagine can undergo isoaspartimide formation, 
followed by dehydration to give the β-cyanoalanine derivative (Scheme 5.5). This occurs 
prominently when coupling with phosphonium salts. The cyano group does not interfere with 
couplings, so the dehydrated residue is incorporated into the peptide. The dehydration is 
completely reversed by HF, partly reversed by TFA and very effectively suppressed for 
carbodiimide- or HBTU-mediated reactions by the presence of one equivalent of 1-
hydroxybenzotriazole (HOBt). The role of this additive is to serve as a superior proton donor, 
relative to the NH of the isoaspartimide. Thus the formation of the BtO- anion occurs in 
preference to dehydration to generate a nitrile. 
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Scheme 5.5 Mechanism of β-cyanoalanine formation. 
5.4 Formation of Tetrapeptide 
The benzyl ester of dipeptide 234 was subjected to hydrogenolysis to give acid 239 that was 
coupled to 225. The tripeptide was formed under conditions proven to minimize epimerization of 
Cα of the Phe residue.99 This approach now gave a satisfactory yield of tripeptide 226 (Scheme 
5.6). 
 
Scheme 5.6 Formation of tripeptide. 
5.4.1 Deprotection of α-Amine 
Before elongating 226 in the N-terminal direction with a suitably protected asparagine 
residue, it was necessary to remove the tert-butyl carbamate in the presence of the tert-
butyldimethylsilyl ether (OTBS). This turned out to be challenging and several known methods 
were investigated.  
Greshock and Funk used 10% trifluoroacetic acid (TFA) in dichloromethane  to remove 
the Boc group from intermediate compound 240 for the synthesis of welwistatin (Scheme 5.7-
A).100 Boger et al.94 achieved the deprotection of the Boc group, in the presence of TBS ethers, 
and trityl amides in complex peptides, with B-bromocatecholborane (BCB) (Scheme 5.7-B).101 
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Pearson and Cui102 used TBSOTf for the removal of a Boc group (Scheme 5.7-C). Removal of 
Boc via TBS-carbamates was first introduced by Sakaitani and Ohfune.103  
 
Scheme 5.7 Examples of Boc group deprotection in the presence of TBS ether.  
Preliminary results from attempted deprotection of tripeptide 226 by treatment of 
trifluoroacetic acid (TFA) gave a mixture of starting material and a compound that arises from 
double deprotection of both TBS and Boc groups. We used Boc-Ser(OTBS)-OMe (246) as a 
model system for the deprotection of Boc in presence of TBS ether. Unfortunately, when BCB 
was applied to both model and real systems, no desired product was isolated. The strategy of 
chemoselective transformation of an amino protecting group, via a tert-butyldimethylsilyl 
carbamate and cleaving it with TBAF worked well on a model system (246) but failed on the real 
system. Finally, treatment of compound 226 with an increased amount of trifluoroacetic acid in 
dichloromethane (1:1 TFA /CH2Cl2) resulted in amine 247 (Table 5.1, Scheme 5.8).  
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Table 5.1 Deprotection of N-terminus 
Boc Protected 
Amine 
Reaction Conditions Results 
 
, CH2Cl2 
Recovered starting material. 
246 TBSOTf, CH2Cl2 
Product obtained in 45% yield after 
methanolysis and flash chromatography. 
246 50% TFA in CH2Cl2 
1 h treatment with TFA at 0 °C, product was 
obtained in 98% yield after flash 
chromatography. 
226 TBSOTf, CH2Cl2 
No desired product was isolated 
 
226 50% TFA in CH2Cl2 
1 h treatment with TFA at 0 °C, reaction 
progress was monitored by TLC (6:4:1 
CHCl3:MeOH:H2O). TFA salt of free amine was 
taken in to the next coupling reaction without 
further purification. 
 
5.4.2. Elongation to Tetrapeptide 
Formation of tetrapeptide 249 was carried out using asparagine derivative 248, EDC and 
hydroxybenzotriazole (HOBt) (Scheme 5.8). 
 
Scheme 5.8 Preparation of a tetrapeptide. 
5.5 Model Studies for Cyclization 
Before investigating fragment condensations with valuable tetrapeptide 249 containing 
eHyAsn, a model de-oxy tetrapeptide 252 was prepared, substituting regular Asn for HyAsn. We 
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started with the formation of dipeptide 250 (Scheme 5.9) using commercially available 
asparagine building block 248 and phenylalanine 233 in order to rapidly assemble model 
tetrapeptide 250.  We obtained a poor yield of the product because of the high polarity and 
difficulty in isolation and purification.  
 
Scheme 5.9 Formation of a model dipeptide containing Phe and Asn. 
 Hence we started with Fmoc-Asn(Trt)-OH (251) in place of asparagine with an 
unprotected side chain, and coupled with phenylalanine benzyl ester hydrochloride (233) 
(Scheme 5.10). The dipeptide was then subjected to hydrogenolysis to obtain the free acid and 
coupled to β-Ala-OAll to form tripeptide 253. Next, deblocking of Fmoc was achieved by 
diethylamine and then coupled to Fmoc-Asn(Trt)-OH to form the tetrapeptide 254. It was then 
subjected to Fmoc cleavage with diethylamine and flash chromatography was performed to 
isolate the product. The trityl groups were removed with 1:1 TFA/CH2Cl2 to obtain free amine 
255.   
 
Scheme 5.10 Preparation of a model tetrapeptide.   
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 In collaboration with Chyree Batton, the next step was to couple the τ-histidinoalanine 
residue with the tetrapeptide assembled above. Hydrogenolysis was carried out to deblock the 
benzyl ester in τ-HAL 256 to obtain 257 (Scheme 5.11). The free amine 255 was coupled to -
HAL derivative 257, which afforded 258. The next step is to deprotect the L-His amine of -HAL 
using TFA to give amine 259. 
 
Scheme 5.11 Coupling of model tetrapeptide and -HAL derivative. 
 Proton NMR of compound 258 provided evidence for the successful coupling of the two 
fragments. While the 2.5-5.0 ppm region of the spectrum was complex, integration was 
consistent with the structure of 258 and a strong singlet at 3.8 ppm was assigned to the methyl 
ester. Another strong singlet appeared at 1.4 ppm for the Boc group. The allyl ester of the β-Ala 
residue gave rise to characteristic signals for the three olefinic protons in the 5-6 ppm region. An 
ion was observed at m/z 1065.4655, consistent with (M+H) for the molecular formula of 258 
(C53H65N10O14). 
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 In a parallel experiment, we coupled -HAL with of α-amino adipic acid derivative 195 
(Scheme 5.11). Removal of the Boc group from -HAL was carried out using TFA. The free 
amine 260 was condensed with the acid of α-AAA 195 which afforded 261. Proton NMR of 
compound 261 provided evidence for the successful coupling of the two fragments. A strong 
singlet at 3.7 ppm was assigned to the methyl ester. Another strong singlet appeared at 1.8 ppm 
for the CH3 group of the aceto moiety. Hβs were resonated as multiplet at 2.8-3.0. Hαs were 
appeared in the region of 4.1-4.8 ppm. Benzyl ester protons were characteristically observed at 
5.2 ppm. The allyl ester of the NHAlloc group gave rise to characteristic signals for the three 
olefinic protons in the 5-6 ppm region. Imidazole H5 and H2 were observed at 7.2 and 6.4 ppm. 
Fmoc protons were observed in the aromatic region (7.3-7.4 ppm). An ion was observed at m/z 
751.3841, consistent with (M+H) for the molecular formula of 261 (C41H45N5O9). 
5.6 Precedent for Pairs of Palladium-Labile Protecting Groups  
Hirschmann et al. synthesized homodetic tricyclic peptide 264 to study the conformation 
of the hormone somatostatin (SRIF).104 To execute consecutive ring closures in a controlled 
manner, they paired carboxyl and amine protecting groups that could be simultaneously and 
selectively removed. They chose Alloc/Allyl as one pair of amine/carboxy protecting group 
partners. Deprotection of the Alloc and Allyl group was accomplished simultaneously in 94% 
yield using Pd(0) as catalyst and tributyltin hydride (Bu3SnH) as the allyl acceptor (Scheme 
5.12). Subsequent cyclization was carried out using diphenylphosphoryl azide [DPPA, 
(C6H5O)2P(O)N3, 49]. Diphenylphosphoryl azide (49, DPPA) was also used by Tohdo et al. for 
ring closure of the western hemisphere of theonellamide F (Scheme 5.13).24 However, their 
protecting groups removed prior to cyclization were not allyl-based. 
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Scheme 5.12 Removal of Allyl and Alloc groups by Pd(0), cyclization and formation of the  
homodetic tricyclic peptide. 
 
Scheme 5.13 Cyclization of the western hemisphere of theonellamide F by Tohdo et al.23 
Vernall et al. synthesized an α-helical mimetic 266 for the 8-12 sequence of galanin, a 
peptide with anti-cancer and anti-diabetic properties.105 In the final stages of their synthesis, they 
treated a mixture of diastereomers of 265 with Pd(0) for simultaneous deprotection of the 
Allyl/Alloc protecting groups and used barbituric acid as the allyl acceptor, followed by BOP-
mediated cyclization to obtain cyclized product 266 as a mixture of diastereomers (Scheme 
5.14). 
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Scheme 5.14 Synthesis of cyclic pentapeptide. 
5.7 Future Work 
5.7.1 Formation of Western Ring 
 Coupling of the free γ-acid of α-AAA building block 195 (Scheme 5.15) with the primary 
amine 259 should lead to cyclization precursor 267. Treatment of 267 with Pd(0) will promote 
simultaneous removal of the C-terminal allyl group and the N-terminal allyloxycarbonyl group to 
give amino acid 268.  
 
Scheme 5.15 Formation of the western hemisphere of theonellamide C. 
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 Cyclization will result in the western hemisphere of theonellamide, compound 172. The 
model system presented enables us to optimize the reaction conditions for the coupling and 
cyclization. Moreover, this approach will provide simplified analogs for SARs studies (Section 
5.7.3). 
5.7.2 Completion of Theonellamide C 
The primary goal is to synthesize theonellamide C (7). In a forward sense, the western 
hemisphere will be constructed first followed by coupling of the D-Ala amine component of -
HAL with a serine residue (I) (Scheme 5.16).  
 
Scheme 5.16 Formation of theonellamide C. 
The next peptide bond to be formed (II) will be between the L-His acid component of -HAL 
and the amino terminus of the eastern hemisphere tetrapeptide which will lead to cyclization 
precursor 269. The amine component of serine and acid of Aboa will undergo HATU-mediated 
172 
 
cyclization under high dilution conditions (III). The site chosen for cyclization is ideal, since the 
Aboa residue is not susceptible to racemization during peptide bond formation. Global 
desilylation will be achieved by treating with TBAF as shown by Benson Edagwa’s106 work 
toward the synthesis of allovirodin and analogs. 
5.7.3 Structure Activity Relationships (SARs) of Theonellamides 
Synthesis of the western and eastern hemisphere represent penultimate goals. The plan 
for formation of the western hemisphere was shown earlier in Section 5.1 and the plan for 
synthesis of the eastern hemisphere is the subject of Douglas Wong’s dissertation.12 Each ring 
will be tested separately for antifungal activity. With the exception of the bridging -HAL residue, 
all other residues can be substituted for using commercially available building blocks to produce 
a bicyclic structure with a ring size consistent with the theonellamides (Figure 5.2).  
 
Figure 5.2 Macrocycles related to the western and eastern hemisphere with same ring size. 
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There are two amino acids in the western hemisphere that are not commercially 
available, eHyAsn (purple) and Ahad (green). Synthesis of the western hemisphere by replacing 
one amino acid at a time with a commercially available amino acid could elucidate the 
importance of each modified residue (270 & 271, Figure 5.2). The modified eastern hemisphere 
contains commercially available allo-threonine, serine, phenylalanine, and β-phenylalanine (273, 
Figure 5.2). The tetrapeptide will be coupled with the -HAL-serine tripeptide. Each hemisphere 
analog will be tested for their biological activity to reveal whether or not they independently 
demonstrate antifungal activity. In the end, both hemispheres will be coupled together to form 
the bicycle.    
The identification of a minimal chemical structure that will result in potent antifungal 
activity could be theonellamide X (274, Figure 5.3), an unnatural analog in which all the 
substitutions proposed above are incorporated simultaneously. Our on going synthetic efforts 
are necessary to probe the structure activity relationship of the theonellamides. 
 
Figure 5.3 Chemical composition of Theonellamide X. 
5.8 Experimental Section 
5.8.1 General Methods 
The general methods are as described in Chapter 2. NMR spectra were recorded on a 
Bruker AV-400 or a Bruker AV Nanobay-400 liquid spectrometer. 
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5.8.2 Procedures 
 (2S,3R)-Methyl 3-(benzyloxycarbonylamino)-2-hydroxy-3-(4-
methoxyphenyl)propanoate (228) 
 
Benzyl carbamate (9.05 g, 60.0 mmol, 2.30 equiv.) was dissolved in n-PrOH (70 mL).  A 
solution of NaOH (2.44 g, 61.0 mmol, 2.35 equiv.) in H2O (110 mL) was added and the resulting 
solution stirred for 10 min.  Freshly prepared tert-butyl hypochlorite107 (6.90 mL, 6.62 g, 61.0 
mmol, 2.35 equiv.) was added dropwise and the resulting solution stirred for an additional 10 
min.  (DHQD)2PHAL (0.83 g, 1.3 mmol, 5 mol %) in n-PrOH (40 mL) was added and the 
reaction vessel immersed in a water bath at ambient temperature and stirred for 5 min.  (E)-
Methyl 3-(4-methoxyphenyl)acrylate 227 (5.0 g, 26.0 mmol, 1.0 equiv.) was added as a solid all 
at once, followed immediately by K2OsO2(OH)4 (0.38 g, 1.0 mmol, 4 mol %).  The reaction 
mixture was stirred for 3 h at 0 ˚C.  The reaction mixture was evaporated and the residue 
subjected to flash chromatography (Hex-EtOAc 3:1) to afford compound 228 as a colorless solid 
(6.35 g, 64%).  Rf 0.32 (Hex-EtOAc 1:1). [α]D
25 -5.9 (c 1.0, CHCl3. 
1H NMR (CDCl3, 400 MHz) δ 
3.18 (br s, 1H), 3.80 (s, 6H), 4.45 (s, 1H), 5.07 (dd, J = 17.8, 12.0 Hz, 2H), 5.21 (d, J = 9.1 Hz, 
1H), 5.65 (d, J = 9.3 Hz, 1H), 6.88 (d, J = 8.7 Hz, 2H), 7.25-7.35 (m, 7H); 13C NMR (CDCl3, 100 
MHz) δ 53.1, 55.3, 56.0, 67.0, 73.5, 114.1, 128.0, 128.1, 128.2, 128.5, 131.0, 136.3, 155.7, 
159.2, 173.3; HRMS (ESI) calcd for C19H20NO6 (M-H)
+ 358.1496, obsd 358.1489. 
 (2R,3R)-Methyl 3-(benzyloxycarbonylamino)-2-hydroxy-3-(4-
methoxyphenyl)propanoate (229) 
                                                       
p-Nitrobenzoic acid (855 mg, 5.12 mmol, 5.5 equiv.) was added to a solution of (2S,3R)-
methyl 3-(benzyloxycarbonylamino)-2-hydroxy-3-(4-methoxyphenyl)propanoate 228 (500 mg, 
0.93 mmol, 1.0 equiv.) in dry toluene (10 mL).  Triphenylphosphine (1.43 g, 5.12 mmol, 5.5 
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equiv.) was added under N2 and reaction mixture was cooled to 0 °C.  Diisopropyl 
azodicarboxylate (1 mL, 1.04 g, 5.12 mmol, 5.5 equiv.) was slowly added via syringe.  Upon 
completion of the addition, the ice bath was removed and the reaction mixture stirred at room 
temperature for 24 h.  The reaction mixture was concentrated and the residue dissolved in 
anhydrous MeOH (10 mL).  Sodium azide (302 mg, 4.65 mmol, 5.0 equiv.) was added and the 
mixture heated at 45 ˚C for 18 h.  The solvent was removed under reduced pressure and the 
product isolated from the residue by flash chromatography (Hex-EtOAc, 3:1) to give 229 as a 
pale yellow solid (325 mg, 65%).  Rf 0.32 (1:1 Hex-EtOAc). [α]D
25 -20.5 (c 1.0, CHCl3). 
1H NMR 
(CDCl3, 400 MHz) δ 2.94 (br s, 1H), 3.70 (s, 3H), 3.78 (s, 3H), 4.59 (dd, J = 6.5, 3.3 Hz, 1H), 
5.11 (d, J = 12.2 Hz, 1H), 5.11 (d, J = 12.2 Hz, 1H), 5.10-5.13 (m, 1H), 5.80 (d, J = 8.4 Hz, 1H), 
6.83 (d, J = 8.6 Hz, 2H), 7.18 (d, J = 12.2 Hz, 2H), 7.24-7.35 (m, 5H); 13C NMR (CDCl3, 100 
MHz) δ 52.7, 55.2, 56.4, 67.0, 73.1, 113.9, 128.2, 128.5, 128.6, 136.3, 155.5, 159.5, 172.3; 
HRMS (ESI) calcd for C19H20NO6 (M-H)
+ 358.1296, obsd 358.1295. 
 (2R,3R)-Methyl-3-(benzyloxycarbonylamino)-2-(tert-butyldimethylsilyloxy)-3-
(4-methoxyphenyl)propanoate (230) 
                    
Imidazole (954 mg, 13.0 mmol, 15.0 equiv.) was added to a solution of (2R,3R)-methyl 
3-(benzyloxycarbonylamino)-2-hydroxy-3-(4-methoxyphenyl)propanoate 229 (400 mg, 1.1 
mmol, 1.0 equiv.) in dry CH2Cl2 (5 mL).  The mixture was stirred for 10 min before addition of 
TBSCl (1700 mg, 11.0 mmol, 10.0 equiv.).  The reaction mixture was stirred for 17 h at rt.  The 
reaction mixture was diluted with ethyl acetate (25 mL) and concentrated.  Flash 
chromatography on silica gel (Hex-EtOAc, 2:1) afforded the TBS ether 230 as a clear oil (448 
mg, 85%).  Rf 0.24 (4:1 Hex-EtOAc). [α]D
25.0 -16.8 (c 1.0, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ 
0.03 (s, 3H), 0.07 (s, 3H), 0.89 (s, 9H), 3.53 (s, 3H), 3.74 (s, 3H), 4.59 (d, J = 3.9 Hz, 1H), 5.02-
5.12 (m, 3H), 5.53 (d, J = 8.0 Hz, 1H), 6.79 (d, J = 8.7 Hz, 2H), 7.22 (d, J = 7.9 Hz, 2H), 7.21-
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7.32 (m, 5H); 13C NMR (CDCl3, 100 MHz) δ -5.5, -5.1, 18.3, 25.7, 51.6, 55.2, 57.0, 66.8, 74.3, 
113.7, 128.1, 128.5, 128.9, 129.6, 136.4, 155.5, 159.3, 171.4; HRMS (ESI) calcd for 
C25H36NO6Si (M+H)
+ 474.2106, obsd 474.2114. 
 Benzyl (1R, 2R)-3-amino-2-(tert-butyldimethylsilyloxy)-1-(4-methoxyphenyl)-
3-oxopropylcarbamate (231) 
 
Ammonia gas was bubbled through a solution of (2R,3R)-methyl 3-
(benzyloxycarbonylamino)-2-(tert-butyldimethylsilyloxy)-3-(4-methoxyphenyl)propanoate (230) 
(373 mg, 0.78 mmol) in dry MeOH (20 mL) at 0 ˚C.  The reaction vessel was stoppered and the 
mixture stirred for 7 d at room temperature.  The solution was cooled to 0 ˚C and resaturated 
with ammonia gas.  The reaction vessel was stoppered and the mixture stirred for 7 d at room 
temperature.  The solvent was removed under reduced pressure.  Flash chromatography (Hex-
EtOAc, 3:1) led to recovery of the methyl ester (72 mg, 20%) and isolation of the primary amide 
231 as a colorless foam (239 mg, 66%). Rf 0.29 (1:1 Hex-EtOAc). [α]
26.5
D +3.9 (c 1.0, CHCl3). 
1H 
NMR (CDCl3, 400 MHz) δ -0.02 (s, 3H), 0.01 (s, 3H), 0.92 (s, 9H), 3.77 (s, 3H), 4.43 (d, J = 3.7 
Hz, 1H), 4.95-5.08 (m, 3H), 5.61 (d, J = 6.1 Hz, 1H), 6.03 (s, 1H), 6.09 (s, 1H), 6.82 (d, J = 8.1 
Hz, 2H), 7.23 (d, J = 7.8 Hz, 2H), 7.31-7.33 (m, 5H); 13C NMR (CDCl3, 100 MHz) δ -5.5, -5.4, 
18.0, 25.7, 55.2, 57.6, 66.8, 89.9, 113.6, 128.0, 128.1, 128.4, 129.1, 129.7, 136.4, 155.5, 159.3, 
171.4; HRMS (ESI) calcd for C24H35N2O5Si (M+H)
+ 459.2309, obsd 459.2313. 
 tert-Butyl (1R,2R)-3-amino-2-(tert-butyldimethylsilyloxy)-1-(4-
methoxyphenyl)-3-oxopropylcarbamate (232) 
 
A solution of benzyl (1R,2R)-3-amino-2-(tert-butyldimethylsilyloxy)-1-(4-methoxyphenyl)-
3-oxopropylcarbamate 231 (850 mg, 2.1 mmol, 1.00 equiv.) and Boc2O (443 mg, 2.3 mmol, 1.12 
equiv.) in CH3OH (20 mL) was treated with 10% Pd-C (45 mg).  The reaction mixture was stirred 
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under H2 (1 atm) at 25 °C overnight.  The Pd-C was removed by filtration through Celite
, and 
the filtrate was concentrated.  Flash chromatography (Hex-EtOAc, 2:1) provided 232 as a 
colorless foam (745 mg, 95%). Rf 0.30 (1:1 EtOAc-Hex). [α]
26.5
D 14.6 (c 1.0, CHCl3). 
1H NMR 
(CDCl3, 400 MHz) δ 0.04 (s, 6H), 0.93 (s, 9H), 1.40 (s, 9H), 3.76 (s, 3H), 4.40 (s, 1H), 4.91 (app 
s, 1H), 5.35 (app s, 1H), 6.03 (s, 1H), 6.51 (s, 1H), 6.81 (d, J = 8.3 Hz, 2H), 7.21 (d, J = 8.3 Hz, 
2H); 13C NMR (CDCl3, 100 MHz) δ -5.5, -5.3, 18.0, 25.7, 28.3, 55.1, 57.2, 76.0, 79.4, 113.5, 
129.1, 129.9, 154.7, 159.1, 174.4. HRMS (ESI) calcd for C21H37N2O5Si (M+H)
+ 425.2129, obsd 
425.2135.  
(S)-Benzyl-2-((2S,3R)-4-amino-2-(tert-butoxycarbonylamino)-3-(tert-
butyldimethylsilyloxy)-4-oxobutanamido)-3-phenylpropanoate (234) 
 
A solution of sodium periodate (5.504 g, 26 mmol, 18.1 equiv) in water (130 mL) was 
added, all at once, to a solution of tert-butyl (1R,2R)-3-amino-2-(tert-butyldimethylsilyloxy)-1-(4-
methoxyphenyl)-3-oxopropylcarbamate 232 (604 mg, 1.4 mmol, 1.00 equiv) in a mixture of 
EtOAc (16 mL) and MeCN (16 mL). The biphasic mixture was stirred by an overhead 
mechanical stirrer for 1 h at RT. Ruthenium trichloride trihydrate (60 mg, 0.3 mmol, 0.2 mol %) 
and sodium bicarbonate (464 mg, 5.5 mmol, 3.90 equiv.) were add sequentially, as solids, to 
give a black, biphasic mixture, that was stirred at RT overnight, during which time the mixture 
became orange, then yellow and eventually colorless and milky. The mixture was diluted with 
sat’d aq. NaHCO3 (240 mL) and washed with CH2Cl2 (160 mL). The organic layer was back-
extracted with sat’d aq. NaHCO3 (240 mL). The combined aqueous layers were acidified at 0 °C 
with 10 % aq. HCl (~150 mL) to pH 2.5 and then extracted with EtOAc (12 X 250 mL). The 
combined organic layers were dried over MgSO4, filtered, and concentrated to give acid 
(2S,3R)-4-amino-2-(tert-butoxycarbonylamino)-3-(tert-butyldimethylsilyloxy)-4-oxobutanoic acid 
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as a brown foam (456 mg) that was dissolved in THF (22 mL) and cooled to 0 °C under N2. 
Phenylalanine benzyl ester hydrochloride (233) (368 mg, 1.26 mmol, 1.00 equiv.) was added as 
a solid, followed by Et3N (350 µL, 255 mg, 2.52 mmol, 2.00 equiv.), EDC (253 mg, 132 mmol, 
1.05 equiv.) and HOBt (256 mg, 1.89 mmol, 1.50 equiv.). After 20 min the ice bath was 
removed, the mixture warmed to RT and stirred overnight. The mixture was concentrated and 
applied to a flash column in a minimum volume of CH2Cl2. Elution with a gradient of 
2.5:1.0→1.0:2.0 (Hex-EtOAc) yielded dipeptide 234 as a colorless foam (415 mg, 50% over 2 
steps). Rf 0.53 (1:1 EtOAc-Hex).  [α]D
25 +25.7 (c  1.0, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ 0.08 
(s, 3H), 0.12 (s, 3H), 0.90 (s, 9H), 1.43 (s, 9H), 3.00-3.18 (m, 2H), 4.61-4.67 (m, 2H), 4.84 (dd, J 
= 13.8, 6.2 Hz, 1H), 5.07 (s, 2H), 5.47 (d, J = 6.7 Hz, 1H), 5.84 (br s, 1H), 6.46 (br s, 1H), 6.66 
(d, J = 7.7 Hz, 1H), 7.04-7.16 (m, 2H), 7.18-7.28 (m, 5H), 7.33-7.35 (m, 3H);  13C NMR (CDCl3, 
100 MHz) δ -5.3, -5.1, 18.0, 25.6, 28.3, 37.9, 53.5, 53.5, 57.3, 67.2, 67.2, 69.6, 74.1, 80.1, 85.4, 
127.1, 128.5, 128.6, 129.3, 135.1, 135.6, 154.8, 167.4, 170.8, 174.2. HRMS (ESI) calcd for 
C31H46N3O7Si (M+H)
+ 600.3100, obsd 600.3118. 
 β-Alanine allyl ester hydrochloride (225) 
β-Alanine (502 g, 5.6 mmol, 1.0 equiv.), allyl alcohol (3.4 mL, 2.9 g, 27.0 mmol, 4.8 
equiv.) and chlorotrimethylsilane (1.2 mL, 1.03 g, 9.4 mmol, 1.6 equiv.) were heated at 100 °C 
for 4 h. The reaction mixture was cooled to RT and poured onto diethyl ether (115 mL ) and 
stirred at 0 °C for 24 h. The precipitate was collected by filtration. The allyl protected β-alanine 
225 was obtained as its hydrochloride salt (800 mg, 86%). m.p. 48-51 °C, Rf 0.38 (9:1 DCM-
MeOH); 1H NMR (CDCl3, 400 MHz) δ 2.96 (t, J = 6.7 Hz, 2H), 3.38 (t, J = 6.7, 2H), 4.63 (d, J = 
5.8 Hz, 2H), 5.24 (dd, J= 10.4, 1.1 Hz, 1H), 5.33 (dd, J = 17.2, 1.4), 5.86-5.96 (m, 1H), 8.2 (br, 
2H); 13C NMR (CDCl3, 100MHz) δ 31.3, 35.7, 65.9, 118.8, 131.7, 170.9; HRMS (ESI) calcd for 
C6H11NO2 (M+H)
+ 130.0868, obsd 130.0863.  
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 Boc-HyAsn(OTBS)-Phe-β-Ala-OAll (226) 
To a solution of dipeptide benzylester (234) (100 mg, 0.16 mmol, 1.0 equiv.) in dry 
MeOH (6 mL) was added 10 % Pd-C (9 mg, 0.8 mmol, 0.5 equiv.). The suspension was stirred 
at RT overnight under H2 gas (1 atm). The reaction mixture was filtered through Celite® to 
remove the Pd-C. The solution was concentrated to give the carboxylic acid as a colorless oil 
(85 mg) that was used directly in the next step without further purification. The intermediate 
carboxylic acid (85 mg, 0.166 mmol, 1.05 equiv.) was dissolved in DCM (6 mL) and cooled to 0 
°C under N2. β-Alanine allyl ester hydrochloride (225) (27 mg, 0.159 mmol, 1.00 equiv.) was 
added as a solid followed by 2,4,6-collidine (43 µL, 39 mg, 0.318 mmol, 2.00 equiv.) and HATU 
(64 mg, 0.166 mmol, 1.05 equiv.). After 20 min, the mixture was warmed to RT and stirred 
overnight. The mixture was concentrated and applied to a flash column in a minimum volume of 
DCM. Elution with a gradient of 2:1→1:2 (Hex-EtOAc) gave tripeptide 226 as a colorless oil (85 
mg, 85%), Rf 0.42 (2:1 EtOAc-Hex). [α]D
25 +8.4 (c  1.0, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ 
0.13 (s, 3H), 0.15 (s, 3H), 0.91 (s, 9H), 1.43 (s, 9H), 2.35-2.52 (m, 2H), 2.96 (t, J = 6.7 Hz, 2H), 
2.99 (dd, J = 13.6, 7.0 Hz, 1H), 3.18 (dd, J = 13.6, 6.1 Hz, 1H), 3.34-3.47 (m, 2H), 4.54 (d, J = 
9.9 Hz, 2H), 4.50-4.64 (m, 3H), 5.25 (dd, J = 10.4, 1.3 Hz, 1H), 5.30 (dd, J = 17.2, 1.3 Hz, 1H), 
5.38 br d, J = 6.3 Hz, 1H), 5.84-5.94 (m, 1H), 6.45 (br, 1H), 6.54 (br, 1H), 6.60 (br, 1H), 7.17-
7.30 (m, 5H); 13C NMR (CDCl3, 100MHz) δ -5.3, -5.0, 18.0, 25.7, 28.3, 33.7, 34.8, 37.8, 54.8, 
57.7, 65.4, 74.0, 80.3, 118.6, 127.0, 128.7, 129.3, 131.8, 136.4, 155.0, 167.7, 170.2, 172.0, 
174.0; HRMS (ESI) calcd for C30H48N4O8Si (M+H)
+ 621.3328, obsd 621.3334.  
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 Boc-Asn-HyAsn(OTBS)-Phe-β-Ala-OAll (249) 
To a solution of tripeptide 226 (100 mg, 0.161 mmol, 1.00 equiv.) in dry CH2Cl2 (0.5 mL) 
was added TFA (0.5 mL). The reaction mixture was stirred for 1 hr at 0 °C and then 
concentrated to give the free amine 247 as a colorless oil (84 mg) that was used directly in the 
next step without further purification.  
The intermediate amine 247 (84 mg, 0.161 mmol, 1.00 equiv.) was dissolved in CH2Cl2 
(2 mL) and cooled to 0 °C under N2. Nα-Boc-L-asparagine (248) (39 mg, 0.169 mmol, 1.05 
equiv.) was added as a solid followed by diisopropylethylamine (56 µL, 42 mg, 0.322 mmol, 2.0 
equiv.) and HATU (64 mg, 0.169 mmol, 1.05 equiv.). After 20 min, the mixture was warmed to 
RT and stirred overnight. The mixture was concentrated and applied to a flash column in a 
minimum volume of DCM. Elution with a gradient of 95:5→9:1 (CH2Cl2-MeOH) gave 
tetrapeptide 249 as a colorless oil (64 mg, 54%), Rf 0.42 (2:1 EtOAc-Hex). [α]D
25 +16.2 (c  1.0, 
MeOH). 1H NMR (CD3OD, 400 MHz) δ 0.13 (s, 3H), 0.15 (s, 3H), 0.91 (s, 9H), 1.43 (s, 9H), 2.36 
(dd, J = 13.6, 7.0 Hz, 2H), 2.41-2.52 (m, 2H), 2.96 (t, J = 6.7 Hz, 2H), 2.99 (dd, J = 13.6, 7.0 Hz, 
1H), 3.18 (dd, J = 13.6, 6.1 Hz, 1H), 3.34-3.47 (m, 2H), 4.54 (d, J = 9.9 Hz, 2H), 4.50-4.64 (m, 
3H), 5.25 (dd, J = 10.4, 1.3 Hz, 1H), 5.30 (dd, J = 17.2, 1.3 Hz, 1H), 5.38 br d, J = 6.3 Hz, 1H), 
5.84-5.94 (m, 1H), 7.17-7.30 (m, 5H); 13C NMR (CD3OD, 100MHz) δ -5.3, -5.0, 25.7, 28.3, 30.5, 
33.7, 34.8, 37.8, 38.1, 52.8, 55.7, 57.7, 65.4, 74.0, 80.3, 118.6, 127.0, 128.7, 129.3, 131.8, 
136.4, 155.0, 167.7, 170.2, 172.0, 173.4, 173.5, 174.0; HRMS (ESI) calcd for C34H55N6O10Si 
(M+H)+ 735.3228, obsd 735.3234. 
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 Fmoc-Asn(Trt)-Phe-β-Ala-OAll (253) 
Fmoc-Asn(Trt)-Phe-OBn (252): Nα-Fmoc-N-β-trityl-L-asparagine (251) (194 mg, 0.34 
mmol, 1.00 equiv.) was dissolved in dry CH2Cl2 (2 mL) and cooled to 0 °C under N2. 
Phenylalanine benzyl ester hydrochloride (100 mg, 0.34 mmol, 1.00 equiv.) was added as a 
solid, followed by Et3N (95 µL, 69 mg, 0.68 mmol, 2.00 equiv.), EDC (69 mg, 0.36 mmol, 1.05 
equiv.) and HOBt (69 mg, 0.51 mmol, 1.50 equiv.). After 20 min the ice bath was removed, the 
mixture warmed to RT and stirred overnight. The mixture was filtered through a pad of silica, 
washing well with 98:2 CH2Cl2-MeOH and concentrated to provide Fmoc-Asn(Trt)-Phe-OBn 
(252).  
The dipeptide 252 was dissolved in dry MeOH (2 mL) and 10 % Pd-C (18 mg, 0.34 
mmol, 1.0 equiv.) was added. The suspension was stirred at RT overnight under an atmosphere 
of H2. The reaction mixture was filtered through Celite
® and the filtrate concentrated to give the 
carboxylic acid as a colorless oil (85 mg) that was used directly in the next step without further 
purification.  
The intermediate carboxylic acid (140 mg, 0.188 mmol, 1.05 equiv.) was dissolved in 
CH2Cl2 (2 mL) and cooled to 0 °C under N2. β-Alanine allyl ester hydrochloride (225) (30 mg, 
0.179 mmol, 1.00 equiv.) was added as a solid followed by 2,4,6-collidine (48 µL, 43 mg, 0.358 
mmol, 2.00 equiv.) and HATU (71 mg, 0.188 mmol, 1.05 equiv.). After 20 min, the mixture was 
warmed to RT and stirred overnight. The mixture was concentrated and applied to a flash 
column in a minimum volume of CH2Cl2. Elution with a gradient of 98:2→95:5 CH2Cl2-MeOH 
yielded tripeptide 253 as a colorless foam (152 mg, 55% over 3 steps). Rf 0.50 (9:1 CH2Cl2-
MeOH).  [α]D
25 -5.2 (c  0.5, CHCl3). 
1H NMR (CDCl3, 400 MHz) δ 2.22-2.34 (m, 2H), 2.76 (dd, J 
= 15.3, 6.2 Hz, 1H), 2.80-3.09 (m, 3H), 3.25 (sept., J = 7.7 Hz, 2H), 4.17 (t, J = 6.8 Hz, 1H), 
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4.22-4.52 (m, 4H), 4.49 (d, J = 5.1 Hz, 2H), 4.56 (q, J = 6.6 Hz, 1H), 5.23 (dd, J = 10.4, 1.1 Hz, 
1H), 5.28 (dd, J = 17.2, 1.4 Hz, 1H), 5.87 (ddt, J = 16.2, 10.7, 5.5 Hz, 1H), 6.25 (d, J = 6.7 Hz, 
1H), 6.60 (t, J = 5.9 Hz, 1H), 6.88 (d, J = 8.2 Hz, 1H), 7.06-7.34 (m, 23H), 7.41 (t, J = 7.0 Hz, 
2H), 7.56 (d, J = 6.7 Hz, 2H), 7.76 (d, J = 5.9 Hz, 2H); 13C NMR (CDCl3, 100 MHz) δ 29.7, 33.6, 
34.9, 37.6, 38.2, 47.1, 51.8, 54.7, 65.2, 67.4, 70.9, 118.4, 120.0, 125.1, 126.9, 127.1, 127.2, 
127.8, 128.0, 128.6, 129.2, 132.0, 136.5, 141.3, 143.7, 144.2, 170.1, 170.5, 171.6. HRMS (ESI) 
calcd for C53H51N4O7 (M+H)
+  855.3752, obsd 855.3752. 
 Fmoc-Asn(Trt)-Asn(Trt)-Phe-β-Ala-OAll (254) 
To a solution of tripeptide 253 (80 mg, 0.094 mmol, 1.00 equiv.) in dry acetonitrile (1 mL) 
was added Et2NH (1 mL). The reaction mixture was stirred at RT for 2 h and then concentrated 
to give the free amine as a colorless solid (80 mg) that was used directly in the next step without 
further purification.  
The intermediate amine (59 mg, 0.094 mmol, 1.00 equiv.) was dissolved in CH2Cl2 (2 
mL) and cooled to 0 °C under N2. Nα-Fmoc-N-β-trityl-L-asparagine (251) (58 mg, 0.098 mmol, 
1.05 equiv.) was added as a solid followed by 2,4,6-collidine (27 µL, 25 mg, 0.207 mmol, 2.2 
equiv.) and HATU (37 mg, 0.098 mmol, 1.05 equiv.). After 20 min, the mixture was warmed to 
RT and stirred overnight. The mixture was concentrated and applied to a flash column in a 
minimum volume of CH2Cl2. Elution with 98:2 (CH2Cl2-MeOH) gave tetrapeptide 254 as a 
colorless foam (91 mg, 64%), Rf 0.52 (9:1 CH2Cl2-MeOH). [α]D
25 -18.8 (c  1.0, CHCl3). 
1H NMR 
(CDCl3, 400 MHz) δ 2.28-2.34 (m, 1H), 2.72 (dd, J = 15.7, 6.0 Hz, 2H), 2.85 (dd, J = 15.4, 3.8 
Hz, 2H), 3.00 (d, J = 5.4 Hz, 2H), 3.30 (sept., 6.4 Hz, 2H), 4.22-4.27 (m, 1H), 4.50 (d, J = 4.6Hz, 
2H), 4.58 (dd, J = 11.8, 7.7 Hz, 2H), 5.22-5.27 (m, 1H), 5.32 (dd, J = 15.9, 5.7 Hz, 1H), 5.87 
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(ddt, J = 16.3, 10.7, 5.4 Hz, 1H), 6.55 (t, J = 6.4 Hz, 1H), 6.89 (d, J = 7.4 Hz, 1H), 7.03-7.30 (m, 
39H), 7.56 (d, J = 6.7 Hz, 2H), 7.76 (d, J = 5.9 Hz, 2H); 8.34 (t, J = 6.4 Hz, 2H); 13C NMR 
(CDCl3, 100 MHz) δ 28.2, 33.6, 34.9, 37.4, 37.5, 45.5, 47.1, 48.5, 50.8, 54.8, 65.3, 70.9, 118.4, 
126.9, 127.1, 127.2, 128.0, 128.5, 128.7, 128.8, 129.3, 132.0, 136.6, 142.3, 143.1, 144.1, 168.8. 
169.6. 170.0, 170.2, 172.3. HRMS (ESI) calcd for C76H71N6O9 (M+H)
+  1212.4025, obsd 
1212.4006. 
 Boc--HAL-Asn-Asn-Phe-β-Ala-OAll (258) 
H.Asn-Asn-Phe-β-Ala-OAll 255: To a solution of tetrapeptide 254 (20 mg, 0.016 mmol, 
1.00 equiv.) in dry acetonitrile (1 mL) was added Et2NH (1 mL). The reaction mixture was stirred 
at rt for 2 h and then concentrated to give the amine as a colorless solid (16 mg) that was 
dissolved in dry CH2Cl2 (0.3 mL) and cooled to 0 °C under N2. Trifluoroacetic acid (0.3 mL) was 
added dropwise. The reaction mixture was stirred for 1 h at 0 °C. The mixture was concentrated 
three times from toluene (1 mL each time), then diluted with MeOH (3 mL) and neutralized by 
the addition of solid Na2CO3 to ~pH 7. The reaction mixture was filtered through a pad of silica 
gel with a gradient of 9:1→4:1 (CH2Cl2-MeOH) to afford tetrapeptide amine 255 (8 mg). 
-HAL-COOH (257): The -HAL derivative 256 (11 mg, 0.016 mmol, 1.0 equiv.) was 
dissolved in dry MeOH (2 mL) and 10 % Pd-C (2 mg, 0.016 mmol, 1.0 equiv.) was added. The 
suspension was stirred at RT overnight under an atmosphere of H2. The reaction mixture was 
filtered through Celite® and the filtrate concentrated to give the carboxylic acid 257 as a 
colorless oil (9 mg) that was used directly in the next step without further purification.  
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The intermediate amine 255 (8 mg, 0.0158 mmol, 1.00 equiv.) was dissolved in CH2Cl2 
(1.5 mL) and cooled to 0 °C under N2. -HAL-COOH 257 (9 mg, 0.016 mmol, 1.05 equiv.) was 
added as a solution in CH2Cl2 (1.5 mL) followed by collidine (2 µL, 1.8 mg, 0.322 mmol, 2.0 
equiv.) and HATU (6 mg, 0.016 mmol, 1.05 equiv.). After 20 min, the mixture was warmed to rt 
and stirred overnight. The mixture was concentrated and applied to a flash column in a 
minimum volume of CH2Cl2. Elution with a gradient of 95:5→9:1 (CH2Cl2-MeOH) gave 
hexapeptide 258 as a colorless oil (6 mg, 36%). Rf 0.35 (9:1 CH2Cl2-MeOH). HRMS (ESI) calcd 
for C53H64N10O14 (M+H)
+  1065.4676, obsd 1065.4655. 
-HAL-Nα(Alloc)-Cα(Ac*)-AAA (261) 
To a solution of -HAL 256 (10 mg, 0.015 mmol, 1.00 equiv.) in dry CH2Cl2 (0.5 mL) was 
added TFA (0.5 mL). The reaction mixture was stirred for 1 h at 0 °C and then concentrated 
three times from toluene to give the free amine 260 as a colorless oil (8.5 mg) that was used 
directly in the next step without further purification.  
The intermediate amine 260 (8.5 mg, 0.015 mmol, 1.00 equiv.) was dissolved in CH2Cl2 
(1.5 mL) and cooled to 0 °C under N2. Free acid 195 (5 mg, 0.015 mmol, 1.00 equiv.) was 
added as a solution in CH2Cl2 (1.5 mL) followed by collidine (4 µL, 3.5 mg, 0.030 mmol, 2.0 
equiv.) and HATU (6 mg, 0.016 mmol, 1.05 equiv.). After 20 min, the mixture was warmed to rt 
and stirred overnight. The mixture was concentrated and applied to a flash column in a 
minimum volume of CH2Cl2. Elution with a gradient of 95:5→9:1 (CH2Cl2-MeOH) gave tripeptide 
261 as a colorless oil (6 mg, 54%). Rf 0.43 (95:5 CH2Cl2-MeOH). HRMS (ESI) calcd for 
C41H45N5O9 (M+H)
+  751.3852, obsd 751.3841. 
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                  5.8.3 Spectra 
Compound 228 (Scheme 5.3) – 1H NMR spectrum 
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Compound 228 (Scheme 5.3) – 13C NMR spectrum 
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Compound 229 (Scheme 5.3) – 1H NMR spectrum 
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Compound 229 (Scheme 5.3) – 13C NMR spectrum 
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Compound 230 (Scheme 5.3) – 1H NMR spectrum 
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Compound 230 (Scheme 5.3) – 13C NMR spectrum 
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Compound 231 (Scheme 5.3) – 1H NMR spectrum 
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Compound 231 (Scheme 5.3) – 13C NMR spectrum 
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Compound 232 (Scheme 5.3) – 1H NMR spectrum 
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Compound 232 (Scheme 5.3) – 13C NMR spectrum 
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Compound 234 (Scheme 5.3) – 13C NMR spectrum 
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Compound 234 (Scheme 5.3) – 13C NMR spectrum 
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 Compound 225 (Scheme 5.6) – 1H NMR spectrum 
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Compound 225 (Scheme 5.6) – 13C NMR spectrum 
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Compound 226 (Scheme 5.6) – 1H NMR spectrum 
 
200 
 
 
 
Compound 226 (Scheme 5.6) – 13C NMR spectrum 
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Compound 249 (Scheme 5.8) – 1H NMR spectrum 
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Compound 249 (Scheme 5.8) – 1H NMR spectrum 
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Compound 253 (Scheme 5.10) – 1H NMR spectrum 
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Compound 253 (Scheme 5.10) – 13C NMR spectrum 
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Compound 254 (Scheme 5.10) – 1H NMR spectrum 
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Compound 254 (Scheme 5.10) – 13C NMR spectrum 
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